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Abstract
The heritability of Rheumatoid Arthritis is approximately 60%. Although 
association with the HLA region is well recognised, these genes account for 
only 40% of the total genetic contribution. Linkage mapping and association 
studies need to proceed in parallel to identify which non-MHC genes are 
involved in the remaining 60% of the genetic contribution. The work 
described in this thesis represents a systematic approach to identifying these 
non-HLA effects, using genome-wide linkage mapping and candidate gene 
methods.
To identify regions exhibiting genetic linkage to rheumatoid arthritis a 
systematic, whole genome linkage analysis was undertaken. Two hundred 
and fifty-one affected sibling pairs from 182 United Kingdom families were 
studied using 365 highly informative microsatellite markers. Highly significant 
linkage was identified around the HLA region on chromosome 6 (max LOD =
4.8 at 44.9cM, p=0.000001). Eighteen other sites of nominal linkage (p<0.05) 
were identified on chromosomes 1, 2, 3, 4, 6, 7, 10, 12, 14, 16, 21 and the X 
chromosome by single point analysis (23 markers). Eight of the non-MHC 
regions (on chromosomes 1, 6, 7, 14, 16, 21, and X) also showed evidence 
of linkage by multi-point analysis.
A parallel linkage study designed to replicate the 25 regions of nominal 
linkage (p<0.05) reported following a genome-wide linkage study of 97 
European affected sibling pair families was also undertaken. Fifty-nine 
microsatellites within the 25 regions of interest (including IDDM6 on 
chromosome 18 and IDDM9 on chromosome 3) were used to genotype 368 
affected sibling pairs from 280 families. Markers on chromosomes 12, 15, 
and 21 (d12s95, CYP 19, d21s1252) showed evidence of nominal linkage 
with p values £ 0.05. Markers close to IDDM 6 on chromosome 18 showed p 
values of between 0.1 and 0.5, not lending additional support to a locus near 
IDDM6 in RA.
Interleukin 10 (IL10), an immunoregulatory cytokine, is a potent up-regulator 
of B cell production and differentiation but has anti-inflammatory capabilities 
and can directly down-regulate TNF, IL1, IL8 and IFNy production. Data from 
twin and family studies suggest large inter-individual variations in secretion 
which are 75% heritable and as such IL10 is a plausible candidate gene for 
involvement in RA. It is highly polymorphic with point mutations in the 
promoter region and two microsatellite loci IL10.R and IL10.G, 1.1 and 4kb 
upstream of the transcription initiation site. Higher levels of IL10 secretion 
have been associated with allele 2 of IL10.R (IL10.R2) and IL10.R3 has been 
associated with decreased secretion. Additionally, a case-control study 
including two independent Caucasian populations and one African-American 
cohort found an over-representation of the IL10.R2 allele with a concomitant 
reduction of IL10.R3 in all three rheumatoid arthritis populations.
Three studies investigating IL10 were undertaken. Two case-control studies 
including two cohorts of racially distinct RA patients (186 UK Caucasians with 
severe rheumatoid arthritis and 138 South Africans of Zulu or Sotho origin) 
were performed. An association with RA was not confirmed in either study 
but demonstrated significantly different frequencies of the IL10.R2 allele in 
the two study populations. The third study was a family-based association 
study and included 163 probands and their families. Single marker and 
haplotypic association analysis was performed by transmission disequilibrium 
testing (TDT analysis) using the software package TRANSMIT. The IL10.R1 
allele was transmitted to affected individuals more frequently than expected 
(p<0.05) and the IL10.R3 allele was transmitted less frequently than expected 
(p<0.05). This effect was particularly pronounced with the IL10.R3/IL10.G10 
haplotype (p<0.005). The still stronger negative association identified with 
the IL10.R3/IL10.G10 haplotype suggested it was not IL10.R itself but 
another polymorphism on the particular haplotype that may be primarily 
involved with RA.
xix
The application of these methods to the examination of the genetic 
component of RA is discussed. Plans for future work include systematic 
genome-wide screening of positional candidates and evaluation of 
candidates from studies of other human and animal models of inflammatory 
disease.
xx
Chapter 1 -  section 1
Plate A is a photograph of an 18th century oil painting by William Hoare depicting a rheumatology and orthopaedic combined 
clinic at the Mineral Water hospital in Bath. Dr William Olliver and Mr Jeremiah Peirce are reviewing a child with a skin disease, 
a man with a wrist drop and woman with inflammatory arthritis. Between 1752 - 1756 one third of patients seen at the Bath 
hospital had musculoskeletal conditions. In 1935 the hospital was renamed the Royal National Hospital for Rheumatic diseases 
as by then all patients were referred with musculoskeletal diseases.
CHAPTER 1 - section 1
1.1.1 Rheumatoid Arthritis: a natural history.
Hippocrates first described rheumatic diseases in the fourth century B.C. The 
term ‘rheuma’ was used in the first century A.D. to describe a flow of pain 
through the joints of the body (Sangha, 2000). Although the study of ancient 
North American skeletons suggest that rheumatoid arthritis (RA) existed at 
least 3000 years ago (Goemaere et al., 1990; Sangha, 2000), the first 
recorded clinical description of RA is normally credited to Augustin-Jacob 
Landre-Beauvais in his thesis written in 1800. Archibald Garrod coined the 
term ‘rheumatoid arthritis’ (RA) in 1859 but included inflammatory polyarthritis 
and polyarticular osteoarthritis (Garrod, 1859; Halberg, 1998). By 1922 
polyarticular osteoarthritis was excluded from the definition (Parish, 1963) as 
were the sero-negative arthritides in 1958 (Ropes etai ,  1958).
Classification of the rheumatic diseases has been hampered by the absence 
of firm evidence for disease aetiology. With no unique clinical or laboratory 
features, disease classification has been dependent upon a combination of 
common clinical, radiological and laboratory findings. The use of 
predominately clinical criteria to define these diseases has inevitably resulted 
in broad categories of differing rheumatic conditions with considerable clinical 
and pathological overlap. Diagnosis of a particular condition can therefore be 
difficult in the early stages of disease (Sangha, 2000). For example, it has 
been reported that RA was not diagnosed at presentation in up to twenty per 
cent of patients with polyarthritis attending an early synovitis clinic (Salmon et 
al., 1993; Wordsworth and Brown, 1997).
1
Plate 1.1.1 shows a hand with MCP and PIP joint 
swelling. This hand shows the changes of relatively 
recent onset RA.
2
1.1.1.1 Rheumatoid arthritis: clinical features.
RA is a chronic systemic inflammatory condition predominately involving 
synovial joints and affecting up to 1% of the population. The cause is 
unknown and the disease is clinically heterogenous with a wide range of 
disease severity. Most people affected (-80%) have elevated titres of serum 
rheumatoid factors. The majority develop a chronic form of the disease 
characterised by relentless progressive joint destruction and disordered 
immune function leading to marked functional impairment and disability. 
Some people experience only mild oligoarticular synovitis and the disease 
resolves spontaneously within two to three years of onset. Yet in others 
extra-articular features are prominent (Matteson et al., 1998).
1.1.1.2 Rheumatoid arthritis: presentation
Disease onset and the subsequent clinical course vary considerably, hence 
the measurement of disease activity or prognosis is not easily defined. A 
gradual onset is most common (at least 50%) whilst a minority (10 -  25%) 
developing an acute widespread symmetrical polyarthropathy over a few 
hours or days (Gordon and Hastings, 1998). The classical presentation of RA 
initially involves a distal symmetrical polyarthritis affecting the small joints of 
the hands and feet with associated fatigue and early morning stiffness 
[Gordon, 1998] (plates 1.1.1, 1.1.2 and 1.1.3). Bone erosions, leading to joint 
destruction generally develop within three years of disease onset [van der 
Heijde et al., 1992] (plates 1.1.5 and 1.1.6). Frequently, the arthritis spreads 
to involve proximal joints and can lead to severe functional disability if weight­
bearing joints are affected (Gordon and Hastings, 1998). Many require joint 
replacements as a consequence of joint damage resulting from inadequately 
controlled disease (Gordon and Hastings, 1998).
RA is a multi-system disease and constitutional features, such as fatigue and 
weight loss, may occur early in the course of the disease and may
3
Plate 1.1.2 shows the hands and wrist changes that can occur in severe RA. 
Subluxation and ulnar deviation can be seen at the wrist and MCP joints. 
Boutonnieres deformity and swan necking can be seen in the fingers.
predominate over shadowing the joint manifestations (Matteson et al., 1998). 
Associated non-articular features include subcutaneous nodules (~20%) 
(Matteson et al., 1998) (plate 1.1.4), vasculitis (plate 1.1.7), pericarditis, 
pulmonary nodules or interstitial fibrosis, normochromic normocytic anaemia, 
thrombocytosis, episcleritis or scleritis. Between 10 -  35% of patients 
develop secondary Sjogren's syndrome with conjunctivitis sicca and 
xerostomia (Matteson et al., 1998). Pleurisy and pericarditis are common. 
Up to 50% of patients have echocardiographic evidence of pericarditis but 
most have no overt symptoms (Matteson et al., 1998). Rheumatoid vasculitis 
may result in extensive cutaneuous ulceration, a peripheral neuropathy (with 
a glove and stocking sensory loss), mononeuritis multiplex and myocardial or 
bowel ischaemia. As many as one in nine men with RA sustain an episode of 
major vasculitis during their lifetime (Wordsworth and Brown, 1998). Less 
than 1% of patients develop Felty’s syndrome, a combination of rheumatoid 
disease, neutropenia, splenomegaly and lymphadenopathy (Matteson et al., 
1998). This rarely develops within ten years of disease onset and is 
frequently associated with pronounced extra-articular features. 
Overwhelming infection reduces the life expectancy in this group.
1.1.2 Epidemiology of rheumatoid arthritis
Epidemiological studies of RA are dependent on the criteria used to define 
the disease (Sangha, 2000). However, choosing the criteria used for 
diagnosis is difficult without the identification of an aetiological agent or 
specific clinical or laboratory feature to define the disease. Hence, various 
different criteria have been produced in an effort to improve diagnostic 
sensitivity and specificity. Therefore, the criteria used to diagnose an 
individual with RA have changed over the years making it difficult to compare 
disease prevalence over the decades and hampering most population
5
Classification of Rheumatoid Arthritis 









Arthritis in at least 3 joint 
areas *
With soft tissue swelling 
or fluid 
- lasting > 6 weeks
Definite 
rheumatoid arthritis
Arthritis of hand joints Wrist, MCP +/or PIP 
joints 
- lasting > 6 weeks
Classical 
rheumatoid arthritis
Symmetrical arthritis * At least one area 
- lasting > 6 weeks
5 Subcutaneous rheumatoid 
nodules
Observed by a 
physician
6 Radiographic changes 
typical of RA
Seen on an 
anteroposterior 
radiograph of the hands 
and wrists
7 Serum rheumatoid factor Assessed by a method 
positive in < 5% of 
control subjects
‘ includes right or left proximal interphalangeal (PIP) joints , metacarpophalangeal (MCP) joints, 
metatarsophalangeal (MTP) joints, wrist joint, elbow joint, knee joint or ankle joint
Table 1.1.1. Adapted from Ropes et al [Ropes, 1958 >] summarises the
classification criteria for RA published by the American Rheumatism Association 
(ARA) in 1958. These were defined in 1956 following the analysis of 332 cases 
and 11 criteria with 19 exclusions were proposed. The criteria were revised in 
1958. “Classic” RA required at least 7 criteria, whereas “definite” RA required at 
least 5 criteria and 6 weeks of joint symptoms. “Probable” RA required at least 3 
criteria and 6 weeks of joint symptoms.
6
studies. Until recently, the most widely used diagnostic criteria were 
published by the American Rheumatoid Association (ARA) in 1958 (Ropes et 
al., 1958). These criteria defined RA with varying degrees of certainty in 
terms of “classic”, “definite”, “probable” and “possible” disease (table 1.1.1). 
This complexity was simplified in the American College of Rheumatology 
(ACR) 1987 revised criteria for the classification of RA (Arnett et al., 1988) 
when at least four criteria had to be fulfilled for the diagnosis of RA to be 
made (table 1.1.2). The criteria distinguished RA from other rheumatic 
diseases (such as systemic lupus erythematosus) with a specificity ranging 
from 85 -  95% and sensitivity between 77 -  95% (MacGregor et al., 1998; 
Arnett et al., 1988). It is important to note that the ‘gold standard’ used to test 
these criteria against and so determine the sensitivity and specificity was a 
diagnosis made by a physician. Also, as they were defined in a secondary 
care setting (where individuals studied definitely had RA or another defined 
musculoskeletal condition) they do not perform well in diagnosing RA in an 
early arthritis cohort where initial symptoms and signs are not so well defined. 
In a community-based setting (NOAR) they had little more than a random 
ability to predict persistence of arthritis, the development of radiological 
erosions or moderate disability (Harrison et al, 1998). The 1987 ACR criteria 
were modified for epidemiological study by accepting ‘deformity’ in lieu of 
‘current swelling’ as one of the 4/7 criteria needed (table 1.1.3). This 
modification improved sensitivity and specificity in these circumstances 
(section 1.1.3) (MacGregor et al., 1994a).
Disease occurrence is assessed by two measures, both of which present 
methodological problems for those studying RA. Prevalence refers to the 
number of existing cases, and incidence, the rate of new cases arising in a 
given period (Silman and Hochberg, 1993). Studies of incidence require 
large samples and prolonged follow-up as incidence rates are fairly low in RA. 
As yet, no criteria specific for early RA have been described thus a number of 
early cases may be missed. Ideally studies of prevalence should include all
7
The American College of Rheumatology 1987 revised 
diagnostic criteria for the classification of Rheumatoid 
Arthritis
1 Morning stiffness Duration:
>1 hr and lasting > 6 weeks
2 Arthritis in at least 3 joint areas * With soft tissue swelling or fluid 
- lasting > 6 weeks
3 Arthritis of hand joints Wrist, MCP +/or PIP joints 
- lasting > 6 weeks
4 Symmetrical arthritis * At least one area 
- lasting > 6 weeks
5 Subcutaneous rheumatoid 
nodules
Observed by a physician
6 Serum rheumatoid factor Assessed by a method positive 
in < 5% of control subjects
7 Radiographic changes typical of 
rheumatoid arthritis A
Seen on an anteroposterior 
radiograph of the hands and 
wrists
* (criteria 2 and 4) includes right or left proximal inter-phalangeal (PIP) joints, metacarpo­
phalangeal (MCP) joints, wrist, elbow, knee, ankle or metatarso-phalangeal (MTP) joints.
A (criteria 7) must include erosions or unequivocal bony decalcification (peri-articular 
osteoporosis) localised to or most marked adjacent to the involved joints
Table 1.1.2. Adapted from Arnett et al (Arnett et al, 1988) summarises the 
American Rheumatism Association (ARA) 1987 revised criteria for the 
classification of RA. The criteria were defined following the comparison of 262 
individuals with RA and 262 control subjects. The sensitivity and specificity of 
the criteria for RA were 91-94% and 89% respectively. The categories are 
different from the 1958 ARA criteria in that RA is defined by the presence of 4 or 
more criteria, and no further qualifications (classic, definite, or probable) or list of 
exclusions are required.
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Plate 1.1.4 shows the hands of an individual with RA and rheumatoid nodules.
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past and inactive cases of RA. However, to achieve this the use of criteria 
specifically designed to recognise quiescent disease are required (table 
5.1.3). It is frequently difficult to establish the extent to which remitted 
disease has been included in published reports (MacGregor etal., 1998).
1.1.2.1 Rheumatoid arthritis: prevalence
RA occurs throughout the world. Most studies in Caucasian, European and 
North American populations report a point prevalence of between 0.5 and 2% 
(table 1.1.5) (Spector et al., 1990; MacGregor et al., 1998). Prevalence rates 
have been based on large cross-sectional population samples and age- 
specific prevalence increases in all studies (MacGregor and Silman, 1998) 
(Symmons et al, 2002). Prevalence rates are higher in women and it has 
been estimated that the overall male to female ratio of affected individuals is 
~3:1. However, at age 30 years the ratio is 6:1 but this falls almost to equality 
by age 60 years (Wordsworth and Brown, 1997).
1.1.2.2 Rheumatoid arthritis: incidence
Few incidence studies have been reported because of the difficulty in 
establishing an early diagnosis. Most studies have been retrospective, 
although there have been two recent prospective studies of incidence rates in 
RA (table 1.1.6). The Norfolk Arthritis Register has been able to derive 
incidence rates from a population registry of all individuals with polyarthritis 
presenting to hospital and general practitioners in Norfolk (Symmons et al.,
1994), (Wiles et al, 1999). Dugowson et al identified new cases occurring in 
women attending a health maintenance program in Seattle, USA between 
1987 and 1989 (Dugowson et al., 1991). The annual overall incidence of RA 
ranges from 0.24 to 0.29/1000. For males it is between 0.14 to 0.2/1000 and 
for females from 0.36 to 0.5/1000 (Dugowson et al., 1991; Linos et al., 1980; 
MacGregor and Silman, 1998; Symmons et al., 1994). RA may present at 
almost any time of life but the peak incidence is between the ages of 45 -  75 
years (Symmons etal., 1994) (Wiles etal, 1999).
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1974 0.37 0.48 0.22
RCGP, UK 
(1979)
Prospective -  
new episodes in 
primary care
1970-
1972 2.99 4.20 1.63
RCGP, UK 
(1986)
Prospective -  
new episodes in 
primary care
1981-



















Prospective -  
community 
ascertained 
cases (5 year 
data) §
1999 0.54 0.24
RCGP = Royal College of General Practictioners 
* = new female RA cases attending a health maintenance organisation 
§ = all cases of inflammatory polyarthritis presenting to general or hospital 
practitioners
Table 1.2.6 adapted from MacGregor and Silman (MacGregor, 1998) 
summarises the available data used to assess the incidence of RA.
11
1.1.2.3 Rheumatoid arthritis: geographical variation
Although similar estimates of the prevalence of RA have been obtained from 
diverse populations worldwide there are exceptions (table 1.1.5). Despite 
fairly standard levels of RA in the urban black South African population the 
disease appears to be exceptionally rare in rural Sub-Saharan Africa. It is 
rare in both urban and rural Chinese populations. However, certain native 
North American Indians including the Pima, Chippewa and Yakima have a 
much higher prevalence at ~5% although the disease is rarely seen in other 
groups such as the Blackfeet or Haida Indians (MacGregor et al., 1998; 
Silman, etal. 1993) (table 1.1.5). The relative genetic factors influencing this 
geographical variation are discussed later (section 1.2.3) but it is likely that 
environmental factors are also involved. An association with urban industrial 
environments has been suggested by the low disease prevalence rate in rural 
South African blacks when compared with the higher frequency of disease in 
their urban counterparts (Beighton etal., 1975; Solomon etal., 1975), but this 
has not been confirmed in other populations. For instance urban Hong Kong 
Chinese have the same low prevalence as those in rural Kinmet (Silman and 
Hochberg, 1993) and blacks living in inner-city Manchester have a lower 
prevalence than whites living in the same area (MacGregor et al., 1994b). It 
is possible that the rural environment could be protective and it has been 
suggested that chronic stimulation of the immune system by tropical 
infections including malaria may in some way be protective against the 
development of autoimmunity (Greenwood, 1968).
1.1.2.4 Rheumatoid arthritis: variation over time
In some populations the incidence of RA seems to be declining. For 
instance, the Rochester Epidemiology Program data show a decline in female 
incidence from 1960 onwards (Linos et al., 1980) and the incidence in Pima 
Indians has halved in both males and females between 1965 and 1990 
(Jacobsson et al., 1994). However, data from a Finnish population register
12
Prevalence of definite Rheumatoid Arthritis in 







North America US National Health Survey 1.0
Native
Populations
Chippewa Indians, USA 5.3
Inuit, Canada 0.6
Inpiat Eskimos, USA 1.0
Pima Indians, USA 5.3
Africa Liberia and Nigeria 0.1
South Africa (urban) 0.9
South Africa (rural) 0.1
Asia China 0.3
Japan 0.6
Table 1.1.5 adapted from Wordsworth and Brown (Wordsworth, 1997) lists the 
differing estimates of prevalence of definite RA in various adult populations 
including European, North American, African and Asian populations. It can be 
seen from this table that the prevalence of RA varies from 0.1% in the rural 
South African population to over 5% in some North American Indian populations. 
Of note, the prevalence of RA in the South African urban population is nearly 1% 
which is in the same order of magnitude to the prevalence reported by the US 
National Health Survey and throughout most European populations. This figure 
is at odds with that of the South African rural population.
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showed the incidence remained static between the years 1970 to 1980 
(MacGregor, et al. 1998). The severity of RA may also be declining over 
time. Silman et al analysed successive birth cohorts and found peaks in 
erosive, seropositive and nodular disease in individual presenting with RA in 
the 1960s. Subsequently, the severity of the condition has been in decline 
(Silman etal., 1983).
1.1.2.5 Rheumatoid arthritis: risk factors
a) Host factors
Given the predominance of rheumatoid arthritis in women many studies have 
investigated the association of sex hormones, menstrual and reproductive 
factors in relation to disease onset, severity and remission. It is well 
established that pregnancy is associated with disease remission and 
exacerbations are common in the postpartum period (Nelson et al., 1993; 
Persellin, 1976). Several studies have suggested that nulliparity is a risk 
factor (Spector et al., 1990) although no association was found in a recent 
large prospective cohort study from Finland (Heliovaara et al., 1995). In a 
prospective study of 23,000 United Kingdom women the oral contraceptive 
pill (OCP) was associated with halving the incidence of rheumatoid arthritis 
(Wingrave and Kay, 1978) but further studies have been unable to confirm 
this. A meta-analysis concluded that although OCP use may not protect 
against disease it may postpone disease onset (Spector and Hochberg, 
1990). One large study investigating age of disease onset found that the 
average women developed the first symptoms of RA at the time of her 
menopause (Goemaere etal., 1990).
b) External environment
There is no convincing epidemiological data to support the role of infection. 
Cases of RA do not cluster over space or time and concordant monozygotic 
twins, sibling pairs and spouse couples have not shown any similarity in the
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Plate 1.1.5 is a radiograph of the hands and wrists of an individual with RA. Erosions 
can be seen particularly in the wrists.
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timing of disease onset. However, it is conceivable that a ubiquitous 
infectious agent may be responsible for RA in a genetically susceptible host. 
Animal models have suggested a number of plausible mechanisms. Specific 
agents have been isolated from human synovium and homology exists 
between the antigenic components of infectious organisms, synovium and 
cartilage (Phillips, 1988). Raised titres of Epstein-Barr virus have been 
demonstrated in those with RA, but in one small longitudinal study titres were 
raised prior to disease onset (Kouri et a/., 1990). Raised titres of parvovirus 
and cytomegalovirus have also been reported but not consistently in all 
studies (Hajeer et al., 1994; Walker et al., 1987). No conclusive evidence of 
association has been found with numerous other putative infectious agents 
such as mycoplasma, proteus, rubella or mycobacteria (Walker etal., 1987).
Some studies have associated low socio-economic status with a worse 
disease outcome but conflicting data are available regarding the influence on 
disease susceptibility. Recently, prospective data from the Norfolk Arthritis 
Register have shown no association with social class or economic status 
(Bankhead et al., 1996). Specific occupations such as coal mining, granite 
working and those handling organic solvents have been implicated but these 
reports have never been confirmed (MacGregor et al., 1998; Silman et al., 
1993).
1.1.3 Classification criteria modified for genetic and
epidemiological studies
In genetic or epidemiological studies the failure to recognise “cases” with 
inactive or mild disease has lead to the misclassification of disease status 
and has important consequences. In family studies it may lead to an 
underestimation of disease recurrence risks. The presence or absence of
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disease needs to be ascertained through a single encounter with a study 
subject. Hence, the classification of disease status needs to be consistent, 
incorporating disease features present during current examination but also 
those that have occurred in the past (e.g. the difference between current 
synovitis and evidence of past synovitis). The information regarding past 
disease activity can be given by the patient or come from clinical records. 
Many existing criteria have shortcomings as they do not specifically take into 
account features of inactive disease. The 1958 ARA and 1987 ACR 
diagnostic criteria (Arnett et al., 1988; Ropes et al., 1958) were developed to 
distinguish RA from other rheumatic conditions and are weighted towards the 
recognition of currently active disease (tables 1.1.1 and 1.1.2). These 
diagnostic criteria are considered to have high levels of sensitivity and 
specificity but were initially tested in a hospital setting where the proportion of 
active disease is inevitably higher than in the community where there may be 
a relatively large number of individuals with inactive disease. The lack of a 
specific diagnostic test for RA also presents problems as the study 
population, unless carefully selected, may exhibit considerable clinical 
heterogeneity. MacGregor and colleagues compared seven different sets of 
RA criteria and compared them to the ‘gold standard’ of a physician 
diagnosis. The individuals included were participating in an epidemiological 
study of twins, where at least one of the pair had RA (MacGregor et al., 
1994a). Differences in disease classification substantially altered the 
estimation of disease concordance for RA in the twin pairs studied. Only 124 
of the 283 individuals reporting polyarthritis fulfilled all seven sets of disease 
criteria. Differences were most obvious between the criteria that accepted 
‘current swelling’ only and those accepting ‘current swelling’ or ‘deformity’ as 
part of the criteria set. The ‘current swelling only’ criteria recorded point 
prevalence or currently active disease whereas the ‘current swelling or 
deformity’ criteria recorded cumulative prevalence or “ever disease”. When 
“ever disease” was taken into account sensitivity and specificity increased. 
Overall, the 1987 ACR criteria modified for epidemiological study performed
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The American College of Rheumatology 1987 revised 
criteria for the classification of Rheumatoid Arthritis 
-  modified for population and family studies
1 Morning stiffness Duration: >1 hr - at any time during the 
disease course
2 Arthritis in at least 3 joint 
areas *
With soft tissue swelling or fluid - 
currently or documented previously
3 Arthritis of hand joints Swelling of wrist, MCP or PIP joints - 
currently or documented previously
4 Symmetrical arthritis * Simultaneous bilateral involvement of 
the same area with swelling - currently 
or documented previously
5 Subcutaneous rheumatoid 
nodules
Observed by a physician - currently or 
documented previously
6 Serum rheumatoid factor Assessed by a method positive in < 5% 
of control subjects - currently or 
documented previously
7 Radiographic changes § Seen on an anteroposterior radiograph 
of the hands and wrists
* (criteria 2 and 4) includes right or left proximal inter-phalangeal (PIP) joints, metacarpo­
phalangeal (MCP) joints, wrist, elbow, knee, ankle or metatarso-phalangeal (MTP) joints.
A (criteria 7) must include erosions or unequivocal bony decalcification (peri-articular 
osteoporosis) localised to or most marked adjacent to the involved joints
Table 1.1.3. Adapted from MacGregor et al (MacGregor etal, 1995) summarises 
the American Rheumatism Association (ARA) 1987 revised criteria for the 
classification of RA modified for population and family studies. These criteria 
are very similar to the original 1987 revised criteria (table 1.1.2) but vary in that 
previously documented arthritis, subcutaneous nodules or positive rheumatoid 
factor may be included in the criteria even if the individual is currently in 
remission (i.e. without current soft tissue swelling or joint fluid). Hence these 
criteria identify both individuals who have currently active disease and those 
who have had active RA in the past.
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best in terms of sensitivity and specificity. These criteria accept deformity in 
lieu of current swelling. The United Kingdom family collection of affected
sibling pairs with rheumatoid arthritis has therefore used the 1987 ACR
criteria modified for epidemiological study (table 1.1.3) as the basis of disease 
diagnosis during recruitment.
1.1.4 Disease costs
RA is an important cause of chronic disability. Poor joint function and 
disability are initially caused by active disease where involved joints are too 
swollen and painful to undertake normal tasks. In the longer term, bony 
erosions leading to significant joint damage, tendon rupture and muscle 
wasting cause a permanent loss of joint function and subsequent disability. 
The cost of any disease can be described in many ways but areas common 
to all include morbidity, mortality and financial loss. By any criteria, RA is very 
costly disease.
1.1.4.1 Morbidity
Quality of life may deteriorate significantly following the diagnosis of RA and 
is affected by many factors. Swollen, painful, stiff joints lead to poor function 
and RA is an important cause of chronic disability. Some of these effects can 
be readily measured with a range of outcome measures developed for RA 
(see appendix 5.1 for some examples) but the consequences of poor function 
leading to loss of a working or a social life are less easily documented. 
Compared to disease-free individuals of the same age most have greater 
difficulty in carrying out household work, social relationships, leisure and 
recreational activities, work etc. (Felts and Yelin, 1989). In one longitudinal 
study functional disability was assessed in 1274 patients using the Stanford 
HAQ disability index (Wolfe et al., 1988) (appendix) and Functional Disability 
Index (FDI) over a 12 year period. Within 2 years of diagnosis half the
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OPlate 1.1.3 shows the forefeet of an individual with severe RA. Bilateral hallux valgus can be 
seen. Both second toes over-ride the big toes. The MTP joints are subluxed and some of the 
toes show clawing as a result of fixed flexion at the PIP joints.
patients showed moderate loss of function, but this became severe within 6 
years and very severe by 10 years. The progression of disability was most 
rapid in the early years and worsened more quickly in women (Wolfe and 
Cathey, 1991). A recent community-based study undertaken in Finland 
showed that RA was associated with more than a seven fold increased risk of 
disability compared with a general population of adults from the same 
community (Sokka et al., 2003). The impact of disability due to RA was 
greater in younger and middle-age people than in eiderly patients.
Factors indicating an unfavourable prognosis in RA were found to be 
uncontrolled polyarthritis, functional disability, erosions, positive rheumatoid 
factor, RA susceptibility or severity genes i.e. HLA-DR4 (DRB1* 0401, DRB1* 
0404 etc.), the presence of extra-articular features and psychosocial 
problems.
1.1.4.2 Mortality
The Stanford HAQ disability index (Wolfe et al., 1988) (appendix 5.1.6) is 
useful as a prognostic indicator of disease severity and length of survival. 
Another risk factor predicting greater disability and premature death is the 
requirement for an individual to be treated with prednisolone as this suggests 
greater disease severity. These prognostic factors predict a two-fold increase 
in mortality equivalent to malignant conditions such as Hodgkins Disease or 
chronic heart disease (Wolfe et al., 1994). RA is also a marker for the 
development of co-morbid conditions such as renal disease. A recent 
population-based analysis of survival trends in RA over 40 years revealed 
that patients with RA were at significantly higher risk of death, with an 
standardised mortality ratio (SMR) of 1.27 (95% confidence interval 1.13 -  
1.41). Excess mortality among women was more pronounced than among 
men (SMRs of 1.41 and 1.08 respectively) (Gabriel etal., 2003).
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Plate 1.1.6 is a radiograph of a hand showing the destructive 
changes of advanced RA. This individual has previously had a 
Darrachs procedure where the ulnar styloid has been removed 
surgically for pain relief and to avoid risk of subsequent extensor 
tendon rupture. The MCP joints are subluxed and the PIP joints 
and carple bones of the wrist show signs of significant destruction
2 2
1.1.4.3 Finances and work
A systematic survey undertaken in the United States (US) in 1988 
investigated the direct and indirect costs of major diagnostic categories such 
as musculoskeletal disease, cardiovascular disease and cancer. 
Musculoskeletal diseases cost up to 2.5% of US gross national product 
(GNP), equivalent to a severe recession (Yelin, 1998). In the UK, the 
estimated cost of secondary care and drug treatment for new cases of RA per 
year is roughly £21.8 million (1990-1991 prices) (Cooper et al 2000). The 
total direct cost of RA for 232,825 people in the UK with disease is estimated 
at £604.6 million (1992 prices) (McIntosh, 1996). Non-health service costs 
(incurred by the individual, their family and friends) account for a substantial 
proportion (86%) of the total costs associated with early inflammatory arthritis 
(Cooper et al, 2002). Costs are not equally distributed. Figures suggest that 
incurred costs for those in the 10th percentile are < 2% per capital income, for 
those in the 90th percentile costs are 40% higher than per capita income but 
for those in the 99th percentile costs are four times as large as per capita 
income (Yelin, 1998). In a UK community-based study (NOAR) one third of 
RA patients had stopped work on the grounds of ill-health within two years of 
symptom onset (Barrett et al, 2000), 50% within 10 years and 90% had left 
work before retirement age (Yelin et al., 1987).
RA is a common and costly disease with a two-fold increased mortality, 
significant morbidity and high financial costs. Learning more about factors 




The synovium is a continuous layer, which lines joints, tendon sheaths and 
bursae. It forms a non-adherent surface allowing movement between the 
various components of the joint and encloses a synovial space containing a 
small amount of hyaluronan rich fluid. It consists of two layers: the intima and 
subintima. Synovial fluid and matrix components are synthesised by 
specialised cells within the intima. Hyaluronan and adhesion molecules are 
synthesised by intimal fibroblasts and intimal macrophages carry receptors 
for immune complexes. Inflammatory disease targets the intima and the 
intimal cells interact with B-lymphocytes, antigen-antibody complexes and 
complement proteins. In health, macrophage numbers are comparatively low 
but can account for up to 80% of intimal cells in disease. The binding of 
immune complexes to intimal macrophages in RA releases cytokines and 
may induce synovial fibroblasts to support B cell survival and maturation 
(Edwards, 1998).
1.1.6 Inflammation
Inflammation is the response of living tissues to injury (Prockop and Kivirikko, 
1995; Robinson, 1998). It is an ancient physiological response to insult and 
is an essential factor in the protection of the host from attack by pathogenic 
micro-organisms. Initially it is a destructive process, which should be limited 
by controlling anti-inflammatory processes, which lead to a healing phase. 
The response occurs in vascularised tissues enabling the delivery of essential 
molecules and cells to sites of inflammation in extravascular tissues 
(Robinson, 1998). In some instances inflammation will resolve with little 
tissue damage; in others it is accompanied by significant tissue destruction 
and repair is only partial (for example septic arthritis with articular cartilage
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damage). Attempted repair follows repeated episodes of inflammation in 
conditions such as RA. Chronic inflammation involves many different 
mediators and cell types and is characterised by the presence of 
mononuclear cells such as macrophages, lymphocytes, plasma cells, and the 
proliferation of connective tissue fibroblasts.
The vascular response to injury results in increased temperature, erythema 
and swelling around joints that is the hallmark of RA (Prockop and Kivirikko, 
1995). The process involves dilatation of arterioles and increased 
permeability of the microvasculature. Plasma then exudes into the 
extravascular space and leucocytes migrate through widened gap junctions 
and basement membrane into the extravascular space (Robinson, 1998). 
The loss of plasma increases blood viscosity. These events are induced and 
modified by a large number of inflammatory cells and the proteins produced 
by these cells. Protein synthesis and release depends upon the interaction of 
specific cell receptors and can result in both synergistic and antagonistic 
effects.
An inflammatory reaction requires the activation of different classes of 
leucocytes including, neutrophils, monocytes, macrophages, mast cells, 
eosinophils and basophils (Hardingham and Fosang, 1992). Some 
leucocytes are attracted to sites of inflammation, whereas monocytes reside 
in peripheral tissues and can differentiate into macrophages as a response to 
environmental stimuli. Macrophages are important in inflammatory reactions 
performing two important functions; phagocytosis and antigen presentation 
(Robinson, 1998). Following phagocytosis the ingested material is degraded 
to low molecular weight fragments and presented on the cell surface bound to 
class II MHC antigens (section 1.2.3). The antigenic fragments are 
recognised by T cells in relation to the MHC antigens. This leads to clonal 
expansion and activation of antigen specific T cells.
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Lymphocytes can identify both foreign and auto-antigens and are involved in 
the responses designed to eliminate these antigens (Prockop and Kivirikko, 
1995). B lymphocytes recognise antigenic epitopes and then proliferate and 
differentiate into antibody forming plasma cells. T cells recognise antigens 
through their T cell receptor and this also leads to proliferation. CD4 T cell 
subsets secrete lymphokines including interleukins IL2, IL4, IL5, which 
facilitate the amplification of B cell populations (Robinson, 1998). They 
augment delayed hypersensitivity reactions by enhancing cytotoxic T cells 
and facilitate the activation of macrophages by secreting interferon y (IFNy). 
They promote the growth and differentiation of bone marrow stem cells by 
secreting granulocyte-macrophage colony stimulation factor (GM-CSF). CD8 
T cell subsets carry certain antigens in combination with class I MHC 
antigens (section 1.2.3) and are important in host defence against virally 
infected cells and the rejection of alloantigens. They are cytolytic to cells and 
generally suppress immune responses.
There are many mediators of inflammation including the complement system, 
kinins (such as histamine, adenosine, serotinin) nitric oxide, the clotting 
system and activated forms of oxygen as free radicals (Robinson, 1998). 
Prostaglandins (PG) and thromboxane A2 including PGE2 and PGI2 are 
mediators of the vascular phase of inflammation being potent vasodilators. 
They also stimulate osteoclastic bone resorption, and bone erosions in RA 
may be partly mediated by them. Other mediators of inflammation, 
leukotrienes, platelet activating factors, and proteases, are all important 
mediators of tissue injury and degradation. In health these are tightly 
regulated to avoid uncontrolled tissue destruction and are generally stored 
within leucocyte lysosomes but some are synthesised de novo, and secreted 
in response to inflammation.
Cytokines are polypeptides secreted by a number of cell types, to regulate 
growth, differentiation and activation of leucocytes (Robinson, 1998). The
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interleukins (IL) are a family of cytokines with varying functions, some being 
pro- and some anti-inflammatory. IL-1, tumour necrosis factor (TNF) and IL-6 
have overlapping functions and are produced in large quantities by 
monocytes. They stimulate the synthesis of acute phase proteins by the liver, 
augment T cell growth and facilitate B cell proliferation and immunoglobulin 
secretion. IL-1 induces IL-6 secretion thereby promoting osteoclast 
activation. TNF acts synergistically with IFNy to enhance antiproliferative 
effects. IL-2 is produced by Th cells and stimulates the proliferation of T cells. 
IL-4 promotes T cell growth, can induce immunoglobulin class switching and 
increases the expression of class II MHC antigen on macrophages and B 
cells. IL-3 promotes the growth and differentiation of haematopoietic stem 
cells. IL-5 facilitates the growth and function of B cells and eosinophils. IL-7 
is a growth factor for T cells and IL-8 causes chemotaxis and activation of 
neutrophils. IL-10 is considered to have mainly immunosuppressive functions 
but increases the differentiation and activation of B cells (section 3.1.2).
Inhibitors of cytokine function play a major role in normal immunity and 
homeostasis by interrupting positive feedback loops and restraining cellular 
activation. There are four basic mechanisms of cytokine inhibition including 
soluble receptors (e.g. soluble IL-2 receptor) receptor-binding proteins such 
as IL-1 receptor antagonist (IL-1 ra) (Arend and Guthridge, 2000), anti­
cytokine antibodies (e.g. anti -IL-1 a) and immuno-suppressive cytokines such 
as IL-10 and IFN-a.
1.1.7 Pathology of RA
Chronic synovitis is one of the central features of RA although the pattern of 
synovial involvement varies from case to case. Initially there is evidence of 
hypertrophy of the lining layer of synovium with infiltration by activated 
macrophages and lymphocytes and proliferation of blood vessels. CD4+ (T
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helper) lymphocytes predominate in the peri-vascular areas and are in close 
proximity to antigen presenting cells. B lymphocytes also infiltrate and 
produce rheumatoid factors (RF) (Firestein, 1998). These are auto­
antibodies directed against the Fc fragment of immunoglobulin. The 
synovium develops as an invasive pannus which erodes the articular cartilage 
and bone especially where the synovium attaches to the joint margin 
(Firestein, 1998). This cartilage and bone destruction leads to the loss of joint 
space and erosions evident on X-ray (plates 1.1.5 and 1.1.6). The joint 
becomes painful and an effusion leads to joint swelling (plate 1.1.1). Large 
numbers of cells such as neutrophils, macrophages and lymphocytes are 
found in the synovium and synovial fluid. These cells produce pro- 
inflammatory cytokines such as IL-1, TNFa and IL-6, chemokines such as IL- 
8 and growth factors including transforming growth factor p (TGF-p), platelet 
derived growth factor (PDGF) and fibroblast growth factor (FGF). The acute 
phase response, stimulated by IL-1, IL-6, TNFa, is pronounced with high 
levels of circulating C-reactive protein, serum amyloid protein and polyclonal 
hypergammaglobulinanaemia.
Radiographs of affected joints show soft tissue swelling, juxta-articular 
osteoporosis and joint space narrowing (Bower, 1998) (plates 1.1.5 and 
1.1.6). Cartilage is eroded and this is followed by the development of bone 
erosions and joint deformity leading to instability. Bone re-absorption is seen 
early, partly reflecting disuse but also local cytokine release. The 
metalloproteinases are responsible for matrix degradation and remodelling. 
They are generally secreted as inactive proenzymes by synovial lining cells, 
requiring proteolytic cleavage for activation. Their secretion is mediated by 
other cytokines. IL-1 and TNF-a are potent inducers whilst interferon y (IFN- 
y) decreases activity. Tissue inhibitor of metalloproteinase (TIMP) is a key 
inhibitor and blocks activity by binding to the metalloproteinase. Stromelysin, 
and collagenase are two of the most important metalloproteinases because in 
combination they can degrade virtually all important structural proteins within
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Plate 1.1.9 shows the toes of an individual who has RA and a nailfold vasculitis. This suggests that 
RA vasculitis may be developing and additional treatment may be required.
a joint. Stromelysin digests interstitial collagenase, cleaves proteoglycans, 
laminin and fibronectin and activates latent collagenase which in turn digests 
native triple helical collagen leading to matrix destruction (Firestein, 1998). 
Stromelysin mRNA and protein has been identified in synovial tissues early in 
the disease process and collagenase levels are higher in RA synovial tissue 
than osteoarthritis (OA) (Firestein et a i , 1991). A long term study of low dose 
methotrexate (section 1.1.9), a drug shown to reduce the progression of bone 
erosions in RA, showed a 70% decrease of collagenase mRNA but no 
change in stromelysin orTIMP expression (Firestein etal., 1994)
Prostaglandins are synthesised by cells within the synovial fluid and 
synovium. Prostaglandins (for instance PGE2) potentate both vasodilation 
and the changes in vascular permeability induced by complement fragments, 
histamine and leukotrienes. PGs can also inhibit the production of anti­
inflammatory cytokines such as IFN-y. The immune complexes within a joint 
affected by RA can lead to complement activation. Rheumatoid factors (RF) 
are a consistent component of the immune complexes and serum rheumatoid 
factor levels correlate positively with complement. Complement components 
are mainly synthesised in the liver but can also be produced locally within the 
joint.
Human leucoctye antigens (HI_A) associations have been reported in a 
number of rheumatic diseases but only certain HLA-DRB1 alleles have been 
associated with RA (section 1.2.3). Peptide is presented to T cells by antigen 
presenting cells in conjunction with class II MHC antigens (section 1.1.6). 
There are a number of plausible explanations (Weyand and Goronzy, 1995) 
regarding the mechanism of the class II association and these are discussed 
in section 1.2.3.
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Polycyclic (70% of cases)
Monocylic 
(20% of cases)
60 1 2 3 4 5
Years from onset of RA
Fig 1.2 adapted from Gordon and Hastings [Gordon, 1998 
illustrates the various patterns of the clinical disease course in RA. The 
majority (70%) of individuals with RA follow a polycyclic pattern of 
disease activity where disease activity is either intermittent with short 
periods of remission or continuous with differing levels of severity. Up 
to 20% of individuals have a monocyclic pattern of disease activity with 
a single cycle followed by remission for at least one year. 
Approximately 10% of people follow a progressive disease pattern with 
increasing joint involvement and no sign of remission.
31
1.1.8 Predicting disease severity
Predicting disease severity in any individual is difficult. Prognosis may be 
associated with differences in presentation. Those who experienced an acute 
onset of disease may have a better functional outcome than those presenting 
with insidious progressive disease but this is by no means clear cut (Fleming 
et ai, 1976; Fleming et a/., 1976; Jacoby et al., 1973). Additionally, 
subsequent disease progression may follow several different patterns off 
disease presentation. Three articular patterns have been described and 
include a monocyclic pattern affecting approximately 20% of cases who 
experience a single cycle of disease activity with remission for at least one 
year. The second is a polycyclic pattern where the majority (~70%) 
experience an intermittent disease course and the disease smoulders with 
incomplete remission in some individuals. The third is a progressive pattern 
where approximately 10% have progressive joint involvement with 
uncontrolled disease activity (Gordon and Hastings, 1998) (fig 1.1.1). 
However, RA is a systemic disease despite predominately affecting synovial 
joints. Extra-articular involvement can affect multiple organ systems and 
systemic features may be associated with a poor prognosis (Vollertsen et al., 
1986). To accurately predict who will develop extra-articular features or who 
will continue with smouldering or uncontrolled disease activity is at present 
impossible.
The development of better ways to predict who will have a poor outcome 
early in the disease course, before significant joint damage has occurred, is 
of great importance. If this could be achieved, patients with a poor prognostic 
outlook could be treated aggressively with drug regimes that would be 
inappropriate to give to others.
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Valid measures of outcome are necessary to follow the disease natural 
history and to measure success or otherwise of treatment. Two principal 
outcome measures are the development of radiological erosions and 
functional disability. Both have some correlation to long term outcome (see 
section 1.1.4.1). A number of studies have investigated the predictive powers 
of screening for HLA-DR4 or the ‘shared epitope’ (section 1.2.3) in those with 
early RA (Emery and Salmon, 1995; Reveille et al., 1996; Weyand et al., 
1992). Although some evidence supports the association of HLA-DRB1 
alleles with radiological erosions (Gough et al., 1994; Harrison et al., 1999; 
MacGregor et al., 1995; Reveille et al., 1996), the Norfolk Arthritis Register 
(NOAR) study has shown that the ‘shared’ or ‘rheumatoid’ epitope has only a 
modest effect on functional disability (Harrison et al., 1999). Other studies 
have found no improvement with predictions of severity associated with 
knowledge of HLA-DRB1 status (Drossaers-Bakker et al., 2002; Eberhardt et 
al., 1996). Combinations of clinical and laboratory measurements taken early 
in the course of the disease have been studied to show whether it is possible 
to predict future disease severity. Levels of rheumatoid factor, number of 
bony erosions, patient’s age and the number of swollen / tender joints at 
diagnosis (+/- the HLA-DRB1 antigen) have been shown to partially predict 
the outcome of the disease process (Drossaers-Bakker et al., 2002).
1.1.9 Treatment
The current strategy for the treatment of RA is to fully suppress disease 
activity as quickly as possible (Wilske, 1993). A number of disease modifying 
drugs (DMARD) are available to achieve this end. These include 
methotrexate, sulphasalazine and intra-muscular gold (Jeurissen et al., 1991; 
Rich et al., 1999; van der Heijde et al., 1989). These drugs are used singly, 
or in combination if disease suppression is not achieved using a single 
DMARD (O'Dell etai ,  1996; Tugwell etal, 1995; Wilske, 1993). These drugs 
are potentially toxic and require careful monitoring. They also take some
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months to have an effect upon the disease process. However, despite the 
time taken to settle the joint symptoms and to reduce the acute phase 
response evidence is available to show that radiographic progression of joint 
disease can be slowed (Pincus et al., 2002). Function should be preserved if 
joint destruction is limited. Non steroidal anti-inflammatory drugs (NSAIDs) 
are often used in conjunction with DMARDs to help treat day to day 
symptoms of pain and stiffness. Alternatively low dose corticosteroids are 
used in conjunction with DMARDs. There is evidence that these have some 
disease modifying effect and reduce the occurrence of erosions (Kirwan,
1995) but there are many potential serious side effects and these drugs need 
to be used with caution. In recent years biologic therapies have become 
available, in particular anti-TNF therapies (Maini et al., 1999; Weinblatt et al., 
2003; Weinblatt et al., 1999). This approach has improved disease control in 
many patients who had failed conventional DMARD treatment. They have 
slowed radiological progression (Arend, 2002; den Broeder et al., 2002). 
Additionally biological therapies appear to have a more profound effect on 
many of the constitutional symptoms such as fatigue than conventional 
therapy (Arend, 2002). Short-term side effects appear to be fewer and less 
rigorous monitoring of liver and marrow function is required than for some 
conventional DMARDs. However these drugs have only recently become 
available and the longer-term side effects remain unknown. Particular 
concerns remain with respect to infections such as tuberculosis and the risk 
of malignancy.
1.1.10 Iatrogenic effects of treatment
The treatments used to control rheumatic disease frequently cause adverse 
drug reactions or unintended side effects. These can be divided into two 
groups: the relatively predictable ‘toxic’ reactions and the unpredictable 
idiosyncratic reactions. The former are usually dose-dependent and related
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to the intrinsic reaction of the drug whereas the latter are usually immune- 
related. Prevention of these adverse events is very important. Before 
treatment with DMARDs is commenced patients should be screened for 
contra-indications such as pre-existing liver disease, potential drug 
interactions or pregnancy. Adverse drug reactions are more likely to occur 
early in the course of treatment therefore monitoring should be carried out 
more frequently during the first few months of treatment. Table 1.1.7 lists the 
common adverse effects of the various DMARD treatments currently 
available for RA. A substantial minority of patients develop side effects to 
many ranging from mild effects such as nausea to more serious problems 
including renal or liver disease, severe rashes or pulmonary fibrosis. There 
are concerns regarding the long-term use of some DMARDs and the potential 
to develop a malignancy, particularly a B cell malignancy (Wijnands and van 
Riel, 1995). This is a particular concern when considering the biological 
therapies as long-term data is not yet available regarding the risk of 
developing a malignancy or serious infection.
The adverse effects of long-term corticosteroid treatments are well 
recognised and depend upon both the size of the dose and the length of 
treatment. Monitoring (± treatment) for hypertension, diabetes, osteoporosis, 
peptic ulceration, cataracts, and steroid induced myopathy is important 
because all are recognised complications of steroid treatment. However, if 
steroid doses are kept to a minimum and strategies of pro-active treatment 
are instituted in those at particular risk of a complication (e.g. bone protection 
treatments in those at a higher risk of osteoporosis) these drugs can be very 
effective at reducing disease activity. Steroids can be given orally, by intra­
muscular injection, by intra-articular injection or intravenously in the form of a 
high dose ‘pulse’ of treatment used to gain prompt control of disease activity. 
Each route can lead to particular adverse reactions. Daily doses of oral 
corticosteroids or frequent intra-muscular administration may cause those 
side effects mentioned above. Intra-articular steroids are frequently used to
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control local synovitis, producing prolonged relief of joint symptoms and 
improved function. Potential adverse events include the introduction of intra- 
articular sepsis and concerns that too frequent administration may lead to 
bone and cartilage damage (although little data is available to support this 
view). Intravenous administration can lead to facial flushing, psychological 
disturbances, palpitations and occasionally severe adverse reactions such as 
cardiac arrest or severe infections in those with failing cardiovascular or 
immune systems. However, intravenous administration of corticosteroid is 
usually free of longer-term side effects.
NSAIDs are very commonly prescribed for those patients with any form of 
arthritis or musculoskeletal pain. They are almost always prescribed to 
individuals with RA at some stage in the disease course. For a few with very 
mild disease or arthritis in remission a NSAID is sufficient to control disease 
activity but usually they are used as an adjunct to DMARD therapy. The 
commonest adverse events are related to the gastrointestinal (Gl) system 
and include dyspepsia, peptic ulceration or perforation and gastrointestinal 
bleeding. Reports suggest that between 2-300 individuals per year die in the 
UK from NSAID induced Gl side effects (usually peptic ulceration, perforation 
or bleeding) (Blower et a/., 1997). The anaemia an individual with chronic 
inflammation is likely to develop is normochromic and normocytic, hence a 
microcytic, hypochromic anaemia usually indicates Gl bleeding (possibly 
related to NSAID treatment). Other adverse events associated with NSAID 
therapy include bronchospasm in asthmatics, abnormal liver function tests, 
rashes, renal impairment and diahorroea.
The range of adverse events, both predictable and idiosynchractic, 
associated with treatment for RA emphasises how important it is to 
understand the natural history of disease more fully and to be able to identify 
those who may be at a greater risk of severe disease. If this were possible it 



































































Infliximab ? Infection ? malignancy
Anakinra ? Infection ? malignancy
Table 1.1.7 adapted from Wijnands and van Riel (Wijands and van Riel, 1995) illustrates the 
relationship between the dose of a DMARD and the adverse events that may occur when a 
patient is treated with that particular DMARD. Some adverse events are more likely to occur 
depending upon either the current or the cumulative dose of the DMARD whereas others are 
idiosyncratic and may occur at any time. As the biological therapies are relatively new forms 
of treatment the effect of a cumulative dose can only be guessed at.
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drugs. It may also be possible to predict individuals who are likely to develop 
side effects when treated with certain drugs. Some progress has been made 
in this area and certain tests can be performed prior to starting some DMARD 
therapies such as testing for thiomethylpurine transferase deficiency prior to 
starting azathioprine (Corominas et al., 2003; Marra et al., 2002). Another 
test that can be undertaken prior to starting methotrexate is the level of the N 
terminal fragment of procollagen III (P3NP) (Mitchel etal., 1990). These tests 
can help predict individuals who are more likely to develop some of the more 
serious adverse effects associated with these particular therapies. However, 
greater progress is needed in these areas.
1.1.11 Conclusion
Rheumatoid arthritis is a common disease associated with significant 
morbidity, disability, financial cost and an excess mortality. It is clinically 
heterogeneous and although diagnostic criteria and outcome measures are 
available it can be difficult to adequately categorise patients in terms of 
disease severity or prognosis. This can lead to difficulties in determining the 
extent (or aggressiveness) of initial treatment and which individuals to include 
in drug or genetic studies. Ultimately it may be necessary to abandon the 
concept of RA as a single disease entity. Distinct RA subsets could then be 
identified and patients stratified into categories that differ with respect to 
aetiology, disease course, clinical pattern and treatment response. 
Understanding more about the causes of RA, disease pathogenesis and 
predictors of severity is very important. Onset of disease is likely to occur 
when a genetically susceptible individual encounters some form of trigger 
(which may be quite a ubiquitous trigger). A greater understanding of the 
genes contributing to genetic susceptibility or even disease severity should 
improve our understanding of the natural history of RA, may allow the 
identification of those who require aggressive treatment from an early stage 
and may help in the development of novel therapies in the future.
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Chapter 1 -  section 2
CHAPTER 1 - section 2
Genetic principles and techniques
1.2.1 Introduction
Rheumatoid arthritis has a complex or multi-factorial inheritance in common 
with many diseases and the majority of non-pathological traits such as height, 
skin and eye colour. Disease onset is thought to occur when an individual 
with a susceptible genetic background encounters an environmental trigger or 
triggers (Nepom and Nepom, 1998). Both need to be present for the disease 
to develop and progress. However, it is important to recognise that non- 
genetic factors do not simply consist of exposure to an environmental 
influence such as infection but also include processes that may occur early in 
development (Seldin et al., 1999). The environmental trigger(s) may be 
unknown but some evidence does exist as to the genes involved in 
susceptibility. As a result of this rather complex interplay between genes and 
environment, any genetic associations with RA are unlikely to be a simple 
one to one correlation between a gene and a phenotype. The relationship is 
likely to be obscured by a considerable level of noise and will only be 
resolved by undertaking a large number of observations (Seldin etal., 1999).
1.2.2 Genetic predisposition to RA
Evidence regarding the genetic predisposition to rheumatoid arthritis is 
available from a number of sources. These include epidemiological studies 
documenting prevalence rates amongst the family members of a proband 
(familial aggregation), twin studies and case control studies showing 
association between rheumatoid arthritis and certain HLA-DRB1 alleles 
(shared epitope hypothesis, section 1.2.3). Variation in disease severity is
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also due (in part at least) to genetic factors. For instance, the number of 
erosions documented on a hand x-ray (one predictor of severity) is 
associated with the MHC class II genotype (Eberhardt et al., 1996; Harrison 
et al., 1999; MacGregor et al., 1995; Reveille e ta i, 1996).
1.2.2.1 Twin and family studies
Family studies show that the first-degree relatives of probands with RA are at 
increased risk of developing RA and that this is particularly true if the proband 
has severe RA (Lawrence, 1970). This lends support to the hypothesis that 
the genetic background of an individual contributes to RA pathogenesis. The 
relative recurrence risk ratio (X) is defined as the prevalence of the disease in 
the target group such as the siblings of probands (Ks) divided by the 
prevalence of the disease in the general population (K). Thus Xs = Ks / K. 
First degree relatives (with 50% gene sharing) such as offspring, parents or 
siblings are at greatest risk; this risk is reduced for second degree relatives 
(e.g. aunt, niece, grandchild); and less closely related individuals (e.g. first 
cousins) have a risk very near that of the general population (fig 1.2.1). This 
implies that a limited number of genes are required to have a genetic 
predisposition to RA and second-degree relatives are much less likely to have 
inherited the full complement of genes required in comparison to first-degree 
relatives. A recurrence risk in a complex disease is proportional to the 
population risk of the phenotype. This has relevance when studying a fairly 
common disease such as RA (section 1.2.2.2). Determining disease 
prevalence is subject to various methodological difficulties (section 1.1.2.1) 
and it is preferable to estimate disease prevalence and familial aggregation in 
the same population, using the same criteria (section 1.1.3). The disease 
severity in the proband will also affect the sibling recurrence risk (Xs). Where 
the proband has mild non-erosive sero-negative disease Xs is barely greater 
than unity but it increases in the siblings of patients with sero-positive erosive
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Recurrence risk ratio in Rheumatoid Arthritis
* A C T U A L S I N G L E  LOCUS - ± -  MULTIPLICATIVE
20 i
0 1 2 3
Relationship to proband
Fig 1.2.1 illustrates a recurrence risk curve drawn for RA using UK prevalence data. It can be seen that the recurrence risk 
falls sharply with increasing distance of relationship to the proband. Although much of the risk reduction seen with less 
closely related individuals is thought to be due to a difference in the extent of genetic similarity it is also likely that first- 
degree relatives will share more common environments than those who are more distantly related. The red line indicates 
the likely curve for a single locus model and the pink line the likely curve for a multiplicative model.
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disease (Lawrence, 1970). The recurrence risk ratio in the siblings of 
probands with severe disease may be as high as = 15 suggesting that 
genes are involved in determining disease severity (Wordsworth and Brown, 
1998). This is because the prevalence of severe RA in the general 
population (K) is lower than with milder forms of RA while the recurrence risk 
ratio is higher. Siblings of RA probands who share both HLA haplotypes with 
the proband are at particular risk of developing the disease (Nepom and 
Nepom, 1998).
Concordance rates in monozygotic twins vary between 12 and 30% but 
different methodologies have been employed in the studies. Lawrence 
studied twins with sero-positive erosive disease and obtained a disease 
concordance figure of 30% (Lawrence, 1970). This contrasts with the lower 
rate of 12% reported by Aho in a nationwide survey of twins, which included 
individuals with less severe disease (Aho et a/., 1986). A United Kingdom 
survey found an overall figure of 15% but reported that concordance rates 
were highest in monozygotic twins who were HLA DR4 positive (Silman et al., 
1993). These figures represent the results from cross-sectional studies in a 
disease where it is known that there may be a delay of up to 40 years 
between the development of the disease in the proband and that of the 
second twin. Hence there are problems in assessing the heritability.
1.2.2.2 Heritability
The study of twins has been the classical method of determining the extent of 
genetic and environmental influences on quantitative traits and disease 
predisposition. However, interpreting the results of these studies is often not 
straightforward. Rheumatoid arthritis is a good example. The MZ twin 
disease concordance from two large twin studies was between 12 -15% (Aho 
et al, 1986; Silman et al, 1993). This is often incorrectly assumed to indicate
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that the predominant influence in disease predisposition is environmental and 
the genetic contribution to disease is low. However, absolute levels of 
concordance are dependent on the population prevalence of a disease 
[MacGregor et al, 2000]. As the prevalence of a disease increases so too 
does the twin concordance, irrespective of the genetic contribution. 
Therefore twin concordance figures provide only a limited insight into the 
overall contribution of genetic factors. The estimation of ‘heritability’ is more 
readily interpretable and can better gauge the relative genetic and 
environmental contributions. ‘Heritability’ estimates the extent to which the 
variation in the population’s liability to disease can be explained by genetic 
variation. It is independent of disease prevalence and a quantitative estimate 
of the genetic influence. The estimate of RA heritability is in the region of 
60% (MacGregor et al, 2000).
Twin studies are unique in that they provide an estimate, unconfounded by 
age, of the extent of genetic influences on disease predisposition which can 
be estimated separately from the influence of the shared family environment. 
The magnitude of heritability determines the power and hence the likely 
success of programmes designed to identify specific genes involved in the 
disease (MacGregor et al, 2000). It also provides a yardstick against which to 
assess the relative importance of candidate genes that may be identified as 
being associated with disease. The genetic contribution to rheumatoid 
arthritis may not be constant across all disease subgroups. Rheumatoid 
arthritis is more prevalent in females, and its incidence and severity may be 
declining over time (Jacobsson et al, 1994; Linos et al, 1980). RA is more 
prevalent in families with other autoimmune diseases such as autoimmune 
thyroiditis or Type 1 diabetes mellitus suggesting the presence of common 
autoimmune susceptibility loci (Myerscough et al, 2000). The strength of the 
genetic association with HLA is reported to vary according to gender and 
disease severity phenotype and may also vary in different birth cohorts 
[Silman etal, 1983]. An understanding of the extent of the differences in
43
Class II region
The human leucocyte antigen (HLA) complex 




Class II region 
TAP1 DNA DQ
DPB2
DR subregion Fig 1.2.2b





\  DQB1 





Fig 1.2.2a illustrates the class 1, 2 and 3 regions of the human leucocyte antigen complex (FILA) I  Functional gene
on chromosome 6. An expansion of the class 2 region is shown in fig 1.2.2b where functional
genes are shown in black and pseudogenes in red. Genes within the DR, DQ and DP regions are I Pseudogene
shown. Subtypes of DRB1 have been associated with RA. This is an example of an HLA-DR3 ■
haplotype which has DRB1 and DRB3 loci.
genetic contribution between sexes and between those with different disease 
characteristics is therefore important if subgroups with increased genetic risk 
are to be targeted for linkage and association studies.
1.2.3 The Major Histocompatibility Region (MHC)
The major histocompatibility region (MHC) region maps to the short arm of 
chromosome 6 (6p21.3) and contains a cluster of genes governing immune 
reactions called the human leukocyte antigen (HLA) complex (Figs 1.2.2a and 
b). HLA class I genes, located at the telomeric end of the MHC region, 
include HLA A, B and C loci encoding the main transplantation antigens in 
humans. These are expressed on all nucleated cells and are highly 
polymorphic due to a high degree of allelic variation at each locus. The HLA 
class I heavy chain complexes with p2 microglobulin to form the mature HLA 
class I molecule. HLA class II genes are expressed on specialised antigen 
presenting cells including B cells, activated T cells, dendritic cells and 
macrophages. They are also highly polymorphic clustering into three main 
subregions, HLA-DR, DQ and DP. The mature class II HLA-DR molecule is 
formed from a and p polypeptides encoded by the HLA-DRA and DRB1 loci. 
The HLA-DQ and DP molecules are formed from the polypeptides encoded 
by HLA-DQA1 and DQB1 and DPA1 and DPB1, respectively
HLA class I and class II genes represent fewer than half of the known genes 
lying within the 4 megabases (Mb) of the human MHC. The HLA class III 
region lies between class I and II encoding, among other genes, the 
complement components C2, C4 and Bf. The TAP and LMP genes lie 
between the DQ and DP clusters encoding polypeptides implicated in HLA 
class I antigen processing and peptide processing. Other genes in this 
region with immunological functions include heat shock protein 70 (hsp 70) 
and tumour necrosis factor (TNF) (fig 1.2.2b).
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Most HLA alleles at a single locus have highly conserved nucleotide 
sequences with one or two specific sites of diversity, mainly in the 5’ proximal 
exons. These areas encode segments of the HLA molecule situated furthest 
from the cell membrane and include the recognition domains of the HLA 
molecule consisting of a deep groove or pocket. The floor of the pocket is 
made of p-pleated sheets and the sides a-helical loops. Most of the amino 
acid variation that distinguishes different HLA alleles occurs within this region 
because any amino acid variation can alter the properties of the antigen 
binding groove.
The main function of HLA molecules is to bind antigenic peptides and present 
them to T-cells, a process which allows the discrimination between self and 
non-self. Binding of the peptide depends upon the characteristics of the 
antigen binding groove which incorporates a number of pockets that 
accommodate the side chains of so-called anchor residues in the peptide 
(Doherty and Nepom, 1998). Differences in the amino acid composition of 
these pockets may have important effects on the array of peptides bound by 
a specific HLA molecule. An adequate ‘fit’ allows permissive binding to take 
place leading to antigen presentation and an immune response (if T cells are 
exposed to a ‘foreign’ antigen). A poor structural ‘fit’ means no binding, no 
presentation and no immune response. Hence, only those peptides able to 
bind to an HLA molecule have the potential to activate the immune response. 
With individual variation between HLA molecules, a peptide antigenic in one 
individual may not elicit a response in another if binding between the HLA 
molecule and peptide does not take place.
Antigen presentation by the class I pathway is distinct from that of the class n 
pathway. Cytosolic proteins (self and non-self) are proteolytically cleaved into 
peptides and bind to HLA class I molecules in the endoplasmic reticulum 
(ER). The class I-peptide complex is then transported to the plasma
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membrane where both the peptide and class I molecule are essential for 
binding and activation of an antigen-specific T cell. There is increased affinity 
between T-cell and antigen presenting cell when the T-cell co-receptor, CD8, 
binds to the class I molecule. This facilitates activation and accounts for the 
apparent ‘restriction’ of CD8+ cytotoxic T cells for MHC class I-associated 
antigens.
The Class II molecule is stabilised during formation in the ER by the invariant 
chain which blocks the peptide binding groove. This prevents association of 
peptide with the class II molecule whilst the molecule is in the ER. The class 
II-invariant chain complex then forms an acidic endosome outside the Golgi 
apparatus and partially digested ‘foreign’ material is deposited within this 
endosome. The acidic environment activates proteases to cleave the 
invariant chain allowing the ‘foreign’ antigen to bind to the class II molecule in 
the antigen binding groove. The class II-peptide complex then moves to the 
cell surface where it can be recognised by the T-cell receptor (TCR) (fig 
1.2.3). Affinity between the TCR and class II-peptide complex is increased 
by the antigen CD4 binding with the class II molecule. This accounts for the 
class II / CD4+ cell restriction.
Linkage disequilibrium (section 1.2.10.1) is common in the HLA region. 
Hence inheritance of a specific allele at one locus is frequently accompanied 
by the inheritance of a specific allele at another. Therefore if a particular HLA 
marker is associated with a certain disease the actual susceptibility gene may 
be the HLA marker itself or another nearby gene in linkage disequilibrium with 
that marker (i.e. different alleles tend to exist as haplotypes and these 
haplotypes are relatively fixed within a population). HLA associations have 










Figure 1.2.3 illustrates the association of the T cell receptor molecule, antigen and 
MHC class II molecule. Antigens are recognised by the a and p chains of the MHC 
which are expressed on the surface of the antigen presenting cell and the V regions 
of the T cell receptor.
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different genetic mechanisms are involved with these associations. For 
instance, HLA-DR3 is associated with systemic lupus erythematosis (SLE) 
and the C4A null allele is significantly increased in disease. However, the 
C4A gene is in linkage disequilibrium with the haplotype HLA-A1, B8, Cw7, 
C4A and DR3. This is an example where the HLA gene associated with 
disease is in linkage disequilibrium with the true predisposing gene. In some 
cases, two HLA genes interact. For instance the risk of developing RA with 
the genotype HLA-DRB1*0401 and DRB1*0404 is 1 in 7 whereas the risk of 
disease is only 1 in 35 for the genotype DRB1*DRB1*0401 / X (where DRX is 
not DRB1*04 or DRB1*01) and 1 in 20 for the genotype DRB1*0404 / X 
(Nepom and Nepom, 1998).
A number of different HLA-DRB1 molecules have been associated with RA. 
However, only certain HLA-DRB1 alleles are associated and these differ in 
different geographical locations despite the few specific structural or genetic 
differences between the DR4 alleles. The shared epitope hypothesis (SE) 
explains these variable results (Gregersen et al., 1987). HLA-DRB 1*0401 
and DRB1*0404 are the most commonly associated with RA (Wordsworth et 
al., 1989) and these alleles carry the sequence LLEQKRAA or LLEQRRAA 
between codons 67 to 74 of the DRp molecule. HLA-DRB1*0101, 
DRB1*0405 and DRB1*1402 also share the same sequence as DRB1*0404 
at this site and are associated with RA in populations with a low prevalence of 
HLA-DRB1*0401 and DRB1*0404 genes. DRB1*0405 is associated with RA 
in the Japanese population, DRB1*0101 with Israeli Jews and DRB1*1402 
with Yakima Indians (Nepom and Nepom, 1998) (table 1.2.1). HLA-DRB1 
genes not associated with RA have a different DNA sequence in this region 
frequently including negatively charged amino acids such as aspartic acid at 
position 70 or glutamic acid at position 71 nor 74. This area between codons 
67 to 74 forms part of the antigen binding groove and the fourth binding 
pocket; the size and shape of the groove could be altered by a positively or 
negatively charged amino acid hence determining peptide binding (Nepom
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HLA-DR associations with RA amongst different ethnic 
groups
IM P !
HLA-DR4 *0401 ++ N. European, N. American 
Whites, S. African Blacks
+ S. European, N. American Blacks
+ Italy, Greece
*0404 ++ N. Europe, N. American Whites, 
S. African Blacks
+ Chinese, Japanese, Polynesia
± Jews, Italy
*0405 ++ Japan, Polynesia
+ Chinese
± Jews, Greeks, S. African Blacks, 
UK
HLA-DR1 + S. Europe, Indians
± N. Europe, Jews, N. American 
Whites
HLA-DR10 ++ Spanish, Jews
+ Greeks, N. American Indians
± UK
HLA-DR6 ++ Yakima American Indians
Table 1.2.1 adapted from Wordsworth and Brown [Wordsworth, 1998] 
summarises the known of HLA DR associations with RA amongst different 
ethnic groups. The strength of the association is illustrated by the use of a + or 
-  sign, ++ indicating a strong and consistent association, + a weaker but 
consistent association and ± a weak or variable association
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1998). Therefore, it is the DNA sequence between codons 67 to 74 rather 
than any particular HLA allele which is the principle determinant of genetic 
susceptibility to RA.
HLA-DRB1*04 and DRB1*01 genes are fairly common within the Northern 
European Caucasian population (population frequency of 30 -  40% for 
DRB1*04 and 5 -15% for DRB1*01) but most individuals with this genotype 
are unaffected by RA. The risk ratio for RA is 1 in 20 for the genotype 
DRB1*0404 / DRX, 1 in 35 with DRB1*0401 / DRX and 1 in 80 for 
DRB1*0101 / DRX (assuming a disease frequency of 1%). The absolute risk 
for a compound heterozygote with the genotype DRB1*0401 and DRB1*0404 
is approximately 1 in 7 and some studies suggests this higher gene dosage 
also correlates with severity (Nepom and Nepom, 1998). The high population 
frequency of DR4 and DR1 makes screening for RA by HLA genotyping 
impractical and although there are advocates for its use in conjunction with 
testing for rheumatoid factor as a prognostic marker the evidence is 
inconsistent (Drossaers-Bakker et al., 2002; Eberhardt et al., 1996; Gough et 
al., 1994; Harrison eta!., 1999).
1.2.4 Complex inheritance
1.2.4.1 Threshold model
Complex inheritance can be fairly well explained by the threshold model. 
This suggests that a complex disease, such as RA, is a result of an individual 
inheriting a certain number of risk alleles from a range of potential genes. 
The number of ‘risky’ alleles inherited must reach a threshold level of genetic 
risk before an individual can be described as having a genetic susceptibility to 
the disease. The individual must then encounter or be exposed to a 
threshold of environmental factors or triggers. The combination of reaching
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both the genetic and environmental thresholds results in the development of 
the disease (Horwitz, 2000; Sham, 1998).
The recurrence risk for a complex disease is proportional to the population 
risk of the phenotype (section 1.2.2.2). The more ‘disease genes’ in the 
population, the greater the risk of disease recurrence in the offspring. The 
risk is also greater if more than one family member is affected as there will be 
more predisposing genes within the family and consequently the greater the 
risk of transmission from either or both parent(s).
This threshold for developing a complex disease may vary between men and 
women as is true of RA where the mean incidence rate is 3:1 in favour of 
women. The ratio is higher at a young age of onset implying that a man who 
develops RA under the age of 45 must have many more risk factors than a 
women developing disease at the same age, because the overall disease 
threshold is higher in a man. As a consequence the recurrence risk is greater 
in the offspring if the proband is male (Horwitz, 2000).
1.2.4.2 Models for genetic interaction
A multifactorial disease will generally involve two or more genetic loci that 
may interact in several ways. Epistasis is the term used to describe the 
interaction of two or more loci. An additive model describes the situation 
where the penetrance (section 1.2.4.3) of a disease is represented by the 
sum of the separate terms contributed by two or more loci. In a multiplicative 
model, the penetrance of a disease is represented by the product of separate 
terms (or penetrance factors) contributed by two or more loci. The 
heterogeneity model, assumes that genetic loci act independently (i.e. not 
epistatically) so that an individual can become affected through possessing a 
particular genotype at a locus regardless of the alleles at the other loci 
(Sham, 1998; Terwilliger and Goring, 2000).
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The number of genes involved in the predisposition to a complex disease and 
whether each of the contributory genes have equal weight in conferring risk 
are other factors to be determined when identifying a model. A polygenic 
model implies an infinite number of genes involved, all contributing a small 
but equal risk of disease. An oligogenic model suggests fewer genes (maybe 
between 5 to 10). Some of these genes may have major effects in conferring 
risk whereas others might make relatively minor contributions.
Identifying the genetic model underlying a complex disease such as RA is 
important because knowing how the loci interact allows certain assumptions 
to be made during the analysis which can improve the power of a linkage 
study (section 1.2.8.2). It is also helpful when attempting to show exclusion 
of a particular chromosomal region (section 1.2.8.3). However, it can be 
difficult and if incorrectly identified can lead to power reductions (section 
1.2.8.2). A way of choosing an appropriate multilocus model is to examine 
the recurrence risk in first, second and third degree relatives. The relative 
risks will decrease as the relationship becomes more distant. The rate of 
decrease can suggest a model for the disease loci interactions (Risch, 1990b; 
Risch, 1990c). For instance, under the additive model (which also applies for 
monogenic traits) the risks to successive degrees of relatives falls off at a 
steady rate but under the multiplicative model the recurrence risks decrease 
at a faster rate. The recurrence risk for relatives of an RA proband illustrated 
by fig 1.2.1. The decrease in relative risk in second and third degree relatives 
fits well with a multiplicative model and the rapid fall off in disease risk is 
clearly seen.
Parametric linkage analysis assumes that certain factors are known including 
the mode of inheritance, the allele frequencies, the phenocopy rate, the order 
and position of all markers, that all the diagnoses are correct and that the 
affectation status is known. Non-parametric linkage analysis (NPL) is used
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where no clear model of inheritance can be identified. The model assumes 
there is no interaction between alleles at different loci. If the correct model is 
known parametric linkage analysis is more powerful than NPL quite but 
significant power is lost if an incorrect model is used. Hence, NPL is often 
used when studying complex multifactorial diseases.
1.2.4.3 Penetrance and phenocopies
The penetrance of a particular genotype at a disease locus is the probability 
that individuals possessing that genotype will develop that disease. The 
penetrance of a disease is complete if all individuals with the high-risk 
genotype will eventually develop the disorder (if they live for long enough). 
The penetrance of a disease is incomplete, reduced or partial if not all 
individuals possessing the disease genotype develop the trait. Incomplete 
pentrances may be a function of many variables including age, sex, 
environment and the presence of certain alleles at other genetic loci.
An individual is said to be a phenocopy if they manifest the same phenotype 
(or disease) as individuals having a particular genotype but do not possess 
the high-risk genotype themselves. It is a term often used to refer to a 
disease state caused by non-genetic effects. The power of any method to 
detect linkage is reduced by phenocopies in a data set. The phenocopy rate 
is defined as the proportion of cases in the population that are phenocopies, 
while the sporadic risk is defined as the probability of the disorder developing 
in individuals without a high risk genotype (Sham, 1998). The effect of any 
particular disease locus will be partially obscured by phenocopies due to 
other disease loci or to environmental effects, an inaccurate clinical diagnosis 
or random errors in data gathering and transcription. The problem of an 
inaccurate clinical diagnosis is increased if the clinical criteria used to define a 
disease are too broad. This is a continuing problem with a disease such as 
RA or a connective tissue disease.
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1.2.5 Meiosis
All human cells are ultimately derived from a single cell, the zygote, formed 
by the union of two gametes, the ovum and the sperm. Each gamete 
contributes a half (or haploid) set of 23 chromosomes to form a full (or diploid) 
set of 23 pairs of chromosomes in the zygote. Normal gametes contain 22 
autosomes and one sex chromosome. Two chromosomes are homologous if 
they belong to the same family of chromosomes e.g. both chromosome 16. 
Homologous chromosomes are similar in length and sequence and as such 
humans have two copies of every gene. Every time a cell division occurs in 
the zygote the 23 pairs of chromosomes are duplicated and this is called 
mitosis. Gametes however undergo meiosis where daughter cells containing 
only a haploid set of 22 autosomes and a sex chromosome are formed. This 
ensures that the union of two gametes will produce the correct number of 23 
chromosome pairs. A recombination event occurs during meiosis when two 
chromosomes meet at a chiasma (or crossing point) and then separate 
leading to an exchange of genetic material between homologous 
chromosomes. Chiasma may occur at approximately equal frequency at any 
point along the chromosome. Chromosomes consisting of alternating 
segments of paternally and maternally derived DNA are formed. The 
reconstituted chromosomes then segregate independently into two daughter 
cells and these develop into gametes. With each generation the length of the 
DNA segments remaining in continued proximity to each other becomes 
shorter.
1.2.5.1 Mendel’s laws of independent segregation
Mendel’s first law of independent segregation states that genes occur in pairs 
and during gamete formation one of each pair is passed down to each 
gamete. The second law states that Genes controlling different characters 
segregate independently (Jacquard, 1978). This law is violated when two loci
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are linked, i.e., when the recombination fraction between them is less than 
0.5 (section 1.2.7.2)
1.2.5.2 Hardy-Weinberg equilibrium
Hardy-Weinberg equilibrium or law states that the frequency of alleles in a 
large population will be constant from one generation to the next, providing 
mating is random (i.e. the genotype does not influence mating) and the 
genotype has no selective effect on the success of the production of 
offspring. There are many possible explanations for a significant deviation 
from Hardy-Weinberg equilibrium. One possible reason is that the genetic 
basis of the trait has been mis-specified. Another reason is non-random 
mating in the population. One form of non-random mating is population 
stratification where matings between individuals from different strata are less 
likely to occur than matings between individuals from the same stratum. 
Another form of non- random mating is assortative mating, where the 
probability of mating between two individuals is related to their phenotype 
similarity. Non-random mating may also arise from prohibition against or 
encouragement for matings between certain classes of relatives. Even when 
matings are random deviations from Hardy-Weinberg equilibrium can arise. 
Differential survival distorts the relative frequencies of possible mating types 
and consequently the distribution of genotypes among offspring. The 
preferential loss of individuals with certain genotypes can have a direct effect 
on the distribution of genotypes in the surviving population. Preferential 
selection for individuals with certain genotypes in the sampling process can 





O  = female 
®  = affected female
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Fig 1.2.4 illustrates an extended family where individuals 4, 5 and 6 have 
RA (as indicated by symbols with a red colouring). Male or female gender 
are indicated by either a square or a circle respectively and a line crossing 
diagonally through a symbol denotes that the particular individual is dead. 
This applies to individuals 1 and 2 who were the parents of individuals 4 
and 5. Hence, it is impossible to tell definitively whether the ‘A’ allele 
shared by individuals 4 and 5 comes from the same parental chromosome 
because the parental information is completely missing. The ‘A’ allele is 
therefore described as identical-by-state (ibs) i.e. although the same 
marker is the same it may not have come from the same parental 
chromosome. Without the genotype of individual 3 it is impossible to 
determine whether individual 6 shares the A or the B allele in common with 
her father. With extremely polymorphic loci the ibs relationships will 
approximate the ibd relations
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1.2.5.3 Identity by state and identity by descent
The aim of linkage and association analysis is to identify excess sharing of 
certain alleles or haplotypes either in related individuals (linkage analysis) or 
unrelated people who share the same disease phenotype (association 
analysis). Linkage analysis can be undertaken using affected sibling pairs 
(ASP) who have been diagnosed with the same condition. The null 
hypothesis is that there is no excess sharing of specific alleles. However an 
allele can be identical by state (ibs) or by descent (ibd). Alleles may have the 
same value but they may not have descended from the same specific 
ancestral allele. In these circumstances they are said to be identical by state 
(fig 1.2.4). Testing for linkage based on ibs sharing is heavily dependent on 
the estimates of the allele frequencies used because the expected parental 
alleles are based on those estimates.
Two alleles are said to be identical by descent (ibd) if both alleles are 
descended from the same specific ancestral allele (fig 1.2.5). It is possible for 
two individuals to have the same allele without the alleles being ibd, e.g. 
children of a homozygous parent who each inherit a different parental 
chromosome.
1.2.6 Identifying disease susceptibility genes: linkage
and association analysis.
The classic strategy used to identify disease-causing genes begins with 
linkage analysis (fig 1.2.6). Systematic linkage screening of the entire human 
genome has the potential to detect all disease susceptibility loci. A 
methodical process of establishing linkage initially by coarse and then by fine 
mapping is undertaken. Once a region has been defined all genes mapping 
to the area are studied and mutations identified. Association studies can then 
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Fig 1.2.5 illustrates a nuclear family where both children have RA (as 
indicated by symbols with a red colouring). Male and female gender are 
indicated by a square or a circle respectively.
Individuals are identical by descent (ibd) if they share the same alleles 
and the ancestral origin of those alleles is the same. This can only by 
determined if both parents are heterozygous for the marker allele and all 
parental genotypes are available (unless sufficient unaffected siblings can 
be genotyped to infer the missing parental genotype). Power is improved 
by using ibd analysis as error rates are reduced (section 1.2.7.5).
If there is no linkage, the probabilities of the ASPs sharing zero, one or 
two alleles in common is 1/4, 1/2 and 1/4.
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alternative approach used to identify disease causing genes is to perform 
‘candidate gene’ studies using association analysis alone to evaluate a 
number of candidate genes without first performing a linkage study. Both 
methods are often used simultaneously (Terwilliger and Goring, 2000) (fig 
1.2 .6).
Linkage analysis is methodical but time consuming and expensive, both 
financially and in terms of DNA expenditure. It essentially generates 
hypotheses by identifying chromosomal regions where there may be 
candidate genes. The candidate gene approach is simpler, less costly but 
likely to miss a large number of potential candidate genes if used alone 
because only 15 -  20% of the 35,000 human genes have been identified to 
date. Association analysis is more powerful than linkage analysis but only 
over small chromosomal regions (i.e. thousands rather than millions of base 
pairs). Figure 1.2.13 illustrates the type of family that need to be recruited for 
linkage and association analysis.
1.2.7 Linkage analysis
1.2.7.1 Linkage analysis: the past, present and the future.
Linkage analyses using markers to follow disease inheritance have been 
undertaken since the 1950s in various different guises. Initially the markers 
were biochemical, based on blood groups and HLA, when at the time the 
chromosomal location of these markers was unknown.
In the 1980s restriction fragment length polymorphisms (RFLPs) were 
developed, based on the premise that for some marker sequences adjacent 
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Fig 1.2.6 Illustrates the significance of and differences between association and 
linkage analysis.
Fig 1.2.6a shows that association analysis can be performed using either a case 
control or a family based study design. Association analysis relies on linkage 
disequilibrium and therefore markers need to be placed close to the disease 
causing gene for the test to have the required power. For susceptibilty loci with 
a low relative risk (1.5 -  4) association methods can provide substantially more 
power than nonparametric linkage studies such as sibling pair analysis.
Fig 1.2.6b shows that linkage analysis does not depend upon linkage 
disequilibrium. No assumptions need to be made regarding mode of inheritance 
and information is still yielded even when markers are placed 1 0 - 2 0  -cM away 
from the disease causing gene. A marker with a high LOD score (logio of the 
odds for linkage) suggests that the disease causing gene may be nearby and is 
of greater significance if the linkage peak is narrow.
LOD
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the sequence between two restriction cleavage sites. However, the 
technique was cumbersome, DNA usage high and the markers not very 
informative. For a marker to be informative each parent should be 
heterozygous and genotypically distinct from her mate to allow inheritance to 
be easily traced (section 1.2.5.3). Hence for a marker to be informative a 
dozen or more alleles will be identified in the general population. Most 
RFLPs have just two or three different alleles but microsatellite markers 
(section 1.2.7) derived from polymorphic repetitive sequences of DNA, are 
highly informative.
Most linkage studies (to date) have been performed with PCR-based 
microsatellite markers consisting of variable numbers of dinucleotide CA 
repeats or tetranucleotide repeats of other sequences. Microsatellite 
technology is faster than RFLP, the markers are informative and less DNA is 
used. More than 5,000 microsatellites have been described widely dispersed 
throughout the genome (fig 1.2.7). In the future, most linkage studies will be 
undertaken using a third generation of markers called single nucleotide 
polymorphisms (SNPs). These have the advantage of high throughput, high 
marker frequency as SNPs can be found approximately every thousand base- 
pairs and genotyping is undertaken using new hybridisation technology [DNA 
chips]. Their disadvantage is that there can be four alleles in the population 
for any given SNP (i.e. at any single position there will be either A, C, T or G). 
But with the combination of high marker frequency and throughput, although 
the information content (section 1.2.8.2) per marker will be less, the overall 
information will be far greater if SNP haplotypes are studied. This has the 
potential to revolutionise the genetic analysis of complex traits by studying 
large numbers of people with sufficient power to examine genes with weaker 
effects.
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Fig 1.2.7 illustrates a microsatellite situated close to a gene and shows two 
of the microsatellite alleles. The PCR primers are designed to be 
complementary to short DNA sequences (approximately 20 bases) either 
side of the microsatellite (itself a series of dinucleotide CA repeats). The 
section of DNA between the primers is then amplified by PCR. In this 
example only alleles 1 and 2 of the microsatellite are shown although most 
microsatellites used in linkage analysis have between 10 to 20 alleles 
allowing for greater heterozygosity. Once the microsatellite is amplified the 
resulting products are separated using gel electrophoresis. Shorter 
fragments travel further and therefore allele 1 fragments will separate from 
allele 2 fragments and two bands will be seen if an individual is 
heterozygous for alleles 1 and 2.
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1.2.7.2 Linkage analysis: recombination fraction
The goal of linkage analysis is to determine whether two loci segregate 
independently during meiosis. Approximately one recombination event per 
chromosome occurs during meiosis, so the alleles of loci on different 
chromosomes segregate independently of each other. The alleles of loci on 
opposite ends of the same chromosome also segregate independently. 
However, when two loci are close together on a chromosome their alleles will 
be co-inherited more than 50% of the time and such loci are said to be linked 
(Terwilliger and Goring, 2000) (fig 1.2.8). The closer loci are to each other on 
a chromosome, the lower the probability of recombination of their alleles. 
This probability is referred to as the recombination fraction 6. Alleles at two 
linked loci tend to be co-inherited because any cross-over of genetic material 
during a given meiosis is unlikely to occur because of the physical proximity. 
Hence, 0 is correlated with (or proportional to) the physical distance between 
loci and the tightness of linkage is defined by recombination frequency 
(Horwitz, 2000; Terwilliger, 2000). The recombination fraction, 0, ranges 
between 0 (completely linked) and 1/2 (unlinked) and the essence of linkage 
analysis is to estimate the recombination fraction 0 and to test whether 0 = 
0.5 (null hypothesis).
The genetic distance between two loci is measured in terms of the expected 
number of cross-overs of genetic material, between loci, each meiosis. One 
Morgan (M) corresponds to the genetic distance over which one cross-over 
per meiosis is expected. One centiMorgan (cM) is equivalent to a 1% 
probability of a recombination per meiosis. As genetic distance is generally 
proportional to the physical distance between two loci, on average 1-cM 
corresponds to about 1 one million base pairs (one megabase (Mb)) of DNA 
(Horwitz, 2000). However, the correlation appears to be vary throughout the 
genome (Watkins et al., 1994). Genetic distance and recombination fraction 
in males and females between the same markers may be different, with 
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Fig 1.2.8 illustrates the likelihood of recombination between a gene and a 
marker during meiosis and depends upon the genetic distance between the 
marker and gene. One recombination per chromosome arm is expected 
during each meiosis. Marker A is more likely to remain co-segregated with 
the gene than marker B because it is nearer the gene. Linkage analysis 
tests for excess sharing of marker alleles between affected individuals, if 
recombination occurs between the marker and disease causing allele any 
excess sharing will not be identified. Hence markers where excess sharing 
has occurred are likely to be close to a disease susceptibility gene.
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genome is known, genetic linkage can be used to estimate of the 
chromosomal position of a second locus relative to the first. Genes 
predisposing to a phenotype can therefore be mapped relative to a large 
number of marker loci located at known positions throughout the genome. If 
these markers cover the whole genome this is described as a genome wide 
linkage analysis or whole genome screen. It is important to remember that 
linkage refers to the co-inheritance of two alleles at two loci that are physically 
linked on the same chromosome. It has nothing to do with phenotypic effects 
and a marker locus or genotype cannot be linked to a (disease) phenotype.
1.2.7.3 Assumptions made in linkage analysis
There are many assumptions made in linkage analysis. Some apply equally 
to parametric and nonparametric linkage analysis; other assumptions apply 
solely to parametric linkage analysis. As discussed above (section 1.2.4.2) 
parametric analysis assumes that certain factors are known including the 
mode of inheritance, allele frequencies, phenocopy rate and the order and 
position of all markers. Non-parametric analysis is frequently used where no 
clear model of inheritance can be identified and this model assumes there is 
no epistasis between alleles at different loci. It is also assumed that 
Mendelian segregation occurs with allele transmission and it is often 
assumed that there is no chiasma interference. Recombination between the 
marker locus and the disease locus is assumed not to have occurred but this 
cannot be the case in all circumstances. Any potentially common 
environmental effects are ignored and it is assumed that the phenotype 
depends solely on the genotype (penetrance 1.2.4.3). Random or non- 
assortative mating is assumed to have occurred and that the alleles of the 
study population are assumed to be in Hardy-Weinberg equilibrium. Finally, it 
is assumed that there are no genotype classification errors present in the 
data. This cannot be avoided in practice and occasionally the recombination 
status of a gamete may be misclassified (Terwilliger and Goring, 2000). This
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is one of the reasons why some analysis methods are not as robust when 
used for analysis of real data, despite performing well on simulated error-free 
data.
1.2.7.4 Linkage analysis using affected sibling pairs
The original sibling pair method was proposed by Penrose in 1935 (Sham, 
1998; Terwilliger and Goring, 2000) and is based upon the premise that under 
normal circumstances, there is an equal chance of two siblings inheriting the 
same parental allele at any particular marker locus. Therefore the probability 
that they share the same marker allele is 1/2. However, if both siblings are 
affected by the same genetically based condition they may be more likely to 
inherit a common allele from one or both parents (i.e. probability > 1/2). The 
chromosomal region surrounding the common disease allele should also be 
inherited by both. Therefore if a large number of affected sibling pairs (ASPs) 
were collected and genotyped the number of times a particular allele was 
inherited by both ASPs could be counted. The null hypothesis is that allele 
sharing between siblings is purely random. However, if there is excess 
sharing of a marker allele this implies linkage (figs 1.2.8 and 1.2.9). Affected 
sibling pair analysis does not depend upon a particular disease model and is 
often called non-parametric or model-free linkage analysis.
Non-parametric linkage analysis is most powerful when the identity-by- 
descent (ibd) or ancestral origin of the marker alleles can be determined 
(section 1.2.5.3). This is because ASP analysis tests whether each affected 
sibling pair shares 0, 1 or 2 alleles identical by descent. Therefore, the 
availability of parental DNA for marker-typing and highly informative markers 
is important. For a qualitative trait, ASPs should share alleles identical by 
descent more often than expected under random Mendelian segregation. For 
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Fig 1.2.9 illustrates an extended family covering four generations where a 
grandmother, her daughter, both grand-daughters and great grand son 
have RA (as indicated by symbols with a red colouring). Male and female 
gender are indicated by a square or a circle respectively and a line 
crossing diagonally through a symbol denotes that the particular individual 
is dead.
In this family the “a1” allele has been inherited by all individuals with RA. 
The a1 marker allele and the disease susceptibility gene are linked.
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magnitude of their phenotypic difference and the number of alleles shared 
ibd.
This method only indicates deviation from random inheritance. It has a 
number of advantages over traditional linkage analysis as it is generally 
easier to collect nuclear families rather than extended families and siblings 
are frequently more closely matched for age and environment than other 
relative pairs. No prior assumptions about the disease model, including 
parameters such as mode of inheritance, penetrance, phenocopy rate or 
disease allele frequency, are required. Hence, as discussed earlier, this form 
of analysis is more robust because linkage will not be missed as a result of 
any incorrect assumptions (fig 1.2.10). However, the traditional parametric 
analysis under a correct model is more powerful and will provide an estimate 
of the recombination fraction.
1.2.7.5 Linkage analysis: study design.
The power of a sibling pair study to demonstrate linkage at high levels of 
significance falls dramatically when Xs is less than 3.0 (Risch, 1990c). The 
number of pairs required to detect linkage at a given level of significance is 
approximately inversely proportional to the square of the (Sawcer et a/., 
1997). An optimal study design for a whole genome screen using ASPs is 
therefore the staged approach (Holmans and Craddock, 1997). The key to 
this method is the balance between the power required to detect weak 
genetic effects and the false positive rate. A moderate sized WGS has 
limited power to detect a logarithm of the odds (LOD) score of 3.0 to genes 
with a Xs < 2.0 but it has high (>90%) power to detect linkage at much lower 
significance levels, e.g. LOD score of 0.7 (nominal linkage, p<0.05). Many of 
the LOD scores (section 1.2.8.3) that exceed this threshold will be false 
positives, reflecting random excess sharing in the data set, but a proportion
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Affected sibling pair analysis
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disease gene
Fig 1.2.10 illustrates affected sibling pair (ASP) linkage analysis.
Pedigrees 1 and 2 represent nuclear families (i.e. mother, father and two 
affected siblings) where the mother and both offspring have RA. Marker B is 
close to the disease causing allele D on the mother’s chromosomes. The 
father has alleles d and b and is not affected by RA.
Pedigree 1 illustrates the situation where both offspring have inherited the 
marker B and the disease causing allele D from their mother and no 
recombination has occurred between disease allele D and marker B.
Pedigree 2 however illustrates the situation where one of the offspring has 
inherited the disease causing allele D but not the marker B because 
recombination has occurred. The other offspring has inherited D and B as 
usual. Hence these ASP will not both have inherited marker B which in the 
mother was inherited along with the disease allele D. Linkage analysis tests 
for excess sharing between ASPs if recombination occurs between the marker 
and disease causing allele this will not be identified.
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will reflect genuine linkage to genes will smaller effects. It is vital that the 
second stage has sufficient power to detect linkage at high levels of 
significance (LOD score > 3.0) in order to distinguish reliably the true and 
false positives identified in the first stage.
Initially a sample large enough to demonstrate any weak effects (with a low 
significance) is studied. Marker density is low with markers spaced evenly 
over the genome. For a complex disease a map density with a mean 
distance of 10-20cM probably gives the optimal balance between effort and 
power. Additional families and markers are then typed in regions showing 
nominal evidence of linkage. Each locus (e.g. p<0.05) must be investigated 
thoroughly with more markers and the addition of more ASPs until a higher 
threshold is reached (LOD> 3.0, p^2x10'5). If the size of the first data set is 
inadequate a weak effect may be missed and replication never attempted but 
if the size of the second sample is inadequate a true positive may not be 
replicated. Three factors predominately influence the power to detect a true 
positive. The first is the sample size; the second is the genetic effect and the 
third relates to the marker including the marker informativity and the distance 
from the disease locus. Genetic interactions, heterogeneity, penetrance and 
the frequency of a disease allele all affect the power of a study. Parental 
genotypes are valuable when checking for data error and can be used to 
determine a true allele frequency thereby avoiding the use of estimates 
(section 1.2.5.3).
The power of a study is frequently over-estimated for a number of reasons. 
Firstly, assumptions are made in the calculations that are frequently incorrect 
(section 1.2.7.3). In particular, it is assumed that the marker and 
susceptibility locus is completely linked and that the marker is fully informative 
(section 1.2.8.1). Although highly polymorphic microsatellite markers and 
multipoint analysis reduce the effects of recombination and non-informativity 
these assumptions remains at odds with reality. Secondly, error rates in the
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diagnosis, genotyping and data transcription all have significant effects on 
power. Thirdly, the number of markers typed will alter the power but the 
relationship between marker numbers and power is not linear. For instance, 
a ten fold increase in genotyping is required to reduce the mean marker 
interval from 20cM to 2cM but this only increases the linkage information by 
two fold (Hauser et al., 1996).
Variations in gene sharing between data sets are common. Genetic 
heterogeneity could explain these variations but random chance is probably 
responsible for most variations. In smaller sets of 100 or so fully informative 
sibling pairs values for ibd may vary dramatically. Data sets of 200 or more 
fully informative sibling pairs appear to provide more stable ibd values. A 
high density map of highly polymorphic markers is important when attempting 
to confirm real linkage as linkage evidence may decrease very quickly as the 
distance from the disease gene increases (Luo etal., 1996).
1.2.7.6 Linkage analysis: avoiding bias
There are several potential sources for bias in linkage studies. For instance, 
missing parental genotypes can be most easily deduced when their children 
show a variety of alleles. This will occur most often in cases when the 
children do not share alleles ibd. Hence, deducing such parents and using 
the families may incorrectly bias the results away from sharing.
Some families have multiple affected offspring but these pairs will not all be 
independent of each other. A variety of weighting functions have been 
proposed to correct for non-independence in large sibships (Cordell et al, 
2000; Greenwood et al, 1999; Hodge et al, 1984; Sham et al, 1997). One 
method is to use all possible pairs but correct for the fact they are not 
independent (MAPMAKER/SIBS). Other options are to select a single pair
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from each family (but this is rather conservative) or to use a single affected 
sibling paired with all other possible affected siblings.
In an intercross mating both parents have the same heterozygous genotype 
and therefore in a number of cases it is impossible to distinguish whether 
ASPs share 2 or 0 alleles ibd. Although these cases may be omitted from the 
analysis other intercrosses where sharing can be determined may be 
included resulting in a false excess of sharing 1 allele. This would bias %2 
statistic so intercross sibling pairs may be analysed with the t2 statistic or with 
the MLS method.
Accurate assessment of the phenotype (i.e. diagnosis) is essential for linkage 
studies. Diagnostic criteria should be employed to standardise the 
information. To avoid bias the persons who establish the diagnosis should 
not be informed of genetic marker data and the laboratory personnel should 
not be informed of the diagnosis.
1.2.8 Approaches to data validation
Error detection is very important and needs to be considered at all stages of a 
genetic study. Errors include an incorrect diagnosis, mis-specifying 
genotypes, DNA mix ups, data transcription, non-paternity, mis-specification 
of a pedigree (e.g. identifying a half-sibling as a full sibling) etc. Errors are 
inevitable when dealing with hundreds of families and hundreds of 
microsatellite markers requiring the identification of 250,000 or more 
genotypes (section 1.3.3). By methodically increasing the level of testing, 
error checks can detect increasingly subtle errors and is the most successful 
way to eliminate genotype classification errors and avoid the misclassification 
of the recombination status of a gamete. Some error detection can be 
performed by manually checking all genotypes and pedigrees but higher
73
levels of checking require specific programs. Error detection can be broken 
down into five categories which include errors in the allele frequency used, 
Menedlian inconsistencies, strange segregation, haplotyping and relationship 
errors
Comparing the allele frequencies of study data with published allele 
frequencies (e.g. from Genethon or Marshfield databases) can allow for a 
number of factors to be considered. These include the comparison of the 
expected versus the observed number of homozygotes and heterozygotes. 
Data should fit with Hardy-Weinberg equilibrium and the microsatellite marker 
controls should correspond to the expected number of base pair repeats. 
Both water lanes and microsatellite marker controls should be run with all 
gels to identify contamination.
Mendelian inconsistencies can be checked for at four levels of increasing 
sophistication. Level 1 checks for simple errors and includes the manual 
checking for pedigree inconsistencies (e.g. if the alleles of a child and a 
parent are incompatible or there are more than four alleles in a sibship). This 
level of checking can also be undertaken using the program GAS (Alan 
Young, unpublished). Level 2 checks for more subtle errors. A genotype 
elimination algorithm (performed automatically by the program pedcheck if no 
paternal DNA is available) can detect these more subtle errors (O'Connell 
and Weeks, 1998). Level 3 checking uses a critical-genotype algorithm and 
attempts to identify the possible error by “untyping” one individual at a time 
and applying a genotype elimination (pedcheck) to see if the inconsistency 
has been eliminated. Level 4 checking using an odds-ratio algorithm and for 
each critical genotype, the relative likelihood of a different alternative 
genotype is determined.
“Strange segregation” checking looks for a more than expected dissimilarity in 
ibd sharing among siblings (or affected relatives) i.e. the preferential
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segregation of an allele from heterozygous parents (transmission distortion). 
This type of checking can be undertaken using the 8 parameter of the 
program Gene Hunter plus (Cox et al., 1999b; Kong and Cox, 1997). 
Haplotyping using multipoint analysis can be used to identify excess double 
(or higher) recombinants within a small region. A number of programs are 
available to conduct multipoint analysis e.g. MAPMAKER/SIBS (version 2) 
(Lander et al., 1987), SimWalk (Sobel and Lange, 1996) and Gene Hunter 
plus (Cox et a!., 1999b; Kong and Cox, 1997). SimWalk is useful in that it will 
calculate the probability of the error likelihood, however the calculations are 
extremely time consuming when studying hundreds of ASP families and 
markers.
Relationship error checking is particularly important in sibling-pair analysis of 
a late onset disease, such as RA, where mistakes may go undetected since 
parental genotypes are commonly not known. This level of checking can be 
summarised by two questions: “Which relationship is most likely?” and “How 
likely is the observed ibs sharing, conditional on the assumed relationships?”. 
The verification of relationships can be determined using one of two programs 
RELPAIR (Boehnke and Cox, 1997) or Relative (Goring and Ott, 1997) which 
calculate the likelihood of the marker data, conditional on different assumed 
relationships. RELPAIR also looks for relationships across families allowing 
DNA mix ups to be identified and can identify the likely observed ibs sharing 
conditional upon the assumed relationship (as can ‘siberr’ by Wagner & Ehm 
(Ehm and Wagner, 1998)).
1.2.8.1 Marker informativity
A polymorphism information content (PIC) is the fraction of matings in which a 
parent is expected to be fully informative. A parent is fully informative if it is 
always possible to determine which of their alleles are inherited by their 
children. This will depend in part upon the genotype of their mate as
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information for linkage comes from doubly heterozygous people. 
Microsatellites are highly polymorphic markers and are therefore informative 
with a polymorphic information content (PIC) of approximately 0.8 for most 
microsatellite markers. Single nucleotide polymorphisms (SNP) will be less 
informative for linkage as at any one position there can only one of four 
possible nucleotides and many people will therefore be homozygous at a 
specific marker. However, SNPs occur every thousand or so base pairs and 
SNP haplotyping could be used to increase their informativity.
1.2.8.2 Power
Power is a test of the probability of rejecting the null hypothesis given an 
alternative hypothesis is true (i.e. the likelihood of a type 2 error). It is 
necessary to study very large numbers of affected sibling pair (ASP) families 
if adequate power to detect linkage to non-MHC genes is to be generated 
(Brown and Wordsworth, 1998). Recruitment is difficult in a late onset 
disease such as RA and may require international collaboration. Undertaking 
whole genome analysis on such large numbers of individuals is both 
expensive and time consuming.
1.2.8.3 LOD score
This is a log of the odds (LOD) in favour of linkage of a genetic marker to a 
phenotype as opposed to non-linkage (random segregation). It is the 
logarithm of the likelihood ratio. A LOD of 3 (interpreted as 1000:1 odds in 
favour of a conditional probability of linkage) is arbitrarily accepted standard 
for linkage for an autosomal disease (section 1.2.8.4). A LOD score of 3 
corresponds to a p value of about 2.2 x 10'5. A LOD of 3.6 is expected to 
occur by chance in 1 WGS in 20 (fig 1.2.10). LOD scores can be added 
across independent families.
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1.2.8.4 Levels of significance for whole genome linkage analysis
Corrections for multiple testing are required to avoid excess error in whole 
genome linkage analysis. In 1995 Lander and Kruglyak proposed a set of 
criteria designed to determine levels of significance for WGS (Lander and 
Kruglyak, 1995). Their proposals were based upon the number of likely false 
positives per WGS and are listed below.
• Suggestive linkage -  this is where statistical evidence of linkage is 
expected to occur at random (i.e. a false positive), once in one WGS 
(p<7.4 x KT4, or LOD (or MLS) = 2.2).
• Significant linkage - this is where statistical evidence is expected to occur
0.05 times in a WGS (p <2.2 x 10'5, or LOD = 3.6) i.e. once in 20 WGS.
• Highly significant linkage - this is where statistical evidence is expected to 
occur 0.01 times in a whole genome screen (p <3 x 10‘7 or LOD = 5.4).
• Confirmed linkage -  this is where significant linkage has been 
documented by one study or a combination of initial studies and has been 
subsequently confirmed in a further sample with a nominal p value of 0.01
The above standards are very difficult to achieve for complex traits, 
particularly those for highly significant and confirmed linkages. Several 
possibilities may explain the failure to confirm linkage in these studies. 
Firstly, these linkages may be spurious and no disease gene is encoded in 
these regions. Secondly, it may take many more ASPs to confirm these 
genes because they have such weak influences on the disease phenotype. 
Finally, it would be difficult to obtain significant linkage in the overall data set 
if the linkage evidence is heterogeneous from one subset to another.
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1.2.9 Various forms of analysis
1.2.9.1 Two point and multipoint analysis
Two-point (or single point) analysis fails to make use of the full inheritance 
information available as it is based on studying individual genetic markers 
one at a time i.e. if the number of shared alleles cannot be calculated 
unambiguously certain ASPs are not useful in the analysis. It is not always 
possible to determine the exact ibd status at every marker locus, particularly 
when parents are unavailable for study or are not fully informative. Under 
these circumstances only ibs information for the offspring can be determined. 
Equally, the ibd status at non-marker locations cannot be assessed.
Multipoint analysis uses the genotype information for each sibling pair, 
together with information about parents and additional siblings (where 
available) to infer the ibd distribution at each point along the genome. 
Information from nearby markers is used to increase the informativity at a 
potentially ambiguous marker (Fulker and Cardon, 1994). Multipoint analysis 
also allows for the construction of haplotypes which is important when 
checking for genotype errors.
MAPMAKER/SIBS is a statistical package that can be used to undertake both 
single and multipoint analysis. A number of other sibling pair analyses can be 
performed using MAPMAKER/SIBLINGS and these include:
• Exclusion mapping. This tests specific hypotheses about the degree of 
sharing at each location in the genome i.e. it is used to identify and 
exclude those regions unlikely to have a major effect on the trait and 
hence allow attention to be focused upon the remainder of the genome.
• Maximum likelihood mapping. This identifies loci involved in a qualitative 
trait.
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• Information content mapping. This assesses the extent to which the 
available genetic markers have extracted the full inheritance information at 
each location in the genome.
• Quantitative trait locus (QTL) mapping. This identifies loci involved in a 
quantitative trait by two parametric methods and one non-parametric 
method.
MAPMAKER/SIBS uses the Lander-Green algorithm (Lander et al., 1987) 
and as such is particularly suitable for small nuclear families or sibships since 
the amount of computation increases only linearly with an increase in the 
number of marker locations but exponentially with the size of the family.
The algorithm works by completely specifying, by an inheritance vector V,(S), 
the inheritance pattern of each pedigree P/; at each location S (Lander et al., 
1987). Each component of this vector corresponds to a particular meiosis 
and the co-ordinate 0 or 1 is given according to whether the offspring inherits 
the allele, (at position S) from the paternally or maternally derived 
chromosome. For each ASP the vector therefore has four components - two 
for each sibling. One specifies whether the mother’s maternally or paternally 
derived allele has been transmitted to the sibling and the other specifies the 
corresponding information for the father. The probability distribution for V,<S) 
at each location on the genome can be calculated conditional on the genetic 
marker data. To calculate whether the / th sibling pair shares 0, 1 or 2 alleles 
ibd at position s requires only the addition of the probabilities of the 
appropriate vectors.
For a qualitative trait, each locus can be characterised by the expected 
proportions Z0, Z* and Z2 of the affected sibling pairs sharing 0, 1 and 2 
alleles ibd. Mendelian proportions (ao, ai and 012) are 1/4, 1/2 and 1/4. 
Holmans defined the “possible triangle” in 1993 and z0, Z1 and Z2 will lie within 
this:
i.e. Z0 + Z1 + Z2= 1
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and Z1< 1/2 [1]
and Z* £ 2( Z0)
If no dominance variance is assumed, this is the equivalent to the constraint 
Zv = 1/2 [2]
the sharing proportions are then described by the single parameter Z2
If only a single locus is involved, the sharing proportions (Z0, Z* and Z2) can 
also be expressed in terms of relative risks (Risch 1990a). If Xs is the relative 
risk ratio for a sibling, X0 is the relative risk ratio for an offspring and A.m is the 
relative risk ratio for a monozygotic twin, then the following relationships hold:
Zo ~ OCo / A.s,
Z1 = (a i x A,0) /  A,s; [3]
Z2 “  (oc2 X /  s^;
A*, the relative risk ratio for a sibling, is defined as prevalence in the siblings 
of affected individuals divided by the population prevalence.
If no dominance variance is assumed:
Xo A/s
and Xm -1 = 2(^s -1) [4]
The relationships hold if multiple loci are involved in the trait and interact 
multiplicatively.
1.2.9.2 Maximum likelihood mapping
To identify regions of significant excess allele sharing, the maximum 
likelihood values of the allele-sharing proportions (Zo, Z^  and Z2) are 
estimated at each location along the genome. The maximum LOD score Z(S) 
at each location is computed. The likelihood of the observed data (arising 
under these maximum likelihood values) is compared to the likelihood under 
random Mendelian segregation. MAPMAKER/SIBS allows the calculation of 
the maximum likelihood proportions (Zo, Z^  and Z2) in two forms: subject only 
to the "possible triangle" constraint (equation 1) or subject to the additional 
constraint of no dominance variance (equation 2). A LOD score can never be
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negative because the maximum likelihood solution (Zo, Zi and Z2) at each 
location is never worse than the random Mendelian segregation. To limit the 
genome-wide false-positive rate to 5%, a LOD score threshold of 4.0 is used 
when implementing the "possible triangle" method. This corresponds to a 
single-test significance level of 2 x 10'5 and the calculations are based upon 
the use of an infinitely dense map. However, this significance level is 
recommended even when using moderately spaced markers for two main 
reasons. Firstly, it is anticipated that the marker density will be increased in 
regions showing suggestive evidence of linkage and similar studies are likely 
to be carried out on the same sample. Secondly, the increase in stringency 
over and above the 5% level is comparatively small.
Information-content mapping makes clear whether the vast majority of the ibd 
information has been extracted. It focuses attention on the regions where 
additional markers would provide substantially more information e.g. increase 
or decrease the LOD score in a region with a suggestive result. A simulation 
study can be undertaken as part of the study design to explore the effects of 
map density, marker polymorphism rate and availability of parents for 
genotyping. Assuming a heterozygosity rate of 75% (similar to that of the ABI 
LMSvII marker set used by the UK WGS (chapter 2)), a 10-cM map extracts 
~85% of the ibd information at the markers and approximately 70% midway 
between markers (when parents are available). This falls to 65% and 55% 
without parental DNA (Kruglyak and Lander, 1995). The increase in power of 
multipoint analysis over single-point analysis is greater in studies where 
parents are unavailable (Kruglyak and Lander, 1995). However, in these 
circumstances the marker allele frequencies are very important and if mis- 
specified can lead to false-positive results. Under-estimating the frequency of 
an allele will lead to over-estimating the degree of ibd. If reliable estimates of 
allele frequencies from an appropriate population are available they should be 
used. If this is not possible, a number of software programs such as 
RECODE or DOWNFREQ allow the estimation of allele frequencies to be
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undertaken using all the unrelated individuals from the study or all the 
unrelated individuals and a proportion of the ASPs. A sensitivity analysis can 
be performed to test the sensitivity of the results to changes in allele 
frequencies. Also, the lower allele frequency boundary can be set for all 
alleles making it difficult to under-estimate allele frequencies and thus the 
corresponding LOD scores will be conservative.
1.2.9.3 Exclusion mapping
This is a method to exclude regions of the genome that are unlikely to encode 
susceptibility genes. A LOD score of -2  is the conventional threshold for 
excluding a site from linkage.
1.2.9.4 Genetic models and calculation of expected sharing
In order to determine the power of a linkage study or when attempting to 
show exclusion it is necessary to calculate the expected ibd allele sharing 
that would be observed at one of many possible disease loci. To do this it is 
necessary to model how the disease loci interact to determine the trait 
phenotype. A way of choosing an appropriate multilocus model is to examine 
the risks in relatives of differing degrees. The relative risks will decrease as 
the relationship becomes more distant. The rate of decrease can suggest a 
model for the disease loci interactions (Risch, 1990b; Risch, 1990c). For 
instance under the additive model (and this also applies for monogenic traits) 
the risks to successive degrees of relatives falls of at a steady rate but under 
the multiplicative model the recurrence risks decrease at a faster rate.
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1.2.9.5 Conditional analysis
Conditional analyses of marker can be undertaken by dividing the total 
sample into subsets defined by variation at some other markers (e.g. HLA). 
Such stratification procedures have been used in a number of studies aiming 
to strengthen evidence for linkage. However, the interpretation of results can 
be difficult (Concannon et al., 1998). For the procedure to enhance the 
power to detect linkage, the locus being tested must show a large difference 
in ibd amongst subsets. If the joint effects of two or more loci are non­
additive, the differences seen in ibd after stratification will not be large and if 
the effects are exactly multiplicative no differences in ibd amongst the 
subsets will be identified. However, if the genetic effects are additive 
differences in ibd can be seen but may not be large enough to substantially 
increase the power to detect linkage.
Conditional analyses with modest sample sizes can produce inconsistent 
results as illustrated by the first WGS in insulin-dependent diabetes mellitus 
(Concannon et al., 1998). Two groups reported that the evidence for linkage 
at FGF3 on 11q13 (IDDM4) was much stronger after they had conditioned on 
HLA sharing (or HLA type). However, one group found increased evidence 
for linkage in the subgroup of ASPs who shared HLA alleles but the other 
group found increased evidence in those ASPs who did not share at HLA 
(Davies et al., 1994; Hashimoto et al., 1994). Contradictory findings such as 
these cannot be interpreted as strengthening the evidence for linkage.
1.2.10 Association analysis
The essential difference between linkage and association is that linkage is a 
relationship between loci and association is a relationship between alleles. 
Even very close linkage is not sufficient to cause population association.
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Population association between allele X and disease Y can occur for three 
reasons:
• Allele X can directly cause susceptibility to disease Y. If so, the same
allele X should be associated with disease Y in any population studied,
unless the cause of disease varies between populations.
• If the disease bearing chromosomes in the population are descended
from a few ancestral chromosomes then very close linkage can
produce allelic association at the population level. If linkage 
disequilibrium (section 1.2.10.1) is the cause of the association a gene 
should be discovered near locus X which has mutations in people with 
disease Y. However the particular allele at the locus X which is 
associated with disease Y may be different in different populations.
• Population stratification could be involved (sections 1.2.10.3 3.3.5). 
People with disease Y and those without may be genetically different 
subsets of the population who coincidentally may also have different 
frequencies of allele X. An example is the association between HLA- 
A1 and the ability to eat with chopsticks in the San Francisco Bay area 
(Lander and Schork, 1994). HLA-A1 is more frequent among Chinese 
than Caucasians.
Population based case-control studies of disease-marker associations can 
therefore be problematic for two main reasons. If suitable controls are not 
sought these studies may not be able to distinguish between linkage 
disequilibrium and population stratification. It is essential that patient and 
controls studied come from the same population so that any comparison of 
gene frequencies will be valid. Within family association studies e.g. 
transmission disequilibrium testing (TDT) have been developed to avoid 
some of these problems. TDT (Spielman et al., 1993) can avoid population 
stratification but cannot distinguish associations caused by linkage 
disequilibrium from those where the marker itself is the susceptibility factor. 
These studies involve more work than the standard case-control study as
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three individuals (proband and parents) are typed and in a late onset disease 
such as RA both parents may not be available. Secondly, if the statistical 
analysis is not rigorous enough inadequate corrections may be made for the 
number of questions posed. Each test performed carries an independent risk 
of a false positive result. A Bonferroni correction is sometimes applied and 
the threshold of significance is set at p=0.05/n where n is the number of 
independent potential associations checked. If n loci with m alleles each are 
tested the rigorous correction factor would be n(m-1). The inconsistency of 
published association studies may be due, in part, to this lack of rigorous 
correction.
Two ‘unrelated’ people in the UK would typically share common ancestors 
about 22 generations (500 years) ago and if fully outbred, would have 222 = 4 
million ancestors each. In the 15th century the population of Britain was 
around 4 million. Assuming the UK population interbreeds freely, only about 
44 meioses separate two unrelated individuals. Loci showing 1% 
recombination per meiosis would therefore have a better than 50% chance of 
remaining in the same combination through 44 meioses ((0.99)44 = 0.64). 
This suggests that allelic associations may be noticeable for loci within 1cM of 
each other. Given that the human genome is 2644cM a complete genome 
scan for markers in linkage disequilibrium with a disease would require at 
least 3000 markers. Corrections for multiple testing would need to be very 
robust suggesting only extremely strong associations would be significant 
after correction. Hence, testing for linkage disequilibrium is generally 
restricted to a candidate region where there is an a priori hypothesis.
1.2.10.1 Linkage disequilibrium
Linkage disequilibrium occurs when a particular marker allele is associated 
with the disease-trait locus at a greater than expected frequency across
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multiple families. When a marker and a disease locus are very close together 
on a chromosome genetic crossover will have occurred at such a low rate 
that the marker will appear to cosegregate with the gene regardless of the 
family studied. This is in contrast to the situation where the two loci are 
further apart but still linked in which case repeated crossing over will allow all 
possible combinations of chromosomal haplotypes to appear with frequencies 
as predicted by the equation for Hardy-Weinberg equilibrium. In general, the 
stronger the disequilibrium the closer the marker to the disease locus. 
However, allele frequencies and mutation rates at the marker locus also 
effect the level of observed disequilibrium. Linkage disequilibrium may be 
due to recent population bottlenecks or new mutations. With time and further 
recombinations the nearby loci will return to an equilibrium.
The term linkage disequilibrium is sometimes used interchangeably with the 
term allelic association. Allelic association refers to a significantly increased 
or decreased frequency of occurrence of a marker trait in combination with a 
disease trait. It can be explained either by biological interaction of the marker 
allele with the disease-trait gene or by linkage disequilibrium.
The goal of linkage disequilibrium analysis is to map loci relative to each 
other and thereby estimate the genomic position of new loci of unknown 
position using loci of known location. Linkage disequilibrium mapping, 
although generally conducted using unrelated individuals can be viewed as a
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Transmission disequilibrium testing 
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Fig 1.2.11 illustrates the principle of transmission disequilibrium 
testing or TDT analysis. This is a form of family based association 
testing.
The offspring (red circle) has inherited A and C alleles from the 
parents and the untransmitted parental alleles are B and D. TDT 
analysis compares the frequency of specific alleles transmitted to an 
affected offspring or proband with the frequency (in the parents) of 
the alleles that are not transmitted. The untransmitted parental 






linkage study involving an extremely large hypothetical pedigree with many 
generations of indeterminate structure and availability of DNA only in the 
bottom generations. As discussed above these individuals are in fact, 
distantly related. Association tests measure the linkage disequilibrium 
present between a trait allele and nearby marker loci.
1.2.10.2 Relationship between association and linkage analysis
Both linkage and association analysis have been designed to detect non- 
random co-inheritance of alleles at two loci. Linkage analysis depends on 
studying sets of related individuals. Association analysis appears to study 
unrelated individuals but it depends upon the fact that those subjects are, in 
reality, distantly related. Closely related individuals are descended from 
common ancestors via a small number of meioses and tend to have large 
segments of chromosomes in common. Distantly related individuals are 
separated by large numbers of meioses and therefore have only small 
chromosomal segments in common following numerous recombination 
events. This is the reason why association analysis has a finer resolving 
power compared to linkage analysis but also why it is not as sensitive to 
loose linkage. In some respects they represent two ends of a continuous 
spectrum. Association analysis could be seen as a form of identity-by-state 
analysis between very distant relatives. However, random events cannot be 
fully defined because the exact ‘relationships’ between the individuals cannot 
be fully defined.
1.2.10.3 Transmission disequilibrium testing (TDT analysis)
TDT analysis can identify both linkage and linkage disequilibrium. Only 
linkage disequilibrium can distort the distribution of marker genotypes among 
the parents of affected individuals in comparison to the distribution of 
genotypes in the general population. However, the ability to detect linkage 
disequilibrium only applies if the sample consists of unrelated cases and
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parents (Sham and Curtis, 1995) but it is a valid test of linkage in all 
situations. TDT analysis considers the probabilities of marker allele 
transmission from heterozygote parents to affected individuals, and the 
distortion of these probabilities from 0.5 can only occur if the marker and 
disease loci are linked. This assumes there is no overall distortion from 
Mendelian segregation at the marker locus in the population. The test 
effectively considers the allele transmission from the father and mother of 
affected individuals to be independent events (fig 1.2.11). This assumption is 
valid if the recombination fraction is very small. Occasionally this is untrue 
and in those circumstances the TDT can lose some of the information 
available in the sample. However the assumption holds in most 
circumstances. The TDT can be used to test for association using both 
affected singleton data and affected sibling pair data. It was originally 
designed for bi-allelic markers but has been extended for multi-allelic markers 
(Spielman and Ewens, 1996) and quantitative traits (Abecasis et al., 2000; 
Allison, 1997; Rabinowitz, 1997). It avoids the potential problems of 
population stratification that can occur in case control association studies 
because the ‘control’ alleles are the untransmitted parental alleles (sections 
1.2.10 and 3.3.2). Possible sources of bias occur if parental DNA is 
unavailable when bi-allelic markers are used even if parental genotypes are 
inferred from the offspring genotypes (Curtis, 1997).
1.2.10.4 Monte Carlo Simulation
This is undertaken to provide an empirical estimate of the significance level of 
the maximum LOD score obtained from the actual data (fig 1.2.12) (Kaplan et 
al., 1997). In each simulation disease phenotypic data are retained but 
marker phenotypic data are generated under the null hypothesis of non­
linkage between the disease and marker loci. Therefore the pedigree 
structures and the disease phenotypes are kept but the marker phenotypes of
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Figure 1.2.12 illustrates the principle behind Monte Carlo 
simulation. A series of simulated data sets are generated 
using the pedigree structure and disease phenotypes of the 
actual data set but with generated marker phenotypes based 
on population allele frequencies. The maximum LOD score is 
calculated and compared to the LOD score of the actual data. 
The proportion of simulated data sets for which the maximum 
LOD score exceeds the maximum LOD score of the actual data 
provides an estimate of the support for linkage.
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the founders are generated according to the population allele frequencies and 
the marker phenotypes of the non-founders are generated according to 
Mendelian segregation without regard to disease phenotypes. For each 
simulated data set, the maximum LOD score is calculated and compared to 
the LOD score of the actual data. The proportion of simulated data sets for 
which the maximum LOD score exceeds the maximum LOD score of the 
actual data provides an estimate of the extent of support for linkage. Monte 
Carlo simulations also provide an estimate of how informative the data set is.
If there is no linkage the labels “transmitted and non-transmitted” can be 
permutated and the labels for each heterozygote parent in the sample are 
shuffled. The statistic is recomputed and then this procedure is repeated 
many times. The proportion of times that the statistic is larger than or equal 
to the observed value gives an estimate of p-value.
1.2.10.5 Haplotype
A haplotype is a set of alleles from closely linked loci inherited as a unit from 
the same parent. Traditional haplotyping simply specifies the parent from 
whom each child’s allele is descended. However a more complete form of 
haplotyping can be undertaken that specifies the parental allele from which 
each child’s allele is descended i.e. specifies grandparental source 
information (ibd).
Haplotyping was initially designed to make genetic data used in linkage 
analysis more informative. A locus is informative if parental allele can be 
inferred. For instance, a locus will be fully informative where both parents are 
heterozygotes and have no common alleles. However, for an individually 
uninformative loci, a highly polymorphic ‘mega-locus’ or haplotype can be 
constructed from a number of uninformative but closely linked loci. This 
combined ‘mega-locus’ is often informative at nearly all matings and this
91
Family pedigrees needed for linkage and association
studies
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Fig 1.2.13 illustrates the family pedigrees required for affected sibling pair (ASP) linkage 
analysis and family based association studies or TDT analysis. Circles represent 
females, squares males and solid symbols in red represent affected individuals. 
Symbols with a diagonal line represent deceased individuals.
Pedigrees A and C represent the families required for linkage analysis and pedigrees B 
and D represent the families required for association analysis. Pedigree A is the ideal 
family to be collected for linkage studies because DNA availability from both parents 
improves the power of the study. The next ideal family for linkage analysis would be a 
one parent family. If neither parent remains alive then pedigree C allows the parental 
genotypes to be inferred from the offspring’s genotypes. The least useful pedigree is 
that where DNA can only be collected from two affected siblings.
Pedigree B is the ideal family to be collected for TDT analysis.
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principle will be used in third generation WGS using SNPs and DNA 
microarray technology.
Haplotyping can also be used to identify genotyping or data entry errors. 
Errors indicating in non-Mendelian inheritance are easy to detect but mis­
typing a true 2/2 child as a 1/2 when both parents are 1/2 is difficult to detect. 
However, haplotyping across this locus should highlight the possibility that the 
child’s typing was in error if for instance the haplotyping reveals a double 
recombination (one recombination on either side of the questionable allele).
1.2.10.6 Case-control analysis
It can be difficult to obtain an ideal data set for analysis especially in a 
clinically and genetically heterogeneous disease such as RA. It is tempting to 
devote a disproportionate amount of time to recruiting cases rather than 
controls. Often ‘control’ populations in genetic studies are derived from blood 
donors about whom there may be relatively little information. It is possible 
that the controls and cases may not come from the same population leading 
to potential sources of error. Alternatively, the individuals may come from the 
same population but this population may be composed of non inter-mating 
subpopulations leading to population stratification (sections 1.2.10 and 3.3.2). 
Unless family trees are available or very detailed questions regarding 
grandparents are asked it can be difficult to be certain when recruiting an 
individuals for a study whether their genetic background is similar to that of 
the other cases or controls. For instance, recruitment of individuals classified 
as Caucasoid gives a scope for a wide range of genetic backgrounds, from 
Celts to Anglo-Saxons to those from the Southern Mediterranean. Detailing 
genetic background can be time consuming and such questions may lead to 
fewer numbers recruited. However, case control studies are efficient with 
regard to the ratio of cases to controls genotyped. Recruitment is easier than 
for ASP analysis or TDT analysis. Provided the control populations used are
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An example of a LOD score curve
,The evidence for 
linkage is most likely 
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Fig 1.2.11 illustrates the relationship between a LOD score and 
recombination fraction in linkage analysis. When the LOD score at a marker 
is below -2, linkage at the marker is effectively excluded, if the LOD score at 
a marker is above 3.6 significant linkage is likely. Between a LOD of 2.2 and
3.6 linkage is suggested and between a LOD of 0.8 and 2.2 there is nominal 
evidence for linkage.
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appropriate case control studies can be a useful additional method of 
investigation. Once families have been used to undertake haplotype analysis 
these haplotypes can be investigated in case control studies.
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Chapter 1 -  section 3
Chapter!, section 3
Laboratory procedures and techniques
The importance of statistics in human genetic research is clear and there are 
strong historical links between genetics and statistics. However, many of the 
advances in the science of genetics in recent decades are largely due to the 
emergence of new laboratory techniques. These techniques have 
transformed the approach to fundamental and applied molecular biology. The 
ability to amplify specific segments of DNA made possible by the polymerase 
chain reaction (PCR) is a corner stone technique that should be included in 
this category. PCR is an integral part of most genetic studies and was used 
as the basis for all the experiments described in this thesis.
1.3.2 Polymerase chain reaction (PCR)
PCR was invented by Kary Mullis in the mid-1980s (Mullis et al., 1986) and 
was originally applied to the amplification of human p-globin DNA for the 
prenatal diagnosis of sickle-cell anaemia (Saiki et al., 1988; Saiki et al., 
1985). Specific DNA sequences can be synthesised in vitro using two 
oligonucleotide primers that hybridize to opposite DNA strands flanking the 
region of target DNA. A repetitive series of cycles involving denaturation, 
primer annealing, and the extension of the annealed primers by DNA 
polymerase results in the exponential accumulation of a specific fragment the 
size of which is defined by the 5’ ends of the primers (fig 1.3.1). Primer 
extension products synthesised in one cycle serve as a template in the next, 
therefore the number of target-DNA copies approximately doubles with each 
cycle. Twenty cycles of PCR yield about 220 amplification. The purification of 
highly thermostable DNA polymerase from Thermus aquaticus (Taq DNA
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polymerase) and the introduction of the thermal cycler has enabled the 
automation of PCR. In the original experiments the PCR process involved 
moving the samples between heat sources of differing temperatures and the 
addition of further DNA polymerase each cycle because of the thermal lability 
of the E. coli DNA polymerase used at that time.
DNA polymerase enables the addition of a dNTP at the free 3’ hydroxyl group 
of the synthetic strand. This strand is complementary to the homologous 
strand. The annealing temperature is critical for ensuring that there is 
complementary binding of the oligonucleotide primer to its complementary 
sequence. Any mismatch at the 3’ end of the primer will mean that the 3’ 
hydroxyl group will not be recognised by the DNA polymerase as a site for 
new DNA synthesis.
Many different factors and techniques can alter the outcome of a PCR 
reaction. Varying the reaction parameters (e.g. changing the Mg2+ 
concentration or temperature cycling profile) can alter the specificity and yield 
of the reaction. For any given pair of oligonucleotide primers an optimal set 
of conditions can be established but no single set of conditions will be optimal 
for all possible reactions. Higher temperatures and Mg2+ concentrations 
increase the overall stringency of the reaction minimising the extension of 
primers that are mismatched with template. The concentration of the target 
sequence in the genomic template also influences the homogeneity of the 
PCR product (Saiki et al., 1988). Non-target fragments can be produced if 
there is little target sequence. If there is insufficient Taq enzyme in the later 
cycles annealed primer-template complexes may not be fully extended in a 
single cycle period and a plateau effect can occur resulting in reduced 
efficiency. Other factors such as re-association of the template strands when 
the product concentration is high may also contribute to this effect. The error 
rate for Taq polymerase PCR is in the region of 1 in 104 cycles which does
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not pose a problem for most applications apart from sequencing (Goodenow 
e ta i, 1989; Tindall and Kunkel, 1988).
The possibility of contamination in the amplification reaction has broad 
implications for both research and diagnostic applications. Given the capacity 
of PCR to synthesise millions of DNA copies, contamination of the sample 
reaction with either the product of a previous reaction (product carryover) or 
the material from an exogenous source is a potential problem. Careful 
laboratory procedure include the pre-aliquoting of primers, the use of specific 
pipettes for loading PCR products into gels and the physical separation of the 
reaction preparation from post-PCR product. Minimising the number of 
reaction cycles also can reduce the chance that a rare contaminating 
template DNA will be amplified. ‘Blank’ lanes where no DNA template is 
added to the reaction mix must also be included to detect potential 
contamination.
Primer selection is very important as primers more than anything else will 
determine the success or failure of an amplification reaction. Certain 
guidelines can help with their design.
• Generally primer length should be between 18-24 bases in length
• Where possible select primers with random base distribution and avoid 
primers with repetitious stretches of CCCC or AAAA etc. particularly at the 
3’ end.
• Check primers against each other for complementarity. Especially avoid 
primers with 3’ overlaps to reduce the incidence of ‘primer dimer’. ‘Primer 
dimer’ is an amplification artefact and occurs if the primers are 
complementary to each other or if many cycles of amplification are 
performed on a sample containing only a few initial copies of DNA 
template. The resulting concatenation is an extremely efficient PCR 
template and if amplified at an early cycle can overwhelm the reaction.
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• Avoid sequences with significant secondary structure, particularly at the 3’ 
end.
• Try to keep the GC content of the primer at a fixed level comparative to 
the AT content. The nucleotides cytosine and guanine are bound together 
by triple hydrogen bonds whereas thiamine and adenine are bound by 
double hydrogen bonds. Triple hydrogen bonds require more energy to 
break them than double hydrogen bonds. The melting temperature of the 
ds-DNA will therefore vary accordingly depending upon the GC versus AT 
content.
The specificity and yield of an amplification depend largely upon the 
concentration of Mg2+ and annealing temperature. Concentrations of 1.5 -  2 
mM are optimal with 200pM of each dNTP. Optimal temperatures depend 
upon the Taq used and while some Taq enzymes are designed to work 
immediately others require a ‘hot start’ e.g. 10 minutes at 94°C. Avoiding 
contamination, optimising the conditions and using the correct Taq enzyme 
are of paramount importance.
PCR is one of the integral steps in many basic molecular biological 
techniques. Sequencing of the whole genome (Consortium, 2001) would not 
have been possible without PCR. Other applications include: the 
amplification of microsatellites (section 1.2.7.1), the identification of SNPs by 
direct sequencing, the detection and quantification of gene expression by 
synthesising a cDNA PCR template from an mRNA transcript using a reverse 
transcriptase and the ability to engineer or modify DNA fragments (e.g. 
producing primers with fluorescent tags attached). The process has been 
increasingly steam-lined in recent years. With the advent of DNA microarray 




Sample preparation is also of great importance. Whatever the sample, the 
aim is to obtain a high DNA yield as free from contamination as possible and 
high molecular weight DNA rather than degraded DNA. DNA can be 
extracted from whole blood (using a variety of methods -appendix 5.3), from 
clinical swabs, synovial fluid, plucked hairs, tissue etc. If contamination with 
cell debris occurs whilst DNA is being extracted from whole blood the yield 
will be poor and the subsequent experiments difficult. Contamination can 
lead to difficulty with PCR and later with the assignment genotypes etc. Once 
whole blood is taken from the patient it is either frozen directly or frozen after 
the blood has been spun down and the leukocytes have been separated from 
the red cells. If whole blood has been frozen for more than a few months it 
can be more difficult to extract DNA and the yield may be reduced. 
Spectroscopy is performed to determine the DNA yield and purity of the 
sample (appendix 5.3).
Once extracted, conservation of DNA by careful husbandry is the next 
important step. Large quantities of DNA are frequently required for studies 
especially when undertaking genome wide linkage analysis where multiple 
genotypes are needed for each individual (section 2.2.3.3). It is 
unreasonable to expect volunteers to give more than about 20mls of blood at 
one time and there are problems, both ethically and logistically, in 
approaching an individual on more than one occasion for blood. Therefore 
ways must be found to conserve DNA or produce more DNA from the original 
sample. As technology develops methods to conserve DNA have improved 
but it is still necessary to be able to generate additional stocks of DNA where 
patient collections have taken considerable time and resources to put 
together. The Arthritis Research Campaign (ARC) UK family collection in RA 
has been recruiting RA families for about eight years. Two types of families 
are collected and include ASP families where DNA is available from two or 
more siblings with RA and also their first-degree relatives. The most useful
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family of this type has when DNA available from both parents. The second 
type of family are singleton families where only one individual has RA but 
DNA is available from both parents. The ASP families are used for linkage 
studies and the singleton families are valuable for candidate gene research. 
Both types of families take time to collect; many individuals need to be 
approached, examined and bled and these families are relatively uncommon 
(especially the ASP families).
The ARC UK RA family collection holds labelled DNA stock in -70°C freezers 
but also has immortalised cell lines so that additional family DNA can be 
generated. Generating this additional disease DNA is time consuming and 
expensive therefore the conservation of DNA stocks remains important. DNA 
can be amplified by PEP PCR. This is a PCR amplification reaction which 
randomly amplifies DNA segments using randomly generated PCR primers 
(appendix 5.3). The DNA produced by this method is less robust than DNA 
produced directly from peripheral blood extraction and storage at 
temperatures other than -70°C for any length of time or frequent changes in 
temperature by freeze-thawing increases the likelihood of poor PCR results. 
The PCR amplification reaction is quite time consuming and the reagents 
expensive but it is a useful way of extending the capacity of a small quantity 
of DNA if multiple genotypes are required. It is very important when diluting 
DNA produced by this method that the sterile water used for the dilution is 
thoroughly mixed with the PEP DNA. If water is added and the resulting 
dilute DNA is then aliquoted into Costar plates for subsequent PCR reactions 
unless thorough mixing has taken place the DNA concentrations may vary 
between the different aliquots. This is especially noticeable between the first 
and last aliquots and can lead to PCR problems such as difficulty in assigning 
genotypes.
DNA is less robust to changes in temperature etc. when diluted. PCR 
reactions are often performed with dilutions of 10ng/pil therefore, repeated
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freeze-thawing should be avoided and the dilute DNA should not be kept for 
any more than a few days at 4°C in a fridge. Equally, it should never be kept 
out on a laboratory bench for longer than necessary. This applies to all the 
reagents used to make up a PCR reaction mix. All should be kept on ice, 
especially the Taq polymerase.
Avoiding frequent freeze-thaw cycles for the dilute DNA or primers requires 
planning when undertaking a large study such as a genome wide linkage 
analysis. If many genotypes are required for many individuals, two 
approaches can be taken. Either a single primer can be used for all the DNA 
samples in one go (avoiding freeze-thawing the primer) or all the primers (~ 
450) can be studied in one box of DNA at a time. A ‘box’ of DNA includes the 
90 or so DNA samples that can be accommodated in each Costar plate. This 
second method can lead to primer degradation therefore the first approach is 
often used (especially as once a microsatellite has been amplified and 
separated for all individuals single point analysis of that primer could be 
undertaken).
The number of DNA freeze-thaw cycles can be reduced if the DNA is diluted 
to the necessary working concentration (often 10ng/jal) prior to aliquoting 
small volumes into Costar plates and then freezing. The volumes of the 
diluted frozen DNA need to be large enough to allow for 20 -  25 PCR 
reactions. This will be enough to amplify the 15 -  20 DNA fragments per 
primer set and allow for any PCR failures to be repeated. The number of 
primers per set will be determined by the number of microsatellites that can 
be run simultaneously on a polyacrylamide gel (which in turn will depend 
upon their size and fluorescent tag). For each set of microsatellites, the 
diluted DNA can be thawed and then aliquoted into suitable volumes for a 
single PCR reaction. The PCR mixes for each microsatellite can then be 
made, added to the DNA and a PCR reaction performed. Samples from each 
completed PCR reaction are then tested using an agarose gel. If any set falls
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below a certain standard the PCR reaction is redone. The standards may 
vary depending upon circumstances but for the data presented in this thesis 
the standard used was 90 per cent PCR success (or more) on an agarose gel 
otherwise the PCR was repeated before the samples were run on a 
polyacrylamide gel. Once all microsatellites in a set have been successfully 
amplified the PCR products are diluted, mixed together and then separated 
by electrophoresis on 6% polyacrylamide gels using an ABI 373 semi­
automated DNA sequencer (Applied Biosystems, Warrington, UK) over three 
hours or on 4% polyacrylamide gels and an ABI 377 DNA sequencer over two 
hours (section 2.3.3.7, figs 2.2.1 and 2.3.2). The optimal dilutions are 
determined by running a fluorescent test gel of diluted PCR products. Once 
the amplified PCR products have been successfully separated they are sized 
using the program GENESCAN™672 (version 2.1) (Applied Biosystems, 
Warrington, UK) and genotypes semi automatically assigned using the 
program GENOTYPER™ (version 1.1.1) (Applied Biosystems, Warrington, 
UK) (figs 2.2.3 and 2.3.3). A PCR product from a DNA reference sample 
(CEPH 1347-02) is included on every gel to monitor possible gel-to-gel 
variation. This sequence is applied to each set of primers.
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Chapter 2 -  section 1
CHAPTER 2: LINKAGE ANALYSIS
Systematic linkage screening of the entire genome and a 
replication study 
• Introduction
Linkage analysis is an integral part of the search for susceptibility genes. 
Only the major histocompatibilty complex (MHC) on chromosome 6 has been 
consistently linked to and associated with RA susceptibility (Oilier and 
Thomson, 1992)(section 1.2.3) although family studies suggest that this 
accounts for just one-third of the genetic susceptibility (Deighton et a/., 1989; 
Wordsworth, 1991). It is likely that a number of other susceptibility loci exist, 
each contributing less than the MHC to the total genetic component. Given 
the small increase in disease risk for siblings (sibling recurrence risk or = 6 
-14) (Deighton and Walker, 1991) any non-MHC susceptibility genes are 
likely to be of relatively small effect. Systematic linkage screening of the 
entire genome has the potential to detect all disease susceptibility loci if 
appropriately powered. However, it is necessary to study very large numbers 
of affected sibling pair (ASP) families if adequate power to detect linkage to 
non-MHC genes is to be generated (Brown and Wordsworth, 1998). 
Recruitment is difficult in a late onset disease such as RA and may require 
international collaboration. Undertaking whole genome analysis on such 
large numbers of individuals is both expensive and time consuming. 
Therefore the strategy has been to perform genome-wide screens on 
manageable numbers of families aiming to study any overlapping regions of 
nominal linkage (p<0.05) reported in two or more independent data sets in
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greater detail with larger numbers of independent ASPs (Holmans and 
Craddock, 1997).
Three genome-wide linkage screens studying ASP families with rheumatoid 
arthritis have been reported. The studies have varied in size and have 
included 41 Japanese (Shiozawa et al., 1998), 97 European (Cornelis et al., 
1998) and 251 North American ASP families (Jawaheer et al., 2001). 
Linkage to the MHC was confirmed (p< 2.5x1 O'5) in the European (ECRAF) 
and North American (NARAC) studies (Cornelis et al., 1998; Jawaheer et al., 
2001). All three studies identified a number of non-MHC regions with 
evidence of nominal linkage (p<0.05) and a few regions with suggestive 
linkage (p<0.001). It is inevitable that many apparent linkages will be false 
positives (Lander and Kruglyak, 1995), hence, all findings need to be 
confirmed in independent data sets. Candidate regions likely to contain true 
RA susceptibility loci are those where nominal linkage (p<0.05) has been 
reported in two or more of these studies. The eight regions on chromosomes 
3q, 8p, 12q, 14q, 16p, 16q, 18q and Xp (Cornelis et al., 1998; Jawaheer et 
al., 2001; MacKay et al., 2002) where this has occurred are summarised in 
table 2.1.1.
No linkages outside the HLA region have been confirmed (p<2.5x10'5) in RA 
and the very large numbers of ASPs required to detect linkage to genes of 
small effect may mean that some regions of true linkage may have been 
missed. Hence, further genome-wide linkage screens studying ASP families 
with RA are of value. Larger studies are less prone to type 1 or type 2 error 
and any overlapping regions identified in another independent cohort of ASPs 
with RA will increase the likelihood that one of the candidate regions listed in 
table 2.1.1 contains a true RA susceptibility locus.
Once regions of nominal linkage have been identified (particularly overlapping 
areas) replication studies can be undertaken. These can be efficient in terms
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of time and resources so larger numbers of individuals can be genotyped 
(Holmans and Craddock, 1997). Also with fewer markers studied the 
adjustment required to correct for multiple testing will be smaller (section 
1.2.8.4).
Two studies are reported below, both undertaken in collaboration with the 
ARC Epidemiology unit, at Manchester University. The first is a replication 
study undertaken in 1998/99 before the publication of the North American 
genome screen (Jawaheer et al., 2001). It was designed to confirm in a 
larger independent cohort of 368 ASPs 25 regions of nominal linkage as 
reported by the European genome screen (Cornelis eta l., 1998) (table 2.2.1). 
The second is a genome-wide linkage analysis of 182 UK ASP families (252 
ASPs). This WGS was initiated because it was important to identify 
additional sites of nominal linkage in an independent cohort of ASPs with RA. 
It was undertaken prior to the NARAC study and included more that twice the 
number of ASPs studied by ECRAF (thereby improving power). Hence, the 
aim was two-fold: to determine whether there were any overlapping regions of 
nominal linkage in the independent cohorts of RA ASPs and secondly to 
identify novel regions of nominal linkage (which may not have been identified 
in the ECRAF cohort of only 114 ASPs). If the UK ASPs had been used as a 
replication cohort only any novel regions would not have been identified and 
maybe important areas for further study missed. Although the costs of a 
WGS (both in terms of time and money) are high these could be justified as 
only one moderate sized WGS had been published at that time. As more 
data becomes available efforts should be aimed at replicating already 
identified sites of nominal linkage with high density markers.
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2.2 Linkage analysis of putative non-HLA rheumatoid
arthritis susceptibility loci in 368 UK affected 
sibling pair families.
2.2.1 Abstract
Objective: Using an independent cohort of 368 United Kingdom sibling pairs 
affected by rheumatoid arthritis (RA), this study was designed to test for 
linkage to candidate susceptibility loci identified in the first systematic linkage 
screen of the whole genome in RA
Methods: Using 59 informative microsatellite markers 368 affected sibling 
pairs (ASPs), from 280 families, were genotyped. These microsatellites 
mapped to regions identified in the first genome-wide linkage study in RA. 
Markers mapping in the region of estrogen synthase were also analysed 
based on previous reports of linkage to this gene. Automated genotyping 
was performed using fluorescent PCR primers and ABI DNA sequencers. 
Statistical analysis was undertaken using ANALYZE for single point analysis 
and MAPMAKER/SIBS (version 2) for multipoint analysis.
Results: Markers on chromosomes 12, 15, and 21 (d12s95, CYP 19,
d21s1252) showed evidence of nominal linkage (p<0.05) by single point 
analysis. However, no evidence of nominal linkage was found following multi­
point analysis.
Conclusion: Consistent evidence of linkage was not found for any of the 
regions previously reported as potential non-HI_A RA susceptibility loci in a 
large independent cohort of UK RA ASPs.
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2.2.2 Introduction
The first systematic linkage screen of the whole genome of individuals with 
RA was published in 1998 and was undertaken using 114 RA affected sibling 
pairs (ASPs) from 97 families (Cornelis et al., 1998). These ASPs were 
recruited from a number of European countries including France, Italy, Spain, 
Holland, Belgium. Linkage to HLA was confirmed (p<2.5x10'5) and nominal 
evidence of linkage (p <0.05) was obtained for a further 14 regions (19 
markers) based on multipoint analysis and for a additional eight regions 
based on single point analysis (Cornelis et al., 1998)(table 2.2.1). Two of the 
regions (18q22-23 and 3q13) contained loci previously linked to insulin- 
dependent diabetes mellitis (IDDM-6 and IDDM-9). These were investigated 
with additional markers in a second cohort of 194 European ASPs but further 
support for linkage was only found for the IDDM-9 region on chromosome 3 
when all individuals were analysed together (Cornelis etai ,  1998).
A second much smaller study of 41 Japanese families suggested linkage with 
regions on chromosome 3, 8 and X (Shiozawa et al., 1998). Unusually, 
linkage to HLA was not confirmed in this study which may demonstrate ethnic 
differences in susceptibility genes or may be as a result of the smaller 
number of ASPs studied. Linkage to the marker CYP 19 on chromosome 15 
has been demonstrated in two large samples (225 and 107) of UK RA ASPs 
(John et al., 1999). CYP 19 is a polymorphic tetranucleotide marker in intron 
D of the estrogen synthase locus. The evidence for linkage was strongest in 
patients with an age at onset that was >50 years.
The results of linkage analysis of candidate loci in a large independent cohort 
of UK RA ASPs are reported below. The candidate loci were identified from 
the ECRAF study but also include Cyp 19 following the reports of linkage 
above.
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European whole genome screen in RA: results of single 
and multipoint analysis
D1S228 32.4 0.0035 0.0065
D1S238 206.7 0.022 0.099
D2S377 228.2 0.024 0.013
D2S2354 235 0.0043 0.0054
D3S1267 141 0.032 0.039
D5S422 163.9 0.033 0.045
D6S292 138.2 0.036 0.034
D12S99 13.9 0.0077 0.083
D12S95 97.7 0.0067 0.043
D13S170 65.4 0.039 0.015
D13S1315 105.2 0.00035 0.0037
D14S285 50 0.049 0.33
D16S420 43.2 0.047 0.039
D16S401 45.5 0.008 0.028
D18S57 63.2 0.018 0.033
D18S474 71.3 0.038 0.012
D18S68 94.4 0.032 0.02
D18S61 102.8 0.0016 0.0098
D18S469 109 0.0055 0.02
D20S864 0 003 0.11
D21S270 41.3 0.038 0.11
D21S268 44.9 0.025 0.13
D22S264 0.9 0.019 0.0098
DXS1068 56.2 0.044 0.27
DXS998 183.8 0.0078 0.019
Table 2.2.1 summarises the results of the genome wide linkage analysis 
undertaken using the European consortium of RA families (ECRAF) [Cornelis, 
1998], This WGS examined 97 families, containing 114 ASPs. Significant 
linkage to the HLA region was observed, as expected. This table shows the 
additional 14 regions identified that were compatible with nominal linkage 
(P<0.05 without correction for multiple testing). Results for single and 
multipoint analysis are shown. Nominal linkage was identified at more than 
one marker in some of the regions.
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2.2.3 Methods
RA Affected Sibling Pairs
Three hundred and sixty-eight UK Caucasian sibling pairs, affected by 
rheumatoid arthritis, were studied. The affected sibling pairs, from 280 
families, were identified from the Arthritis and Rheumatism Campaign United 
Kingdom (ARC-UK) National Repository of family material 
(www.htto://arc.man.ac.uk). Table 2.2.2 documents the pedigree structure of 
the 368 ASPs and table 2.2.3 the number of siblings per family. The affected 
sibling pairs and their families were recruited following a nation-wide publicity 
campaign in newspapers and local radio. Rheumatologists throughout the 
UK also identified ASPs who were willing to enrol in the study. Multi-centre 
ethics committee approval was obtained. All family members were examined 
according to a standard protocol and agreed to a detailed structured interview 
regarding joint symptoms. A trained metrologist performed a joint 
examination to detect swelling, tenderness and deformity. Individuals with 
erosive disease were identified from hand radiographs (all reviewed by a 
rheumatologist) and rheumatoid factor (RF) status (ascertained using a 
particle agglutination test). Subjects were classified as having rheumatoid 
arthritis if they satisfied the 1987 American College of Rheumatology (ACR) 
criteria (Arnett et al., 1988) modified for genetic studies (MacGregor, 1995) 
(section1.1.3 and table 1.1.3).
DNA from the affected individuals and their first-degree relatives was 
prepared from peripheral blood. Technicians employed by the ARC-UK 
National Repository performed all the DNA extraction according to standard 
techniques. Concentrated DNA, received from the ARC-UK National 
Repository on ice, was kept in labelled tubes at -70°C at the Wellcome Trust 
Centre from Human Genetics (WTCHG) in Oxford or the Arthritis Research 
Campaign Epidemiology Unit (ARC-EU) in Manchester. It was diluted with
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A fluorescent gel from the replication study
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Fig 2.2.1 shows a fluorescent gel from an ABI 373 having been run through the software package 
Genescan^. The red lines are marker lines allowing the software package Genotyper" to determine 
the size of each microsatellite allele relative to the known size of the markers. The yellow, blue and 
green lines are the fluorescently tagged microsatellites. Each column represents one individual and up 
to 20 microsatellite markers per person can be separated by PCR provided the fragments of a similar 
size are tagged by a different fluorescent colour.
sterile water to 10ng/jal before use. Dilute DNA was kept at 4°C for the 
duration of the study.
Microsatellite markers
Eighteen regions with nominal evidence of linkage (p<0.05) identified by 
single or multi-point analysis in the European RA WGS (Cornelis et al., 1998) 
were included for study. A 16cM region containing the CYP 19 locus on 
chromosome 15 was also included. Fifty-nine suitable and informative 
microsatellites within these regions were identified (Table 2.2.4). Where 
possible the same microsatellite markers as used in the European RA WGS 
were chosen but when this was not feasible markers nearby were included. 
The microsatellites chosen needed to complement each other with regards to 
their PCR product size so that they could be run together on polyacrilamide 
gels (12-15 microsatellites per lane).
Microsatellite genotyping
Semi-automated analysis of microsatellite genotypes was carried out in two 
centres; the Wellcome Trust Centre for Human Genetics (WTCHG), Oxford 
and the Arthritis Research Campaign Epidemiology Unit (ARC-ERU), 
Manchester. The microsatellites were amplified by PCR using fluorescently 
labelled primers. Reactions were carried out in 96 well plates (Costar) in 
10pL reactions consisting of 50ng DNA, 400nM each primer, 50pM each 
dNTP, 1-3mM MgCI2 and 0.2 units DNA polymerase (Bioline, UK) in the 
manufacturers NH4 buffer, overlaid with liquid paraffin. The cycling conditions 
were 32 cycles of denaturation (1 minute, 95°C), primer annealing (30 
seconds, 55°C - 60°C) and extension (30 seconds, 72°C). Annealing 
temperatures and MgCI2 buffer concentration were optimised for each primer. 
Amplification of each microsatellite was performed separately and the PCR 
products were then combined into pools of 10 -  12 markers before loading. 
Products were separated by electrophoresis either on 6% polyacrylamide 
gels using ABI 373 semi-automated DNA sequencers (Applied Biosystems,
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Genotyper for the marker D21S1252
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Fig 2.2.2 Shows the Genotyper™ output for the marker D21S1252 
using the families 189 and 196. Once the microsatellite D21S1252 
has been amplified by PCR and the fragments separated by gel 
electrophoresis using the ABI 373, the output is run through the 
software package Genescan™ to appropriately align the PCR 
fragments with the red marker fragments and then the result is run 
through Genotyper™. This sequence allows for the size of each 
PCR fragment (or microsatellite allele) to be identified.
Warrington, UK) over three hours (WTCHG) or on 4% polyacrylamide gels 
and ABI 377 DNA sequencers over two hours (ARC-EU). Test gels were run 
to ensure the PCR dilutions were optimised prior to separating PCR products 
by electrophoresis. Products were sized using the program 
GENESCAN™672 (version 2.1) (Applied Biosystems, Warrington, UK) and 
genotypes semi automatically assigned using the program GENOTYPER™ 
(version 1.1.1) (Applied Biosystems, Warrington, UK) (figs 2.2.1 and 2.2.2). A 
PCR product from a DNA reference sample (CEPH 1347-02) was included on 
every gel to monitor possible gel-to-gel variation.
Statistical analysis 
Error checking:
To minimise data errors error-checking procedures were employed. Allele 
assignment by GENOTYPER™ was checked manually for all genotypes and 
the CEPH (Centre d’etude des polymorphisms humaines) control sample was 
used to ensure the consistency of allele assignment. The program GAS 
(Version 2) (A. Young, unpublished) was used to convert the size data into 
discrete allele numbers and samples not following Mendelian patterns of 
inheritance were identified in PEDCHECK (O'Connell and Weeks, 1998) and 
removed from the data set.
Non-parametric analysis:
Allele frequencies were calculated from all of the scored genotypes using the 
software packages DOWNFREQ (J. Terwilliger, unpublished) (WTCHG) or 
SPLINK (version 1.05, David Clayton, MRC Biostatistics Unit, Cambridge) 
(ARC-EU). Sibling pair analysis methods were then used to test for excess 
allele sharing between affected siblings. Non-parametric single point and 
multipoint analysis was implemented in MAPMAKER/SIBS (version 2) 
(Kruglyak and Lander, 1995). Multiple sibships were given a conservative 
weighting of 2/n to account for their lack of independence (Meunier et al., 
1997).
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Between 3 and 8 siblings per family 113
2 siblings (only) 92
Table 2.2.2 shows the pedigree structure of the families included in the 
replication study. For every affected sibling pair (ASP) additional first-degree 
relatives were recruited in order to ascertain the identity by descent of each 
allele studied. This table documents the availability of DNA from parents or 
additional siblings for each ASP family used in the UK replication study. If 
parental DNA was unavailable, unaffected siblings were recruited and 
genotyped if possible allowing the missing parental genotypes to be inferred. In 





Table 2.2.3 shows the number of ASP families recruited for the replication study 
and the number of ASPs per family. Some of the families included were made 
up of multiple sib-ships of between 3 and 8 RA affected siblings and the number 
of multiple sib-ship families are documented here.
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Analysis of markers on the X chromosome was carried out using 
MAPMAKER/SIBS modified for X-linked loci (Cordell et al., 1995). The 
program calculates sharing between sister-sister, brother-brother and sister- 
brother affected sib pairs.
Both multipoint and single point analyses have been presented. The 
suggested thresholds of LOD > 3.6 (p£2x10'5) for significant linkage and LOD 
> 2.2 (p ^ ^ x ic r4) for suggestive linkage have been used (Lander and 
Kruglyak, 1995). Nominal evidence of linkage was taken to be LOD > 0.8 
(p<0.05) by either multipoint or single point analysis (section 1.2.8.4).
2.2.4 Results
The results of the non-parametric, single point and multipoint analysis 
implemented in MAPMAKER/SIBS are shown in table 2.2.4. Fifty-nine 
informative microsatellite markers were genotyped successfully in more than 
85% of individuals. Nominal evidence for linkage was identified for three 
markers by single point analysis: D12S95 (p<0.05), CYP19 (p<0.05) and 
D21S1252 (p<0.02). Multi-point analysis, using MAPMAKER/SIBS, did not 
provide further evidence for linkage.
2.2.5 Discussion
Three markers (D12S95, CYP19 and D21S1252) on chromosomes 12, 15 
and 21 showed nominal evidence for linkage (p<0.05) by single point 
analysis. Multi-point analysis did not provide further evidence for linkage. 
The marker D12S95 (chromosome 12) was also included in the European 
WGS and showed nominal evidence of linkage in that study by both single
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Replication study: results table
Marker Distance from T (cM) LOD (SP) p value (SP) LOD (MP) Marker
Distance 
from T (cM) LOD (SP) p value (SP) LOD (MP)
D1S2667 26.9 0 0.5 0 D13S 1315 105.2 0.011 0.41 0
D1S2740 32.2 0.08 0.27 0 D13S 285




D1S434 32.2 0 0.5 0 D14S 276 47 0.1 0.25 ND
D1S228 32.4 0 0.5 0 D15S 994 43 0 0.5 0
D1S 507 36.2 0.43 0.08 0 D15S 119 51 0 0.5 0
D1S2672 38 g 0.5 0 CYP19 51 1.2 0.02 0
D1S 196 186.4 0.021 0.38 o" D15S 992 51 0.14 0.27 0
D1S238 206.8 0.014 0.4 0 D15S 962 55 0.18 0.2 0
D1S413 216.5 0.18 0.18 0 D15S 117 59 0 0.5 0
D2S 2308 234.5 0.006 0.43 0 D16S 420 43.2 0.057 0.3 0
D2S 2354 235 0.023 0.37 0 D16S 401 45.5 0 0.5 0
D3S 3649 136.7 0 0.5 0 D16S3100 50.8 0.09 0.26 0
D3S 3567 139.9 0 0.5 0 D16S 3040 110 0.017 0.39 0
D3S 1267 141 0 0.5 0 D18S 1102 63.1 0.13 0.22 0
D3S 3646 141.1 0 0.5 0 D18S 465 98.9 0 0.5 0
D3S 1589 143.8 0.27 0.2 0 D18S 488 104.6 0.25 0.14 0
D5S410 156 333331I x ND D18S 469 109 0 0.5 0
D6S 1684 144 0 0.5 ND D18S 462 118 0 0.5 0
D6S 144 155.3 0 0.14 ND D20S 117 2.9 '3333331 0.19 ND
D12S 99 13.9 I 0.5 T *w m mm mm mm. m m m D21S 1256 8.6 0.52 0.06 0
D12S 85 65.6 0.04 0.33 0 D21S 1914 23 0.014 0.4 0
D12S 368 67.3 0.36 0.1 0 D21S263 31.4 0 0.5 0
D12S 83 76.5 0.11 0.24 0 D21S 1254 34 0 0.5 0
D12S 326 87.6 0.08 0.27 0 D21S 1252 38.7 0.82 0.02 0
D12S 351 97.1 0.002 0.47 0 D21S270 41.3 0.2 0.2 0
D12S95 97.7 0.59 0.05 0 D21S268 44.9 marker failed





D12S 346 106 0 0.5 0 D22S 420 " o ' 333, 0.5 ND
D13S 170 65.4 marker failed DXS 1068
m/mmmmm/mm.m/m m /m m -a
56.2 333, 0.56 ND










Table 2.2.4 lists the results of the replication study including the markers used, LOD score, and p value for single point and multipoint analysis (where appropriate). 
ND = not done. Single point analysis on 368 UK-ASPs was performed for each marker implemented in ANALYZE and multipoint for each locus implemented in 
MAPMAKER SIB (LOD mp).
point analysis (p=0.0067) and multi-point analysis (p=0.043). D21S1252 on 
chromosome 21 maps closely to the markers D21S270 (2.6cM telomeric) and 
D21S268 (6.2cM centromeric) used in the European WGS. These European 
WGS markers showed evidence for nominal linkage by single point analysis 
(p<0.05) but not multi-point analysis. CYP 19 on chromosome 15 has
previously shown nominal evidence of linkage in two stage testing, although 
there was some overlap in the families used in the two investigations (John et 
a/., 1999).
It is not surprising that only three of the 14 regions identified by the European 
genome screen were reproduced in this replication study. Linkage analyses 
undertaken in other complex diseases reveal the same lack of consistent 
results when studying independent family collections. Examples include 
studies of insulin dependent diabetes mellitus (IDDM) (Concannon et al., 
1998; Davies et al., 1994; Luo et al., 1996) and multiple sclerosis (Ebers et 
al., 1996; Haines et al., 1996). This inconsistency has been attributed to a 
number of factors including clinical and genetic heterogeneity, the use of 
different markers and analytical methods and poorly powered study designs 
unable to detect weak genetic effects. It is also accepted that a large 
proportion of apparent linkages identified by genome-wide linkage analysis 
will be false positives requiring confirmation of results in independent data 
sets (Lander and Kruglyak, 1995). As the most efficient strategy is thought to 
include an initial WGS screen performed with relatively few ASPs and wide 
marker spacing, followed by the more detailed study of all loci with nominal 
evidence for linkage (p<0.05) in a larger data-set (Holmans and Craddock, 
1997), inconsistent results are inevitable. Candidate regions likely to contain 
true RA susceptibility loci are those where nominal linkage (p<0.05) has been 
reported in two or more of these studies and where both single and mulit- 
point analysis show evidence for linkage. The single point linkage to the 
three regions identified on chromosomes 12, 15 and 21 has not been 
supported by multi-point results but the power to detect weak linkage effects
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is limited in a study of this size. Therefore these regions cannot be formally 
excluded from containing relevant genes and warrant further investigation.
Clinical heterogeneity in RA is well recognised and differences in phenotype 
between study populations may influence results. The two studies recruited 
ASPs in slightly different ways and from different regions within Europe. This 
may have lead to phenotypic differences between the disease cohorts and 
some variation in the results. All individuals included in the ARC-UK National 
Repository of family material were recruited following a detailed structured 
interview and joint examination undertaken by a trained metrologist. Hand 
radiographs were reviewed looking for erosive disease and rheumatoid factor 
status was determined. The ASPs recruited by the European WGS fulfilled 
1987 ACR criteria for RA as reported by one of the rheumatologists 
participating in the study or the clinician in charge of the patient who 
completed a standardised questionnaire (Cornelis et a/., 1998). However 
some family members would not have been seen or examined, and is 
therefore possible individuals with RA may have been missed within the 
family group.
A variety of statistical approaches are available to analyse data generated by 
linkage studied of this kind. The European WGS used the programme 
ANALYZE (J Terwilliger, unpublished) for single point analysis and 
GENEHUNTER 1.1 (Kruglyak et al., 1996) for multi-point linkage analysis. In 
addition, for the few families with multiple affected sib-ships ‘all possible pairs’ 
were used as if they were independent ASPs. The UK replication study used 
the program MAPMAKER/SIBS (version 2) (Kruglyak and Lander, 1995) for 
single and multi-point analysis and multiple sibships were given a 
conservative weighting of 2/n to account for their lack of independence 
(Meunier et al., 1997). The use of different statistical programmes (section 
1.2.9) and different approaches to the analysis of multiple sibships (section 
1.2.7.6) may have lead to small differences in the results of either study.
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MAPMAKER/SIBS (version 2) (Kruglyak and Lander, 1995) was designed for 
the analysis of small nuclear families or sibships and the method is based on 
the Lander-Green algorithm (Lander et al., 1987) (section 1.2.9.1). Power 
calculations often overestimate the power of a study because the calculations 
typically assume that all families are fully informative. It is assumed that DNA 
is available from all parents, marker heterozygosity is 100% and all affected 
sibling pairs are independent (which is not the case in families with more than 
two affected siblings). Recruitment of complete affected sibling pair families 
is difficult in a late onset disease such as rheumatoid arthritis. Thus, parental 
DNA was available in 27% of the families studied. DNA from unaffected 
siblings was available in 55% of the remaining families allowing parental 
haplotypes to be inferred when not directly available.
Two other regions identified by the European WGS, 18q22-23 and 3q13 
contain the IDDM-6 and IDDM-9 loci and were studied in a further 194 
European ASPs from 164 families (Cornelis et al., 1998). The region 18q22- 
23 did not reach significance in the larger cohort. Suggestive linkage to the 
chromosome 3 (IDDM-9) region was found in the combined data set but was 
only evident in HLA concordant RA pairs (p=0.001). Linkage was not 
significant in the remaining RA pairs (p=0.08). Candidate genes within the 
3q13 region include genes coding for CD80 and CD86 which interact with T 
cell molecules CTLA4 and CD28 in the co-stimulatory pathway (Cornelis et 
al., 1998). Although, no evidence for linkage in either region was identified by 
the UK replication study the region on chromosome 3 at 3q13 warrants 
further investigation as this area has been identified in two independent 
datasets. The region 18q22-23 is less likely to harbour important disease 
causing genes as significance was not reached in either the second 
independent European dataset (Cornelis et al., 1998) or the UK replication 
study.
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A second WGS has been reported, which was performed in a small number 
of Japanese families (n=41) (Shiozawa et a/., 1998). Multi-point linkage 
analysis revealed two regions with maximum LOD score >3 (significant 
linkage) on chromosome 1 and the X chromosome. The markers on 
chromosome 1 were D1S253 and D1S214 and mapped 16cM from D1S228 a 
marker with evidence of nominal linkage in the European study. The marker 
on the X chromosome was DX1232 mapping approximately 25cM from 
DSX998 another a marker with evidence of nominal linkage in the European 
study. These findings were not replicated in the UK dataset. Interestingly, 
significant linkage to the HLA-DR region was not detected in the Japanese 
families. This could be due to ethnic differences in HLA associations or more 
likely the relatively low power of such a small study to detect linkage. Both 
disease severity and HLA associations vary amongst different populations 
(section 1.2.3). All the UK families were Caucasoid and the linkage observed 
to the HLA-DRB1 region was similar to that seen in the European WGS 
(MacKay et a l 2000).
RA is a chronic multifactorial disease and is thought to be genetically 
heterogeneous. A number of earlier studies of complex diseases have found 
the strongest evidence for linkage when confining the analysis to specific 
subsets of sibling pairs (e.g. HLA discordant versus HLA concordant), or by 
looking at interactions between loci. However, it is recommended that subset 
analysis should only be undertaken when there is some evidence for linkage 
in the whole data set prior to sub-analysis (Leal and Ott, 2000). Therefore, 
further analysis of the UK replication study was not performed in view of the 
lack of strong evidence of linkage overall.
In conclusion, the contribution of individual disease susceptibility loci is likely 
to be small in RA as in other complex diseases. Additional genome-wide 
linkage studies are required to replicate any evidence of linkage at specific 
loci already identified and generate additional regions where linkage may be
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found. Hence, a WGS using the UK RA ASP families should be undertaken. 
Many of the loci identified by these studies will be false positives and large 
numbers of ASPs will ultimately be required to replicate results. World-wide 
collaboration may be required if suitable families are to be recruited in 
sufficient numbers.
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Chapter 2 — section 3
2.3 Whole genome linkage analysis of rheumatoid
arthritis susceptibility loci in 252 United Kingdom 
affected sibling pairs.
2.3.1 Abstract
Objective: To undertake a systematic whole genome screen to identify
regions exhibiting genetic linkage to rheumatoid arthritis (RA).
Methods: Two hundred and fifty-two RA affected sibling pairs, from 182 
United Kingdom families, were genotyped using 365 highly informative 
microsatellite markers. Microsatellite genotyping was performed using 
fluorescent PCR primers and semi-automated DNA sequencing technology. 
Linkage analysis was undertaken using MAPMAKER/SIBS for single point 
and multipoint analysis.
Results: Significant linkage was identified around the MHC region on
chromosome 6 (maximum LOD score = 4.7 (p=0.000003) at marker D6S276
i
1cM from HLA-DRB1). Suggestive linkage (p < 7.4x1 O'4) was identified on 
chromosome 6q by single and multipoint analysis. Ten other sites of nominal 
linkage (p<0.05) were identified on chromosomes 3p, 4q, 7p, 2 regions of 
10q, 2 regions of 14q, 16p, 21 q and Xq by single point analysis and three 
sites (1 q, 14q and 14q) by multi-point analysis.
Conclusion: Linkage to the MHC region was confirmed. Eleven non-HLA 
regions demonstrated evidence of suggestive or nominal linkage but none 
reached the genome-wide threshold for significant linkage (p = 2.2 x10'5). 
Previous genome screens have tentatively suggested six of these regions to 
be involved in RA susceptibility.
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2.3.2 Introduction
Genome-wide linkage analysis can generate additional regions where linkage 
may be found and can replicate any evidence of linkage at specific loci 
already identified. A third WGS in RA was published in 2001 using 251 North 
American ASP families collected by the North American RA consortium 
(NARAC), Linkage to the MHC was confirmed (i.e. p<2.5x10'5) (Jawaheer et 
a/., 2001) and non-MHC regions with evidence of suggestive linkage (p<7.4 x 
10'4) or nominal linkage (p<0.05) by multipoint analysis were also identified. 
As discussed above many apparent linkages will be false positives and 
confirmation of all findings in further independent datasets is important 
(Lander and Kruglyak, 1995). Table 2.1.1 summarises the eight overlapping 
regions where nominal linkage has been reported in two or more data sets 
(Cornelis et al., 1998; Jawaheer et a/., 2001; MacKay et al., 2002). These are 
important candidate regions for including true RA susceptibility loci. 
However, some regions of true linkage are likely to have been missed 
because most whole genome screens have relatively low power to identify 
linkage to genes of small effect (Brown and Wordsworth, 1998).
A WGS was performed on a large well-characterised cohort of United 
Kingdom ASP families with RA was undertaken to identify novel susceptibility 
loci and confirm linkage to previously identified regions.
2.3.3 Methods
2.3.3.1 Recruitment
Two hundred and fifty-two UK Caucasian sibling pairs, affected by 
rheumatoid arthritis, were studied. The ASPs, from 182 families, were 
identified from the Arthritis and Rheumatism Campaign United Kingdom
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Flow chart for genome wide linkage analysis
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Fig 2.3.1 illustrates the sequence 
of steps followed when 
undertaking linkage analysis on a 
large number of samples e.g. 
performing a genome wide linkage 
analysis. Steps 2c to 2e are 
followed if DNA is in short supply. 
A PEP PCR is performed to 
increase the amount of DNA 
available. Steps 3b to 3e are 
ideally undertaken prior to pooling 
the whole set so that PCR failures 
can be identified and PCR can be 
performed on the failed samples.
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IThe UK genome-wide linkage analysis study 
-an example of a fluorescent gel
Fig 2.3.2 shows a fluorescent gel from an ABI 373 having been run through the software package 
Genescan" . The red lines are marker lines allowing the software package Genotyper" to determine 
the size of each microsatellite allele relative to the known size of the markers. The yellow, blue and 
green lines are the fluorescently tagged microsatellites. Each column represents one individual and 10 
to 20 microsatellite markers per person can be separated by PCR provided the fragments of a similar 
size are tagged by a different fluorescent colour.
(ARC-UK) National Repository of family material (www.http://arc.man.ac.uk). 
The affected sibling pairs and their families were recruited following a nation­
wide publicity media campaign and by involving clinical rheumatologists 
throughout the UK in identifying potential families from their practices who 
were willing to enrol in the study. Multi-centre ethics committee approval was 
obtained. All family members were examined according to a standard 
protocol and agreed to a detailed structured interview regarding joint 
symptoms. A trained metrologist performed a joint examination to detect 
swelling, tenderness and deformity. Individuals with erosive disease were 
identified from hand radiographs, reviewed by a rheumatologist, and 
rheumatoid factor (RF) status was ascertained using a particle agglutination 
test. Subjects were classified as having rheumatoid arthritis if they satisfied 
the 1987 American College of Rheumatology (ACR) criteria (Arnett et al., 
1988) modified for genetic studies (MacGregor, 1995) (section 1.1.2).
2.3.3.2 DNA extraction
As described above for the replication study, DNA from these affected 
individuals and their first-degree relatives was prepared from peripheral 
blood. Technicians employed by the ARC-UK National Repository performed 
all the DNA extraction according to standard techniques. Concentrated DNA 
was kept in labelled tubes at -70°C.
2.3.3.3 Strategy
Undertaking a linkage analysis of the whole genome in a large number of 
families involves a considerable quantity of laboratory and statistical work. 
Three hundred and sixty-eight microsatellite markers were required to span 
the whole genome with a mean marker distance of ~ 10cM resulting in a 
minimum of 368 PCR reactions per individual. The ASP families included in 
the study were those who were the most informative (i.e. most ASPs were
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included if DNA was available for themselves, their parents and/or additional 
siblings). Hence, 650 individuals from 182 families were included in the study 
meaning that over 250,000 PCR reactions would be required to undertake 
genotype analysis in these individuals and the resulting PCR products would 
need to be separated by electrophoresis using over 340 fluorescent gels. 
Therefore, the laboratory work was carried out in two centres; and identical 
box set-ups were designed so both centres would use the same numbering 
and position in the box for each individual. This was to allow both ‘quality 
control’ where each centre undertook to genotype the same individuals and 
also to avoid mistakes during the statistical analysis. Once the box set-ups 
had been designed (K MacKay, S John) concentrated DNA was diluted with 
sterile water to 10ng/pl and aliquoted into 16 boxes (eight duplicates for each 
centre). Statistical analysis was conducted at the Wellcome Trust Centre for 
Human Genetics in Oxford (K MacKay).
DNA was transported to the WTCHG in Oxford on ice and kept frozen, until 
required, at -70°C. To allow for the quantity of DNA required to perform the 
number of PCR reactions needed to genotype each individual a PCR 
amplification reaction (PEP PCR) was performed on the DNA brought from 
the ARC-UK National Repository (section 1.3.3, fig 2.3.1). Once amplified, 
the PEP DNA was aliquoted and frozen at -70°C. Aliquots of the PEP DNA 
were thawed as required and kept at 4°C whilst the microsatellites were 
amplified and the gels run (section 2.3.3.7). Each microsatellite was 
amplified through all boxes of DNA in one go to avoid repetitive freeze- 
thawing of PCR primers (section 1.3.3).
2.3.3.4 RA affected sibling pairs
Parental DNA was available in 37% of the families and available from 
additional unaffected siblings in 94% of the remaining families to facilitate the 
assignment of parental genotypes (table 2.3.1). A total of 252 ASPs were 
identified from the 182 families included because multiple sibships were
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Table 2.3.1 shows the pedigree structure of the families included in the whole 
genome screen (WGS). For every affected sibling pair (ASP) additional first- 
degree relatives were recruited in order to ascertain the identity by descent of 
each allele studied. This table documents the availability of DNA from parents 
or additional siblings for each ASP family used in the UK WGS. If parental DNA 
was unavailable, unaffected siblings were recruited and genotyped if possible 
allowing the missing parental genotypes to be inferred. In total 650 individuals 





Table 2.3.2 shows the number of ASP families recruited for the WGS and the 
number of ASPs per family. Some of the families included were made up of 
multiple sib-ships of between 3 and 8 RA affected siblings and the number of 
multiple sib-ship families are documented here.
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identified in 26 families (table 2.3.2). Of the 650 individuals included in the 
study, 403 had rheumatoid arthritis, (393 siblings, 10 mothers and 3 fathers). 
Three of the affected parents were also members of an affected sibling pair. 
Seventy-six per cent of affected individuals were female, 85% were sero­
positive for RF and 80% had developed erosions on hand radiographs. The 
mean age at disease onset was 39.4 years (SD ± 13.2) and mean disease 
duration at recruitment was 15.3 years (SD ± 11.3). Sex concordance is 
summarised in table 2.3.3.
2.3.3.5 HLA-DR status
HLA-DRB1 genotypes were determined using a commercially available semi­
automated PCR-SSOP typing technique (Inno-LiPa, Abbott Laboratories Ltd., 
Maidenhead, UK) (table 2.3.4).
2.3.3.6 Microsatellite markers
Three hundred and sixty-five highly informative microsatellites from the 
Applied Biosystems (ABI) Prism Linkage Mapping Set Version 2 (LMSv2) 
marker set (Applied Biosystems, Warrington, UK) were genotyped (appendix 
5.4). The microsatellites spanned the whole genome with a mean marker 
distance of -  10cM and a mean heterozygosity of 0.78.
2.3.3.7 Microsatellite qenotvpinq
Semi-automated analysis of microsatellite genotypes was carried out in two 
centres; chromosomes 1 - 7, 16, 21, 22 were typed at the Wellcome Trust 
Centre for Human Genetics (WTCHG) and chromosomes 8 - 15, 17 - 20 and 
X were typed at the Arthritis Research Campaign Epidemiology Unit (ARC- 
EU). The microsatellites were amplified by PCR using fluorescently labelled 
primers and reactions were performed in 10pl volumes (containing 50ng of 
DNA, 400nM each PCR primer, 50pM each dNTP, 0.2 units of Taq 
polymerase (Bioline, London, UK) in 1-3mM MgCfe buffer, overlaid with liquid
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paraffin). The reactions were performed in 96 well microtitre plates with 30 - 
35 cycles of denaturation (1 minute, 95°C), primer annealing (30 seconds, 
55°C - 60°C) and extension (30 seconds, 72°C). Annealing temperatures and 
MgCb buffer concentration were optimised for each primer. Amplification of 
each microsatellite was performed separately and the PCR products were 
then combined into pools of 10 -  20 markers before loading. Products were 
separated by electrophoresis either on 6% polyacrylamide gels using ABI 373 
semi-automated DNA sequencers (Applied Biosystems, Warrington, UK) over 
three hours (WTCHG) or on 4% polyacrylamide gels and ABI 377 DNA 
sequencers over two hours (ARC-EU). Products were sized using the 
program GENESCAN™672 (version 2.1) (Applied Biosystems, Warrington, 
UK) and genotypes semi automatically assigned using the program 
GENOTYPER™ (version 1.1.1) (Applied Biosystems, Warrington, UK) (Figs
2.3.2 and 2.3.3). A PCR product from a DNA reference sample (CEPH 1347- 
02) was included on every gel to monitor possible gel-to-gel variation.
2.3.3.8 Statistical analysis
Error checking:
To minimise data errors extensive error-checking procedures were employed. 
Allele assignment by GENOTYPER™ was checked manually for all 
genotypes and the CEPH control sample was used to ensure the consistency 
of allele assignment. Size data was converted into discrete allele numbers 
and samples not following Mendelian patterns of inheritance were identified in 
PEDCHECK (O'Connell and Weeks, 1998) and removed from the data set. 
The families were then tested with RELATIVE (Goring and Ott, 1997). 
RELATIVE identifies probable monozygotic twins, half-siblings or unrelated 
individuals by testing whether the proportion of alleles shared identity by 
descent at unlinked loci (on the basis of > 50 markers) is consistent with the 
expected proportion for each relative pair.
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Sex concordance between affected sibling pairs
Female : female ASPs 153 (60.7%)
Male : male ASPs 19(7.5%)
Female : male ASPs 80 (31.7%)
Table 2.3.3 shows the sex concordance of ASPs included in the UK WGS. As 
expected for a condition that predominantly affects women there is a 
predominance of female:female ASPs and only a small percentage of male:male 
ASPs.
HLA sharing between affected sibling pairs
Homozygous HLA-DR4 36%
Heterozygous HLA-DR4 48%
No sharing HLA-DR4 16%
Table 2.3.4 shows the HLA sharing of affected sibling pairs (ASPs) included in 
the UK whole genome screen (WGS). The figures are similar to previous 
reports showing increased sharing of both HLA-DR4 alleles and a decreased 
frequency of ASPs with no HLA-DR4 alleles in common. The expected sharing 
of HLA-DR4 alleles (by chance) would be 25% sharing both, 50% sharing one, 
25% sharing neither HLA-DR4 allele.
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Inter and intra-observer variation:
To assess inter-observer variation, a panel of samples was genotyped for six 
microsatellites on chromosome 7 in both centres. A further ten markers were 
re-genotyped in a blinded fashion by the researchers who were undertaking 
the genotype analysis (K MacKay, S Eyre, A Barton, A Myerscough). Intra­
observer variation was then determined.
Non-parametric analysis:
Allele frequencies were calculated from all of the scored genotypes using the 
software packages DOWNFREQ (J. Terwilliger, unpublished) (WTCHG) or 
SPLINK (version 1.05, David Clayton, MRC Biostatistics Unit, Cambridge) 
(ARC-EU). Sibling pair analysis methods were then used to test for excess 
allele sharing between affected siblings. Non-parametric single point and 
multipoint analysis was implemented in MAPMAKER/SIBS (version 2) 
(Kruglyak and Lander, 1995). Multiple sibships were given a conservative 
weighting of 2/n to account for their lack of independence (Meunier et al., 
1997). Analysis of markers on the X chromosome was carried out using 
MAPMAKER/SIBS modified for X-linked loci (Cordell et al., 1995). The 
program calculates sharing between sister-sister, brother-brother and sister- 
brother affected sib pairs.
Both multipoint and single point analyses have been presented. Suggested 
thresholds of LOD £ 3.6 (p^2x10"5) for significant linkage and LOD > 2.2 
(p<7.4x10"4) for suggestive linkage were used (Lander and Kruglyak, 1995). 
Nominal evidence of linkage was taken to be LOD > 0.8 (p<0.05) by either 
multipoint or single point analysis.
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Summary of positive single or multipoint results from 
the UK whole genome screen
D1S2842 1q 277cM 0.05
D1S2836 iq 290cM 0.05
D3S2338 3p 42cM 0.05
D4S1592 4q 69.5cM 0.05
D6S276 6q 1 cM from DRB1 0.000003
DRB1 6q DRB1 LOD = 1.9
D6S434 6q 109cM 0.0006 0.0007
D7S484 7p 53.5cM 0.05
D10S192 10q 124cM 0.05
D10S217 10q 158cM 0.05
D14S283 14q 28cM 0.05
D14S275 14q 28cM 0.05 0.05
D14S276 14q 56cM 0.05 0.05
D16S3103 16p 32cM 0.05
D21S1256 21q 9.7cM 0.05
DXS1106 Xq 66.6cM 0.05
Table 2.3.5 summarises the positive results identified by the UK whole 
genome screen (WGS). The microsatellite markers are listed along with the 
chromosomal arm they can be found on and the distance of the marker in - 
cM from the telomere. Both single and multipoint results are listed.






The results of the non-parametric, single point and multipoint analysis 
implemented in MAPMAKER/SIBS are shown in figures 2.3.2-2.3.24. 
Positive results identified by single or multipoint analysis are summarised in 
table 2.3.5. Linkage to the HLA region on chromosome 6 was confirmed by 
multipoint analysis (max LOD = 4.7 at marker D6S276, p=0.000003, 1cM 
from HLA-DRB1). The allele-sharing ratio for DRB1 was 16:49:35 for zero, 
one and two allele sharers. This significant increase in the inheritance of 2 
alleles identical by descent provides evidence for linkage to DRB1 (single­
point LOD score 1.9). Suggestive evidence of linkage by multipoint analysis 
was identified on chromosome 6q (D6S434, p=0.0007) at 109-cM. Nominal 
evidence of linkage by multipoint analysis was found for 3 additional linkage 
intervals: 1q (D1S2842 and D1S2836, p=0.05) at277-290cM, 14q (D14S283, 
p=0.05 and D14S275, p=0.03) at 28cM and 14q (D14S276, p=0.03) at 
56.4cM. Single point analysis identified suggestive linkage for one marker on 
chromosome 6q (D6S434, p=0.0006) at 109-cM. Nominal linkage (p<0.05) 
was identified by single point analysis for 10 additional linkage intervals on 
chromosomes 3p (D3S2338 at 42cM), 4q (D4S1592 at 69.5cM), 7p (D7S484 
at 53.5cM), 10q (D10S192 at 124cM), 10q (D10S217 at 158cM), 
14q(D14S275 at 28cM), 14q(D14S276 at 56.4cM), 16p (D16S3103 at 32cM), 
21 q (D21S1256 at 9.7cM) and Xq (DXS1106 at 66.6cM). Comparisons are 
made with data from the European and North American whole genome 
screens in Tables 2.3.7.
2.3.4.2 Microsatellite markers:
The microsatellite markers spanned the genome with a mean marker 
distance of 10cM and a median of 9.3cM. Eighty-eight per cent of markers 
were within 14cM of each other and only 11 markers had a gap of > 20cM,
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PCR success per chromosome
1 92 WTCHG 13 88 ARCERU
2 91 WTCHG 14 88 ARCERU
3 92 WTCHG 15 79 ARCERU
4 89 WTCHG 16 95 WTCHG
5 90 WTCHG 17 82 ARCERU
6 96 WTCHG 18 79 ARCERU
7 92 WTCHG 19 68 ARCERU
8 75 ARCERU 20 78 ARCERU
9 85 ARCERU 21 99 WTCHG
10 81 ARCERU 22 92 WTCHG
11 84 ARCERU X 77 ARCERU
12 86 ARCERU
WTCHG = Wellcome trust centre for Human Genetics
ARCEU = Arthritis Research Campaign Epidemiology Research Unit
Table 2.3.6 summarises the overall PCR success per chromosome for each 
microsatellite marker amplified. This is presented as an overall percentage and 
refers to the percentage of DNA samples per chromosome where all the 
microsatellites were successfully amplified.
13G
using the Marshfield map (table 2.3.6), as a result of marker failure (table
5.4.1). The mean heterozygosity was 0.78±0.07 and the mean polymorphism 
information content (PIC) was 0.75±0.08. Tables 2.3.5 and 5.2.1) summarise 
the percentage PCR success for each marker used in the WGS.
2.3.4.3 Error checking:
Fifteen individuals not fitting Mendelian inheritance patterns were identified by 
PEDCHECK (O'Connell and Weeks, 1998) and removed from the analysis. 
Three previously unrecognised half-siblings and two further individual 
samples not fitting Mendelian inheritance patterns were identified by 
RELATIVE (Goring and Ott, 1997) and also removed from the analysis.
2.3.4.4 Inter and intra-observer variation:
There was 98.9 per cent concordance for the six microsatellite markers on 
chromosome 7 that were genotyped at both centres. Intra-observer variation, 
measured by re-genotyping 10 markers blindly, ranged from 0 - 3%.
2.3.5 Discussion
In keeping with two previously reported RA whole genome screens (Cornelis 
et al., 1998; Jawaheer et al., 2001) this study confirmed genetic linkage to the 
HLA region on chromosome 6. In addition, suggestive evidence of linkage 
(p< 7.4 x 10-4) to a non-HLA region on 6q was identified by both single and 
multi-point analysis. Nominal evidence of linkage (p<0.05) to 10 other 
regions was detected by single point analysis (chromosomes 3p, 4q, 7p, 2 
regions on 10q, two regions on 14q, 16p, 21 q and Xq) and to three linkage 
intervals by multipoint analysis (chromosomes 1q, and 2 regions on 14q).
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Summary of potential RA loci identified by three 
independent whole genome screens in Europe, USA 
and UK

























































Table 2.3.7 compares the overlapping regions of positive linkage from the three 
major whole genome screens (WGS) undertaken in European, North American 
and UK populations with RA.
(SP= single-point, all other results = multi-point.).




Regions identified as nominal linkage intervals by two or more WGSs are of 
greater interest than sites identified by only one study, especially where 
corroborative evidence from other autoimmune diseases or animal studies is 
available. Six of the non-HLA regions identified in this study were also 
reported by the ECRAF (Cornelis et al., 1998) and/or NARAC [Jawaheer, 
2001 #1031] studies (chromosomes 3q, 6q, 10q, 14p, 14q and 16p) (table
2.3.1) and a number overlap with regions linked to other autoimmune 
diseases (Tables 2.3.8). The non-HLA region on 6q with suggestive evidence 
of linkage was also identified by the NARAC study (Jawaheer et al., 2001). 
On chromosome 10, the linkage interval including D10S185 (116cM) and 
D10S192 (124cM) was identified in the NARAC study (Jawaheer et al., 2001) 
and has also been identified in an ankylosing spondylitis WGS (Brown et al., 
1998; Laval et al., 2001). In addition, the interval around D10S217 (167cM) 
has been identified in a recent second-generation WGS in insulin dependent 
diabetes (IDDM) (Concannon et al., 1998). The region on 14q including 
D14S276 (56cM) was identified by both the ECRAF (Cornelis et al., 1998) 
and NARAC (Jawaheer et al., 2001) studies as was the interval on 16p 
(D16S3103). Recently, a WGS conducted using mice with proteoglycan- 
induced arthritis (Otto et al., 1999) also identified a linkage interval (named 
pg/a-3) homologous to this same region on 16p.
In keeping with the NARAC study (Jawaheer et al., 2001) no supporting 
evidence was found for the IDDM-6 locus on chromosomes 18, a site which 
had shown evidence for linkage in the ECRAF study (Cornelis et al., 1998). 
Previous investigations using some of the same RA ASP families as in this 
study have reported linkage to 3 candidate genes (MacKay et al., 2000). The 
current study did not attempt to replicate these findings. Using a number of 
single nucleotide polymorphism and microsatellite markers spanning the 
Interleukin 1 (IL-1) gene cluster, Cox etal. detected some evidence of linkage 
using the combined Transmission disequilibrium test (TDT) and sib-TDT in a
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subset of families sharing only one or zero DRB1 alleles identical-by-descent. 
However, they found no evidence of linkage using non-parametric allele 
sharing methods (Cox et al., 1999a). John et al. reported linkage to a single 
marker mapping to an intron within the Estrogen Synthase gene (CYP-19) 
(John et al., 1999). In the current study the closest marker mapped 5cM from 
CYP-19 and this may explain the failure to replicate this finding. Fife et al. 
investigated Corticotrophin Releasing Hormone (CRH) as a candidate RA 
susceptibility locus (Fife et al., 2002; Fife et al., 2000). Linkage to a 10cM 
region adjacent to CRH was reported. No statistically significant evidence of 
linkage was detected in the current study although there was some overlap in 
the families used in the two investigations. It is interesting to note, however, 
that there is an apparent small peak on multi-point linkage analysis to the 
same region in the current study (Figure 2.3.8). With the marker density used 
in this study linkage to these (and other postulated disease) loci could have 
been missed and they cannot, therefore, be excluded as potential disease 
genes.
Power calculations suggest that the current study should have 80% power to 
detect loci contributing X = 1.6 using the threshold for detection as a LOD > 
1.0. This, in fact, may be an overestimate because power calculations 
typically assume that all families are fully informative (i.e. DNA available from 
all parents and 100% marker heterozygosity) and all affected sibling pairs are 
independent (which is not the case in families with more than two affected 
siblings). Recruitment of complete affected sibling pair families is difficult in a 
late onset disease such as rheumatoid arthritis. Thus, parental DNA was 
available in just over one third of our families. However, one of the strengths 
of this study is that DNA from unaffected siblings was available in 94% of the 
remaining families and this was used to infer parental haplotypes when these 
were not directly available.
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Comparing loci detected by the UK WGS with the 


































a: MS = multiple sclerosis; CD/UC = Crohn’s disease/ulcerative colitis; IDDM = insulin dependent 
diabetes mellitus. Linkage results summarised in ref Becker 98 
b: Ref [Brown, 1998; Laval, 2001] 
c: Ref [Concannon, 1998]
Marker locations obtained from Marshfield website:
http:Wwww.research.marshfieldclinic.org/genetics
Table 2.3.8 compares the loci detected by single point linkage analysis of the 
UK whole genome screen (WGS) with the results of other linkage analyses of 
affected sibling pairs (ASPs) with RA or related autoimmune conditions. 
Regions identified as nominal linkage intervals by two or more WGS are of 
greater interest than are sites identified by only one study, especially when 
corroborative evidence from other autoimmune disease or animal studies is 
available.
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Because of the high chance of false positives in a genome-wide linkage study 
the stringent thresholds for significance (p<2.2x10'5) recommended by 
Lander and Kruglyak have been applied (Lander and Kruglyak, 1995). 
However, if stringent thresholds for significance are interpreted too strictly in a 
disease such as RA with a relatively low Xs it would be easy to overlook 
potentially relevant evidence emerging from WGSs. In order to make best 
use of the information arising from this and other similar sized WGS, a 
number of strategies are available. One proposal is to perform the initial 
screen in a relatively small data-set and then to test those loci demonstrating 
nominal evidence of linkage (p<0.05) in a larger data-set (Holmans and 
Craddock, 1997). In this respect, the study could be seen as a replication 
data set in which to test positive linkages detected in the US and European 
WGS. As outlined above, a number of positive linkages from the NARAC and 
ECRAF studies have also shown evidence of linkage in our data set 
suggesting that true RA susceptibility genes may map to these regions. A 
complementary but alternative approach would be to undertake a meta­
analysis analysis of the genotype data already obtained by published whole 
genome screens. By combining this data it should be possible to make more 
robust interpretations of the evidence so focusing the efforts of the replication 
studies.
To conclude, the UK whole genome linkage analysis of RA susceptibility loci 
confirmed significant evidence of linkage in the HLA region by single point 
and multi-point analysis. Suggestive linkage was identified by single and 
multipoint analysis at a non-HLA region on 6q and nominal evidence of 
linkage (p<0.05) has been found for 10 other regions by single point analysis 
on chromosomes 3p, 4p, 7p, 2 regions of 10q, 2 regions of 14q, 16p, 21 p and 
Xq and 3 non-MHC regions by multipoint analysis on chromosomes 1q and 2 
regions on 14q.
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Results of single and multi-point linkage






Fig 2.3.3 shows the results of single and multi-point linkage 
analysis for chromosome 1 using MAPMAKER/SIBS. The bars 
represent the results of single point linkage analysis and the 
continuous line, the results of multi-point linkage analysis. All the 
microsatellite markers used for the analysis are documented 
along the X axis in the order that they are to be found on 
chromosome 1. The distance between them on the graph gives 
some indication of the genetic distance between them on 
chromosome 1.
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Results of single and multi-point linkage






Fig 2.3.4 shows the results of single and multi-point linkage 
analysis for chromosome 2 using MAPMAKER/SIBS. The bars 
represent the results of single point linkage analysis and the 
continuous line, the results of multi-point linkage analysis. All the 
microsatellite markers used for the analysis are documented 
along the X axis in the order that they are to be found on 
chromosome 2. The distance between them on the graph gives 
some indication of the genetic distance between them on 
chromosome 2
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Results of single and multi-point linkage






Fig 2.3.5 shows the results of single and multi-point linkage 
analysis for chromosome 3 using MAPMAKER/SIBS. The bars 
represent the results of single point linkage analysis and the 
continuous line, the results of multi-point linkage analysis. All the 
microsatellite markers used for the analysis are documented 
along the X axis in the order that they are to be found on 
chromosome 3. The distance between them on the graph gives 
some indication of the genetic distance between them on 
chromosome 3.
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Results of single and multi-point linkage






Fig 2.3.6 shows the results of single and multi-point linkage analysis 
for chromosome 4 using MAPMAKER/SIBS. The bars represent the 
results of single point linkage analysis and the continuous line, the 
results of multi-point linkage analysis. All the microsatellite markers 
used for the analysis are documented along the X axis in the order 
that they are to be found on chromosome 4. The distance between 
them on the graph gives some indication of the genetic distance 
between them on chromosome 4.
14 6
Results of single and multi-point linkage








Fig 2.3.7 shows the results of single and multi-point linkage 
analysis for chromosome 5 using MAPMAKER/SIBS. The bars 
represent the results of single point linkage analysis and the 
continuous line, the results of multi-point linkage analysis. All the 
microsatellite markers used for the analysis are documented 
along the X axis in the order that they are to be found on 
chromosome 5. The distance between them on the graph gives 
some indication of the genetic distance between them on 
chromosome 5.
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Results of single and multi-point linkage






Fig 2.3.8 shows the results of single and multi-point linkage 
analysis for chromosome 6 using MAPMAKER/SIBS. The bars 
represent the results of single point linkage analysis and the 
continuous line, the results of multi-point linkage analysis. All the 
microsatellite markers used for the analysis are documented along 
the X axis in the order that they are to be found on chromosome 6. 
The distance between them on the graph gives some indication of 
the genetic distance between them on chromosome 6.
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Results of single and multi-point linkage





Fig 2.3.9 shows the results of single and multi-point linkage 
analysis for chromosome 7 using MAPMAKER/SIBS. The bars 
represent the results of single point linkage analysis and the 
continuous line, the results of multi-point linkage analysis. All the 
microsatellite markers used for the analysis are documented along 
the X axis in the order that they are to be found on chromosome 7. 
The distance between them on the graph gives some indication of 
the genetic distance between them on chromosome 7.
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Results of single and multi-point linkage




Fig 2.3.10 shows the results of single and multi-point linkage 
analysis for chromosome 8 using MAPMAKER/SIBS. The bars 
represent the results of single point linkage analysis and the 
continuous line, the results of multi-point linkage analysis. All the 
microsatellite markers used for the analysis are documented along 
the X axis in the order that they are to be found on chromosome 8. 
The distance between them on the graph gives some indication of 
the genetic distance between them on chromosome 8.
1 5 0
Results of single and multi-point linkage
analysis for chromosome 9
Chromosome 9
Fig 2.3.11 shows the results of single and multi-point linkage 
analysis for chromosome 9 using MAPMAKER/SIBS. The 
bars represent the results of single point linkage analysis and 
the continuous line, the results of multi-point linkage analysis. 
All the microsatellite markers used for the analysis are 
documented along the X axis in the order that they are to be 
found on chromosome 9. The distance between them on the 
graph gives some indication of the genetic distance between 
them on chromosome 9.
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Results of single and multi-point linkage




Fig 2.3.12 shows the results of single and multi-point linkage 
analysis for chromosome 10 using MAPMAKER/SIBS. The bars 
represent the results of single point linkage analysis and the 
continuous line, the results of multi-point linkage analysis. All the 
microsatellite markers used for the analysis are documented 
along the X axis in the order that they are to be found on 
chromosome 10. The distance between them on the graph gives 
some indication of the genetic distance between them on 
chromosome 10.
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Results of single and multi-point linkage






Fig 2.3.13 shows the results of single and multi-point linkage 
analysis for chromosome 11 using MAPMAKER/SIBS. The 
bars represent the results of single point linkage analysis 
and the continuous line, the results of multi-point linkage 
analysis. All the microsatellite markers used for the analysis 
are documented along the X axis in the order that they are 
to be found on chromosome 11. The distance between 
them on the graph gives some indication of the genetic 
distance between them on chromosome 11.
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Results of single and multi-point linkage









Fig 2.3.14 shows the results of single and multi-point linkage 
analysis for chromosome 12 using MAPMAKER/SIBS. The 
bars represent the results of single point linkage analysis 
and the continuous line, the results of multi-point linkage 
analysis. All the microsatellie markers used for the analysis 
are documented along the X axis in the order that they are 
to be found on chromosome 12. The distance between 
them on the graph gives some indication of the genetic 
distance between them on chromosome12.
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Results of single and multi-point linkage





Fig 2.3.15 shows the results of single and multi-point linkage 
analysis for chromosome 13 using MAPMAKER/SIBS. The 
bars represent the results of single point linkage analysis and 
the continuous line, the results of multi-point linkage analysis. 
All the microsatellite markers used for the analysis are 
documented along the X axis in the order that they are to be 
found on chromosome 13. The distance between them on the 
graph gives some indication of the genetic distance between 
them on chromosome 13.
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Results of single and multi-point linkage






Fig 2.3.16 shows the results of single and multi-point linkage 
analysis for chromosome 14 using MAPMAKER/SIBS. The bars 
represent the results of single point linkage analysis and the 
continuous line, the results of multi-point linkage analysis. All the 
microsatellite markers used for the analysis are documented 
along the X axis in the order that they are to be found on 
chromosome 14. The distance between them on the graph gives 
some indication of the genetic distance between them on 
chromosome 14.
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Results of single and multi-point linkage
analysis for chromosome 15
Chromosome 15
Fig 2.3.17 shows the results of single and multi-point linkage 
analysis for chromosome 15 using MAPMAKER/SIBS. The bars 
represent the results of single point linkage analysis and the 
continuous line, the results of multi-point linkage analysis. All the 
microsatellite markers used for the analysis are documented along 
the X axis in the order that they are to be found on chromosome 
15. The distance between them on the graph gives some 
indication of the genetic distance between them on chromosome 
15.
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Fig 2.3.18 shows the results of single and multi-point linkage 
analysis for chromosome 16 using MAPMAKER/SIBS. The bars 
represent the results of single point linkage analysis and the 
continuous line, the results of multi-point linkage analysis. All the 
microsatellite markers used for the analysis are documented 
along the X axis in the order that they are to be found on 
chromosome 16. The distance between them on the graph gives 
some indication of the genetic distance between them on 
chromosome 16.
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Results of single and multi-point linkage




Fig 2.3.19 shows the results of single and multi-point linkage 
analysis for chromosome 17 using MAPMAKER/SIBS. The bars 
represent the results of single point linkage analysis and the 
continuous line, the results of multi-point linkage analysis. All the 
microsatellite markers used for the analysis are documented 
along the X axis in the order that they are to be found on 
chromosome 17. The distance between them on the graph gives 
some indication of the genetic distance between them on 
chromosome 17
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Results of single and multi-point linkage










Fig 2.3.20 shows the results of single and multi-point linkage 
analysis for chromosome 18 using MAPMAKER/SIBS. The bars 
represent the results of single point linkage analysis and the 
continuous line, the results of multi-point linkage analysis. All the 
microsatellite markers used for the analysis are documented along 
the X axis in the order that they are to be found on chromosome 
18. The distance between them on the graph gives some 
indication of the genetic distance between them on chromosome 
18.
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Results of single and multi-point linkage












Fig 2.3.21 shows the results of single and multi-point linkage 
analysis for chromosome 19 using MAPMAKER/SIBS. The bars 
represent the results of single point linkage analysis and the 
continuous line, the results of multi-point linkage analysis. All the 
microsatellite markers used for the analysis are documented 
along the X axis in the order that they are to be found on 
chromosome 19. The distance between them on the graph gives 
some indication of the genetic distance between them on 
chromosome 19.
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Fig 2.3.22 shows the results of single and multi-point linkage 
analysis for chromosome 20 using MAPMAKER/SIBS. The bars 
represent the results of single point linkage analysis and the 
continuous line, the results of multi-point linkage analysis. All the 
microsatellite markers used for the analysis are documented along 
the X axis in the order that they are to be found on chromosome 
20. The distance between them on the graph gives some 
indication of the genetic distance between them on chromosome 
20 .
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Results of single and multi-point linkage
analysis for chromosome 21






Fig 2.3.23 shows the results of single and multi-point linkage 
analysis for chromosome 21 using MAPMAKER/SIBS. The bars 
represent the results of single point linkage analysis and the 
continuous line, the results of multi-point linkage analysis. All the 
microsatellite markers used for the analysis are documented 
along the X axis in the order that they are to be found on 
chromosome 21. The distance between them on the graph gives 
some indication of the genetic distance between them on 
chromosome 21.
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Results of single and multi-point linkage






Fig 2.3.24 shows the results of single and multi-point linkage 
analysis for chromosome 22 using MAPMAKER/SIBS. The bars 
represent the results of single point linkage analysis and the 
continuous line, the results of multi-point linkage analysis. All the 
microsatellite markers used for the analysis are documented 
along the X axis in the order that they are to be found on 
chromosome 22. The distance between them on the graph gives 
some indication of the genetic distance between them on 
chromosome 22.
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Results of single and multi-point linkage
analysis for X chromosome





Fig 2.3.25 shows the results of single and multi-point linkage 
analysis for X chromosome using MAPMAKER/SIBS. The bars 
represent the results of single point linkage analysis and the 
continuous line, the results of multi-point linkage analysis. All the 
microsatellite markers used for the analysis are documented 
along the X axis in the order that they are to be found on X 
chromosome. The distance between them on the graph gives 
some indication of the genetic distance between them on X 
chromosome.
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Chapter 3 -  section 1
CHAPTER 3: CANDIDATE GENE STUDIES
Rheumatoid arthritis susceptibility and interleukin 10 (IL10)
3.1 Introduction
Although linkage analysis is an integral part of the search for susceptibility 
genes it is both expensive and time consuming. The search for candidate 
genes, undertaken in parallel, can be a useful method of investigating 
biologically plausible candidate genes at considerably less cost in time and 
resources. Genes that control cytokine expression are among the most 
obvious candidates to study in a chronic inflammatory disease such as 
rheumatoid arthritis. The reasons why interleukin 10 (IL10) may be involved 
in susceptibility and/or severity to RA are set out below.
3.1.1 Immunology
Pro inflammatory cytokines such as tumor necrosis factor (TNF) and 
interleukin 1 (IL-1) play a significant pathogenic role in the chronic synovitis 
and progressive joint destruction of rheumatoid arthritis (Chu et al., 1992). 
Recently it has been shown that RA can be ameliorated by treatments 
specifically targeting the activity of TNF (Lipsky et al., 2000) or IL-1 (Arend 
and Guthridge, 2000). Anti-inflammatory cytokines can also be found in 
affected joints (Chomarat et al., 1995; Katsikis et al., 1994) where they can 
inhibit many pro-inflammatory cytokines (de Waal Malefyt et al., 1991; 
Fiorentino et al., 1991a; Fiorentino et al., 1991b). It has been postulated that
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chronic synovitis may reflect an imbalance in pro- and anti-inflammatory 
cytokine production in rheumatoid arthritis (Weckmann and Alcocer-Varela,
1996). Consequently, the potential beneficial effects of anti-inflammatory 
cytokines such as interleukin 10 (IL10) (Keystone et al., 1998) and interleukin 
4 (IL-4) (Woods etal., 1999) in RA are of great interest.
3.1.2 Interleukin 10, an immuno-modulatory cytokine
IL10 is produced by a variety of cell types, including monocytes (de Waal 
Malefyt et al., 1991), B lymphocytes (Burdin etal., 1993), activated CD4+ and 
CD8+ T cells (Spits and de Waal Malefyt, 1992) and mast cells (Ishizuka et 
al., 1999). IL10 is a potent up-regulator of B cell production and 
differentiation (Rousset et al., 1992) but has anti-inflammatory capabilities 
that can directly down-regulate TNFa, IL-1, IL-8 and IFNy production 
(Cassatella et al., 1993; de Waal Malefyt et al., 1991; Fiorentino et al., 1989; 
Fiorentino et al., 1991a; Katsikis et al., 1994). By reducing HLA class II 
expression on macrophages IL10 can also inhibit antigen presentation 
(Mottonen et al., 1998). For example, synovial fluid macrophages from 
patients with rheumatoid arthritis incubated with IL10 had a significantly 
reduced capacity to activate T cells in a mixed lymphocyte reaction (Mottonen 
et al., 1998). Also, pulsed methylprednisolone used to produce a rapid and 
sustained decrease in rheumatoid arthritis disease activity also leads to a 
sustained increase in IL10 production by peripheral blood mononuclear cells 
for at least 6 weeks (Verhoef et al., 1999).
Transgenic mice with inactivated IL10 show normal development of 
lymphocytes and antibody responses but most animals are growth retarded, 
anaemic and suffer from chronic enterocolitis. Enhanced epithelial MHC 
class II expression and uncontrolled macrophage activation is found in the gut
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IL-10 promoter microsatellites and SNPs
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Fig 3.1.1 illustrates the promoter region of the IL10 gene.
Fig A shows the IL10 microsatellites IL10.R and IL10.G in the promoter 
region of the IL10 gene. IL10.R is 4kb 5’ of the transcription initiation site 
and IL10.G 1.1 kb.
Fig B shows four of the single nucleotide polymorphisms (SNPs) identified 
in this region. To date, 10 SNPs have been identified but the SNPs 
illustrated here have been studied in some detail. Various studies have 
reported associations with different SNPs or haplotypes but the data has 
been inconsistent.
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of these animals. This may lead to greater antigen presentation and massive 
exposure of lymphoid cells to luminal antigens. The disease is probably 
perpetuated by chronic over expression of cytokines. Mice kept under 
specific pathogen-free conditions develop only a local inflammation limited to 
the proximal colon suggesting the bowel inflammation may be a failure to 
control normal intestinal immune responses against enteric antigens and that 
IL10 is an essential immunoregulator in the intestinal tract. Repeated 
administration of IL10 into these mutants can transiently cure their disease 
(Kuhn eta l., 1993).
Variation in IL10 secretion is largely genetically determined (Westendorp et 
al., 1997) and differences in secretion have been associated with various 
chronic inflammatory and infectious diseases. High levels of secretion are 
associated with a poor or fatal outcome in meningitis (Derkx et al., 1995; 
Lehmann etal., 1995; Westendorp et al., 1997) and low levels are associated 
with susceptibility to severe malarial anaemia (Kurtzhals et al., 1998).
3.1.3 Interleukin 10 gene and protein
IL10 is a homodimeric protein with subunits and is 160 amino acids in length. 
Murine IL10 shows 81% homology at the nucleotide level and 73% amino 
acid homology with human IL10 (de Waal Malefyt et al., 1992; Kim et al., 
1992). Human IL10 is also closely related to the BCRF-1 gene (often called 
viral IL10 or vlL10) of the Epstein-Barr virus. Viral IL10 is more closely 
related at the protein level (84% homoiogy) than murine IL10 (Vieira et al., 
1991).
The IL10 gene (appendix 5.5 for IL10 sequence) maps to the junction of 
1q31-q32 (Eskdale et al., 1997a). It contains four exons and exhibits
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substantial polymorphism in the promoter region which appear to correlate 
with variation in transcription (Crawley et al., 1999; Huizinga et al., 2000) (fig 
3.1.1). Two microsatellite polymorphisms, IL10.G and IL10.R, situated 1.1 
and 4kb 5’ of the transcription initiation site respectively are of particular 
interest (Eskdale and Gallagher, 1995; Eskdale et al., 1996) since variation in 
IL10 secretion has been associated with particular haplotypes defined by 
these microsatellite markers (fig 3.1.1). Haplotypes containing the IL10.R2 
allele are associated with a higher level of secretion than those including 
IL10.R3 (Eskdale et al., 1998a). To date, eight single nucleotide 
polymorphisms (SNPs) have also been identified in the promoter region of 
this gene (D’Alfonso et al., 2000; Eskdale et al., 1999; Turner et al., 1997), 
three of which have been studied in some detail: -1082 (G to A), -819 (C to T) 
and -592 (C to A) (Crawley et al., 1999; Eskdale et al., 1999; Turner et al.,
1997). Haplotype frequencies in 119 Caucasian controls were found to be 
0.51 (GCC), 0.28 (ACC) and 0.21 (ATA) (Turner et al., 1997). Studies 
investigating secretion of IL10 in relation to SNP polymorphisms have 
reported varying results. The -1082G allele has been associated with low 
levels of IL10 in one report (Huizinga et al., 2000) but high levels in another 
(Turner et al., 1997). A third study found decreased secretion in relation to 
the ATA haplotype (Crawley et al., 1999). It is difficult to compare these 
results as the researchers employed different experimental protocols 
(Crawley et al., 1999; Eskdale et al., 1998a; Turner et al., 1997) and the 
variation in IL10 production between different haplotypes is small in 
comparison to the large inter-individual differences (Huizinga et al., 2000). 
Basal levels of IL10 secretion were higher when peripheral blood 
mononuclear culture (PBMC) cultures rather than whole blood cultures were 
used, probably reflecting stimulation of the cells when separated (Crawley et 
al., 1999; de Groote and Zangerel, 1992). Cells can also be stimulated by 
lipopolysaccharide (LPS) stimulation (Crawley et al., 1999) and concanavalin 
A (Con A) stimulation (Turner et al., 1997).
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Various genotypes of IL10.R, IL10.G and SNPs have been reported to show 
association with a variety of chronic inflammatory diseases. The ATA 
haplotype has been associated with both extended oligo-articular juvenile 
idiopathic arthritis (JIA) in Caucasians (Crawley etal., 1999) and nephritis in a 
Southern Chinese population with systemic lupus erythematosis (SLE) (Mok 
et al., 1998). The IL10.G microsatellite has also been associated with SLE 
(Eskdale et al., 1997b) and more recently the IL10.R2 allele was found to be 
over-represented in rheumatoid arthritis whilst the IL10.R3 allele was under­
represented (Eskdale etal., 1998b).
3.1.4 Candidate gene studies
Association studies are generally used to study candidate genes. The 
simplest form of association study is the case control study (section 1.2.10.6). 
This has the advantage of relatively easy collection of ‘cases’ as other family 
members are not required. In genetic studies, where only DNA is needed 
from the control population, cells from normal blood donors can be used 
providing they are of the same ethnic background and sex matched as the 
cases. However, non-random mating in a population leading to population 
stratification or assortative mating can produce spurious results (section 
1.2.10). Most polymorphisms studied are unlikely to be the real cause of 
disease susceptibility unless there is convincing evidence that the 
polymorphism is directly involved in influencing the production of a protein 
such as producing a stop codon and therefore a truncated protein. It is more 
likely that the polymorphism is a marker for other relevant mutations within 
the gene. Therefore, haplotyping is often undertaken to narrow down the 
region of interest (section 1.2.10.5). For instance, it is conceivable that only 
certain haplotypes containing IL10.R2 include the specific SNPs associated 
with increased IL10 secretion. The identification of allele transmission 
through families is required for haplotyping but as case control studies are
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unable to provide this information other forms of family association studies 
are performed such as transmission disequilibrium (TDT) analysis (section 
1.2.10.3).
Three association studies have been undertaken to investigate whether IL10, 
a biologically plausible candidate gene, is associated with susceptibility to or 
severity of RA. Two investigations were case control studies undertaken to 
demonstrate whether an association existed between RA susceptibility and 
IL10.R microsatellite alleles in two ethnically diverse populations (reprint in 
appendix). The third study used a family-based association method to 
undertake haplotyping of the IL10.R and IL10.G microsatellite markers in a 
cohort of UK Caucasians with RA. The haplotyping study was completed to 
determine whether specific haplotypes were associated with RA 
susceptibility.
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Chapter 3 -  section 2
3.2 Studies 1 and 2: Case Control Association
Rheumatoid arthritis susceptibility and interleukin 10: A study of two
racially diverse populations.
3.2.1 Abstract
Introduction: IL10 is an immunoregulatory cytokine which may modulate 
disease expression in rheumatoid arthritis (RA). The IL10 gene is highly 
polymorphic with a number of single nucleotide polymorphisms in the 
promoter region and two microsatellite loci, IL10.R and IL10.G, 4kb and 1.1 kb 
5’ of the transcription initiation site. It has been reported that allele 2 of the 
IL10.R microsatellite (IL10.R2) is associated with increase IL10 secretion and 
IL10.R3 with reduced secretion. Subsequently, over-representation of 
IL10.R2 and under-representation of IL10.R3 in three independent RA groups 
has been reported.
Aim: To determine whether there is an association between the IL10.R2 
allele and RA in two ethnically distinct populations.
Methods: IL10.R genotypes were determined by semi-automated DNA
sequencing technology in 186 UK Caucasians and 138 South Africans of Zulu 
or Sotho origin, fulfilling the 1987 ACR criteria for RA. The Caucasian 
patients had relatively severe disease and comprised 75 patients with RA 
vasculitis, 22 with Felty’s Syndrome and 89 who had undergone a joint 
replacement (hip or knee) within 15 years of the onset of disease. Allele 
frequencies were compared with 296 Caucasians and/or 73 South Africans.
Results: The frequency of the IL10.R2 allele was significantly greater in the 
South Africans (RA and controls) than in the Caucasians (0.78 vs 0.66, 
p=1x10'6) while the frequency of IL10.R3 was less common (0.16 vs 0.3,
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p=1x10'8). No differences were observed in either in IL10.R2 or IL10.R3 
frequencies between patients and controls in either population.
Conclusions: No association between IL10.R alleles and RA was confirmed 
in this study. However, significant differences were demonstrated in the 
frequency of IL10.R2 and IL10.R3 between the two ethnic groups. The 
relatively high frequency of IL10.R2 in the South African population (0.78) 
would have reduced the power to detect an association with RA.
3.2.2 Introduction
IL10 is a biologically plausible candidate gene as described in the section 
above. As such, these studies were undertaken following the report by 
Eskadale and colleagues suggesting an association between the IL10.R2 
allele and susceptibility to RA (Eskdale et al., 1998b). The aim of these case 
control studies was to investigate further the association of IL10.R2 in UK 
Caucasian population with severe RA and to determine whether the 
association extended to another racially distinct population.
3.2.3 Materials and methods
3.2.3.1 Patients and controls
Two cohorts of racially distinct patients with RA and ethnically matched 
control groups were recruited from the United Kingdom and South Africa. 
The patients consisted of 186 Caucasian and 138 Black South African (SA) 
patients of Sotho or Zulu ethnicity, fulfilling the American College of
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IL10.R microsatellite alleles assigned using the 
program GENOTYPER™
140100 115 120 125
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Fig 3.2.2 is an example of the output obtained using the program 
GENOTYPER™. Once the IL10.R microsatellite has been amplified by 
PCR, the products separated by electrophoresis and then sized by the 
program GENESCAN™, the genotypes are semiautomatically assigned 
using GENOTYPER™. The IL10.R2 product is 114 base pairs (bp) in 
length and IL10.R3 is 116 bp. Therefore two of the individuals shown in 
this example are IL10.R2 and IL10.R3 heterozygotes and the other four 
are IL10.R2 homozygotes.
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Rheumatology (ACR) 1987 criteria for RA. The Sotho and Zulu groups have 
a similar genetic background (Spurdle and Jenkins, 1992). The SA patients 
with RA were recruited from the rheumatology outpatient clinic at the Chris 
Hani Baragwanath Hospital, Johannesberg, a tertiary referral centre. They 
were not chosen specifically for disease severity but all required disease 
modifying (DMARD) therapy. Dr M Tikly, their rheumatologist, recruited them 
for this study in 1997. The Caucasian patients were recruited from four 
centres within the UK: Oxford, Birmingham, Norfolk and Norwich and 
Glasgow by their rheumatologists’, Professors P. Wordsworth, P Bacon, DGI 
Scott, R Sturrock and Dr. R Madhok. The UK Caucasian patients were 
recruited if they had relatively severe disease and comprised of 75 patients 
with RA vasculitis, 22 with Felty’s Syndrome and 89 who had undergone a 
large joint replacement (hip or knee) within 15 years of the onset of disease. 
The mean age (± SD) of the SA patients was 49.5 (± 10.9) years, average 
disease duration was 7.6 (± 7.3) years and 76% were female. The mean age 
(± SD) of the Caucasian RA patients was 64 (± 11.6) years and 70 per cent 
were female. Mean disease duration was 18.7 (+ 10.5) years and mean age 
of disease onset was 44.9 (± 14.5) years. The South African controls 
included 73 healthy, ethnically matched hospital workers or outpatients seen 
at the Baragwanath Hospital for minor trauma and unrelated to each other or 
to the cases. The UK Caucasian control group consisted of 210 healthy 
Caucasian blood donors and 86 unaffected Caucasian spouses of patients 
attending a skeletal dysplasia clinic.
3.2.3.2 IL10.R genotyping:
Once the patients had provided a blood sample the whole blood was frozen 
at -20°C prior to DNA extraction. Blood samples taken in South African were 
frozen there and brought to the UK on ice. Genomic DNA was then extracted 
from peripheral venous blood samples using a standard guanidine- 
hydrochloride extraction technique (section 5.2.1). Concentrated DNA was at 
stored -70°C following extraction and a small sample diluted with sterile water
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to a concentration of 10ng/juL for the study. This dilute DNA was stored at 
4°C for the duration (two weeks) of the study. The IL10.R microsatellite, was 
amplified by PCR (primers were 5’ CCC TCC AAA ATC TAT TTG CAT A 
(upstream) and 5’ CTC CGC CCA GTA AGT TTC ATC (downstream), the 
latter being tagged with a fluorescent dye (HEX)). Reactions were optimised 
and carried out in 96 well plates (Costar) in 10piL reactions consisting of 50ng 
DNA, 400nM each primer, 50|uM each dNTP, 2.0mM MgCh and 0.2 units 
DNA polymerase (Bioline, UK) in the manufacturers NH4 buffer. The cycling 
conditions were 94°C 1 minute, annealing 60°C 1 minute, extension 72°C 1 
minute, for 32 cycles on MJ thermal cyclers. PCR products were diluted with 
water and separated by electrophoresis using ABI 373 DNA sequencers 
(Applied Biosystems, Warrington, UK) and 6% denaturing polyacrylamide 
gels over 3 hours. Test gels were run to ensure the PCR dilutions were 
optimised prior to separating PCR products by electrophoresis. Products 
were sized using the program GENESCAN™ Version 2.1 (Applied 
Biosystems, Warrington, UK) and genotypes semiautomatically assigned 
using the program GENOTYPER™ Version 1.1 (Applied Biosystems, 
Warrington, UK) (figs 3.2.1 and 3.2.2). All genotypes were then verified 
manually. The program GAS (Version 2) (A. Young, unpublished) was used 
to convert the size data into discrete allele numbers.
3.2.3.3 HLA-DR typing:
Sequence specific PCR, using 35 primers, was used to differentiate between 
the different HLA-DR alleles and undertake DR4 and DR1 subtyping (Bunce 
et al., 1995). Reactions were performed in 96 well plates (Costar) in 10|iL 
reactions consisting of 50ng DNA, 400nM each primer, 50|iM each dNTP, 
2.0mM MgCfe and 0.2 units DNA polymerase (Bioline, UK) in the 
manufacturers NH4 buffer. Cycling conditions were: 96°C (1min); 5 cycles 
(96°C (35sec), 70°C (45sec), 72°C (35sec)); 21 cycles (96°C (25sec), 65°C
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(50sec), 72°C (40sec)); 6 cycles (96°C (35sec), 55°C (1 min), 72°C 
(1.5mins)); hold at 15°C. Total duration of PCR was 1 hour 30 minutes.
3.2.3.4 Statistical analysis:
Allele and genotype frequencies were calculated by direct counting. Since a 
common source of error in genotype assignment is the over-calling of 
homozygotes, Hardy-Weinberg equilibrium (section 1.2.5.2) was used to 
predict the likely frequencies of IL10.R2 and IL10.R3 homozygotes and these 
figures were compared with the observed frequencies. IL10.R allele 
frequency distribution was compared between the Caucasians and South 
Africans and then between patients and controls. Subgroup analysis included 
disease severity (RA vasculitis, Felty’s Syndrome or an early large joint 
replacement), sex, and shared epitope status (homozygosity or 
heterozygosity). The significance of differences between groups was 
calculated from contingency tables by %2 analysis. Odds ratios with
confidence intervals were calculated.
3.2.4 Results
The frequency of the IL10.R2 allele was significantly higher (p=1 x1 O'6) in the 
South African population overall (0.78) compared to the UK Caucasians 
(0.66) while the frequency of IL10.R3 was correspondingly reduced (0.16 
versus 0.30, p=1x10'8) (table 3.2.1). However, no differences were observed 
in IL10.R allele frequencies between patients and controls in either racial 
group (table 3.2.2). Eight-four per cent of the UK Caucasian patients and 58 
per cent of the SA patients were positive for the shared epitope.
A variety of subgroups were defined from the UK Caucasian RA cohort to 
analyse any possible associations with IL10.R alleles. All alleles frequencies 
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Fig 3.2.1 is an example of the output from an ABI 373 sequencer once the 
microsatellite marker IL10.R has been separated by electrophoresis over 3 
hours using a 6% denaturing poylacrylamide gel. One of the IL10.R primers 
has a green fluorescent marker attached hence the amplified ILO.R 
microsatellite is shown as a green line on the gel. Products are sized using 
the program GENESA CAN“ which compares the size of the green PCR 
product with that of the red fluorescent markers also seen in the figure. 
These are size markers and are loaded at the same time as the PCR 
products. They are spaced at regular intervals throughout the gel and are 
used as a form of ruler.
IL10.R allele frequencies in Caucasian and South
African individuals
No. % No. %
Caucasian IL10.R1 4 0.4 11 2.5 ND
versus IL10.R2 640 66 350 79 1x1 O'6
South IL10.R3 287 30 69 16
1.4x10-8
Africans
IL10.R4 32 3.3 11 2.6 0.4
IL10.R5 1 0.1 1 0.3 0.6
Table 3.2.1 compares the allele frequencies of the various IL10.R alleles in the 
Caucasian and South African populations. It can be seen that the IL10.R2 allele 
occurs more commonly in the South African population than the Caucasian 
population (0.79 versus 0.66) and the IL10.R3 allele less commonly (0.16 versus 
0.3).
1 2 0
IL10.R allele frequencies in Caucasian and South
African patient and control groups.
No. % No. %
Caucasian IL10.R1 3 0.8 1 0.2 ND
patients IL10.R2 253 68 387 65 0.4 1.3(0.8-1.5)




IL10.R4 13 2.7 19 3.2 0.8
IL10.R5 0 0 1 0.2 ND
South IL10.R1 9 3.2 2 1.4 ND
African IL10.R2 223 78 127 77 0.4 0.8(0.5-1.4)
patients IL10.R3 47 17 22 15 0.5 1.25(0.7-2.2)
versus IL10.R4 7 2.5 4 2.7 ND
controls IL10.R5 0 0 1 0.7 ND
Table 3.2.2 compares the allele frequencies of the various IL10.R alleles in the 
Caucasian and South African patients versus the relevant control populations. 
No differences in allele frequencies were found between the South African 
patients and South African controls or between the Caucasian patients and 
controls.
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shared epitope status, extra-articular disease (RA vasculitis and Felty’s 
Syndrome) or early large joint replacement (table 3.2.3). The observed 
frequencies of IL10.R2 and IL10.R3 homozygous genotypes compared well 
with the predicted frequency of homozygotes by Hardy-Weinberg equilibrium 
suggesting alleles were being appropriately assigned.
3.2.5 Discussion
No association between IL10 haplotypes and RA was apparent in the current 
study, in contrast to previous reports of an increase in IL10.R2 and a 
reduction in IL10.R3 alleles (Eskdale et al., 1998b). There are several 
possible explanations for this. Firstly, the previously reported association with 
the IL10.R2 allele may have been spurious. Secondly, it may have been 
relevant that the IL10.R2 allele frequency in UK Caucasian controls in the 
Oxford study were significantly higher (0.65 versus 0.59, p=0.03) than that 
reported by Eskdale et al and the IL10.R3 frequency significantly lower (0.31 
versus 0.38, p=0.02). No difference in allele frequencies of IL10.R2 or 
IL10.R3 was apparent when the UK Caucasian patient groups from the two 
studies were compared (table 3.2.4). This may suggest that IL10 contributes 
a weak genetic effect but the relatively high frequency of IL10.R2 in the 
general population made the effect more difficult to detect reliably. Since the 
frequency of IL10.R2 was even higher in South African Sotho and Zulu 
populations, the power to detect association with RA would be further 
reduced. Previously reported estimates of relative risk for IL10.R in RA range 
between 1.5 and 2.5 (Eskdale et al., 1998b). The study in UK Caucasians 
had 80 per cent power to exclude an association between IL10 and RA with 
an odds ratio of > 1.8. However, in the South African study the higher 
frequency of the IL10.R2 allele (SA control frequency 77% versus 65% in 
Caucasians) meant that the power to detect an effect with an odds ratio of > 
1.8 was only 36 per cent. In contrast the study had 80 per cent power to
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IL10.R allele frequencies in Caucasian patient 
subgroups versus Caucasian control populations
No. % No. %
IL-10R1 0 (0) 1 (0.2) ND
Early large joint IL-10R2 123 (69) 387 (65) 0.4
replacement IL-10R3 49 (28) 184 (31) 0.4
IL-10R4 6 (3.3) 19 (3.2) 0.9
IL-10R5 0 (0) 1 (0.2) ND
IL-10R1 3 (2) 1 (0.2) ND
IL-10R2 100 (67) 387 (65) 0.07
RA vasculitis IL-10R3 42 (28) 184 (31) 0.46
IL-10R4 5 (3.3) 19 (3.2) 0.9
IL-10R5 0 (0) 1 (0.2) ND
IL-10R1 0 (0) 1 (0.2) ND
Felty's IL-10R2 29 (66) 387 (65) 0.9
Syndrome IL-10R3 13 (29) 184 (31) 0.8
IL-10R4 2 (5) 19 (3.2) ND
IL-10R5 0 (0) 1 (0.2) ND
Table 3.2.3 compares the IL10.R allele frequencies in the Caucasian patient 
subgroups with the Caucasian control population. Allele frequencies were 
compared using %2 analysis. No differences in allele frequencies were found.
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exclude a putative genetic effect with an odds ratio of > 3. Thirdly, genetic 
heterogeneity may be operating. The UK patients in this study were 
specifically selected for having more severe forms of RA and were only 
included if they had undergone an early large joint replacement or fulfilled the 
criteria for rheumatoid vasculitis or Felty’s Syndrome. This was in contrast to 
the previous report where the main recruitment criteria was RA fulfilling the 
1987 ACR criteria (Eskdale et al., 1998b). It is therefore likely that the 
disease severity of the Caucasian patients included in the two studies was 
different and it is conceivable that the IL10.R2 allele is not as strongly 
associated with severe forms of RA as it is with milder variants.
Inter-ethnic differences in IL10 allele frequencies were not unexpected as 
similar differences have been described previously for the TNF locus (Fei et 
al., 2002; Gallagher etal., 1997; Rudwaleit etal., 1996). Although in the case 
of TNF, linkage disequilibrium within the MHC may contribute to this variation 
(Rudwaleit etal., 1996).
A number of studies in normal individuals have demonstrated associations 
between IL10 secretion and microsatellite or SNP polymorphisms 
characterising distinct IL10 haplotypes (Eskdale et al., 1998a; Turner et al., 
1997). Other studies have suggested that some of these haplotypes are 
associated with inflammatory diseases (Crawley et al., 1999; Eskdale et al., 
1997b; Mozzato-Chamay etal., 2000). However, there is no really convincing 
evidence that the IL10.R2 or IL10.R3 polymorphisms are directly involved in 
influencing IL10 production or disease susceptibility. They may be markers 
for other relevant mutations within the gene. It is possible that only certain 
haplotypes containing IL10.R2 include the specific SNPs associated with 
increased IL10 secretion and susceptibility to RA. Equally, only certain 
haplotypes containing IL10.R3 may truly be under-represented and 
associated with reduced IL10 secretion. Discrimination between the various 
IL10.R2 or IL10.R3 extended haplotypes is not possible in a case control
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Table 3.2.4 summarises the published IL10.R2 and IL10.R3 allele frequencies in 
different patient groups (3 Caucasian, 1 African American and 1 South African) 
and control populations. It can be seen that the Caucasian control population 
used in this study (row 1 of the table) has a higher IL10.R2 allele frequency than 
other Caucasian control populations.
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study. As current evidence regarding a possible association of IL10 with RA 
is inconclusive it would be appropriate to conduct a within-family association 
study to define the effects of specific haplotypes and avoid any possible 
spurious effects that could occur as a result of unrecognised population 
stratification.
In conclusion, these studies did not confirm an association between IL10.R2 
and susceptibility to RA. However, as the data was inconclusive further 
studies investigating the likelihood that IL10 is associated with susceptibility 
to or severity of RA would be justified. To achieve adequate statistical power 
studies involving a larger cohort of patients would be required. Extended 
haplotyping of the IL10 promoter region should help to define any disease 
causing haplotypes and so improve the chances of identifying an association.
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Chapter 3 -  section 3
3.3 Study 3: a family-based association study.
Interleukin 10 haplotypes are associated with rheumatoid 
arthritis.
3.3.1 Abstract
Introduction: Interleukin 10 (IL10), an immunoregulatory cytokine, may
modulate disease expression in rheumatoid arthritis (RA). The IL10 gene is 
highly polymorphic with a number of single nucleotide polymorphisms and 
two microsatellite loci, IL10.R and IL10.G, in the promoter region. A recent 
report has suggested that allele 2 of the IL10.R microsatellite (IL10.R2) is 
associated with increased IL10 secretion and IL10.R3 with reduced secretion. 
Another report has found over-representation of IL10.R2 in three independent 
RA cohorts and under-representation of IL10.R3.
Aim: To determine by within family association analysis whether particular 
alleles or haplotypes of IL10.R and/or IL10.G are associated with RA.
Methods: The IL10.R and IL10.G microsatellites were used to genotype 163 
individuals, fulfilling the 1987 ACR criteria for rheumatoid arthritis, and their 
first-degree relatives. Single marker and haplotypic association studies were 
performed by transmission disequilibrium testing (TDT) using the software 
package TRANSMIT.
Results: The IL10.R1 allele was transmitted to affected individuals more 
frequently than expected (p<0.05) and the IL10.R3 allele was transmitted less 
frequently than expected (p<0.05). This effect was particularly pronounced 
with the IL10.R3 / IL10.G10 haplotype (p<0.005).
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Conclusions: This study is consistent with previous observations that the 
IL10.R3 allele is under-represented in RA. However, the still stronger 
negative association found with the haplotype IL10.G10 / IL10.R3 suggests it 
is not IL10.R itself but another polymorphism on this particular haplotype that 
may be primarily involved with RA.
3.3.2 Introduction
Results from case control studies investigating the association between RA 
susceptibility and IL10 microsatellite alleles (see above) have been 
conflicting. There is no really convincing evidence that IL10 polymorphisms 
are directly involved in influencing IL10 production or disease susceptibility. 
The IL10 polymorphisms could be markers for other relevant mutations within 
the gene causing true disease susceptibility or severity. Distinguishing 
between a primary effect arising from a genetic variant or an effect arising 
from linkage disequilibrium can be difficult using a case-control study. Also, 
type 1 errors (false positive) can occur as a result of unidentified population 
stratification (section 1.2.10). Family-based association studies avoid 
population stratification by using family members as internal controls (i.e. the 
non-transmitted allele is the ‘control’) and also allow for the analysis of 
haplotype transmission. As haplotypes mark recognisable chromosomal 
segments that are transmitted en-block through a pedigree this may increase 
the likelihood of identifying a true association. Hence a third study was 
designed to investigate a possible association between the IL10 locus and 
susceptibility to rheumatoid arthritis by using intra-familial methods of 
association analysis including transmission disequilibrium testing (TDT 
analysis).
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Information regarding the background work relating to IL10 and its candidacy 
for association with RA susceptibility has been discussed earlier in this 
chapter.
3.3.3 Materials and methods
3.3.3.1 Patients and controls
One hundred and sixty-three simplex Caucasian RA families were studied. 
All were recruited from United Kingdom; 55 from the Oxfordshire area and the 
remaining 108 from the Arthritis Research Campaign (ARC) United Kingdom 
National Repository of multicase RA families (ARC multicase families). All 
affected individuals fulfilled the American College of Rheumatology 1987 
criteria for RA. Families recruited in the Oxfordshire area were recruited if 
blood was available from the proband and both parents (i.e. TDT families). 
Local ethics committee approval was obtained and all patients and probands 
gave fully informed consent. The families were recruited in 1997 by a 
research nurse based at the Wellcome Trust Centre for Human genetics 
(WTCHG) in Oxford. DNA was available from the proband and both parents 
in 108 (66%) of families (from the Oxfordshire TDT families and 38 ARC 
multicase families) but only one parent and the proband were available for the 
remaining 55 (34%) families. Additional siblings were recruited where 
possible (14/55 families) to facilitate the assignation of parental genotypes.
3.3.3.2 Probands
The mean age (+/- SD) of the probands was 38 (+/- 10) years. Eighty-two 
percent of the probands were female. Forty-four percent of the probands 
included in the study had a first-degree relative (62 parents and 11 siblings) 
with rheumatoid arthritis. Twenty-one (15%) probands had an affected father 
and 41 (25%) an affected mother. There was no difference in the frequency
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Fig 3.3.1 is an example of the output from an ABI 373 
sequencer once the microsatellite markers IL10.R and IL10.G 
have been separated by electrophoresis using a 6% 
denaturing poylacrylamide gel over 3 hours. The IL10.G PCR 
product has been tagged with a blue fluorescent label, IL10.R 
is green and the size markers are red (as in fig 3.2.1).
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of having an affected parent between male and female probands (34% and 
38% respectively, p = 0.83). An equal number of male probands had an 
affected father (4 probands, 14%) or an affected mother (4 probands). 
However, more female probands had an affected mother (34 probands, 25%) 
than an affected father (17 probands, 13%) (p=0.008).
3.3.3.3 IL10.G and IL10.R genotyping:
Genomic DNA was extracted from peripheral venous blood samples using a 
standard guanidine-hydrochloride extraction technique (appendix 5.2.1). 
Concentrated DNA was at stored -70°C following extraction and a small 
sample diluted with sterile water to a concentration of 10ng/pL for the study. 
This dilute DNA was stored at 4°C for the duration (two weeks) of the study. 
The IL10.R and IL10.G microsatellites were amplified by PCR. Primers for 
IL10.R were 5’ CCC TCC AAA ATC TAT TTG CAT A (upstream) and 5’ CTC 
CGC CCA GTA AGT TTC ATC (downstream) and IL10.G, 5’ GAA GAA GTC 
CTG ATG TCA CT (upstream) and 5’ GCC TTA GTA GTG TTG TCT TGG AT 
(downstream). The IL10.R primers used were the same as those used for the 
case-control studies (above) and as in the study by Eskdale et al (Eskdale et 
al., 1998b). The IL10.G primers were designed for the study (K.R MacKay) 
and both sets of primers were supplied by MWG-Biotech, UK. Both reverse 
primers were tagged with a fluorescent dye (HEX or FAM). Reactions were 
optimised and performed in 96 well plates (Costar) in 10pL reactions 
consisting of 50ng DNA, 400nM each primer, 50(aM each dNTP, 2.0mM 
MgCI2 (4.0mM MgCfefor IL10.G) and 0.2 units DNA polymerase (Bioline, UK) 
in the manufacturers NH4 buffer. The cycling conditions were 94°C 1 minute, 
annealing 60°C 1 minute, extension 72°C 1 minute, for 32 cycles. PCR 
products were diluted with water, pooled and separated by electrophoresis 
using an ABI 373 semi-automated sequencer (Applied Biosystems, 
Warrington, UK) and 6% denaturing polyacrylamide gels over 3 hours (fig
3.3.1). Test gels were run to ensure the PCR dilutions were optimised prior 
to separating PCR products by electrophoresis. Products were sized using
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155 160 165 170 175
-4 0 0 0
-2000
8 Blue 45.2
-4 0 0 0
-3 0 0 0
-2000
-1000
09*45 .3 9 Blue 45.3
-2000
-1000
13*47.1 13 Blue 47.1





-1 5 0 0
-1000
-5 0 0
15*47.3 15 Blue 47.3
-2000
-1 5 0 0
-1000
-5 0 0
-1 5 0 0
-1000
-5 0 0
Fig 3.3.2 is an example of the output obtained using the program 
GENOTYPER™. The genotypes are semi-automatically assigned using 
GENOTYPER™. The PCR product sizes of the IL10.G alleles range from 
14 2 - 172 base pairs in length.
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the program GENESCAN™ Version 2.1 (Applied Biosystems) and genotypes 
semiautomatically assigned using the program GENOTYPER™ Version 2.1 
(Applied Biosystems) (fig 3.3.2). All genotypes were then verified manually. 
The program GAS (Version 2) (A. Young, unpublished) was used to convert 
the size data into discrete allele numbers.
3.3.3.4 HLA-DR typing:
Sequence specific PCR, using 35 primers, was used to differentiate between 
the different HLA-DR alleles and undertake DR4 and DR1 subtyping (Bunce 
et al., 1995; Olerup and Zetterquist, 1992). Reactions were performed in 96 
well plates (Costar) in 10piL reactions consisting of 50ng DNA, 400nM each 
primer, 50pM each dNTP, 2.0mM MgCL and 0.2 units DNA polymerase 
(Bioline, UK) in the manufacturers NH4 buffer. Cycling conditions were: 96°C 
(1min); 5 cycles (96°C (35sec), 70°C (45sec), 72°C (35sec)); 21 cycles (96°C 
(25sec), 65°C (50sec), 72°C (40sec)); 6 cycles (96°C (35sec), 55°C (1 min), 
72°C (1.5mins)); hold at 15°C. Total duration of PCR was 1 hour 30 minutes.
3.3.3.5 Statistical analysis:
Allele and genotype frequencies were calculated by direct counting. A 
common source of error in genotype assignment is the over-calling of 
homozygotes. Hardy-Weinberg equilibrium was used to predict the likely 
homozygote frequencies of the commonest IL10.R and IL10.G alleles 
(section 1.2.5.2). These figures were then compared with the observed 
frequencies. Single marker and haplotypic association studies were 















Fig 3.3.3 illustrates the IL10.R allele frequencies identified in this 
Caucasian population. The most frequent allele was IL10.R2 with a 




IL10.R and IL10.G genotypes and hapolotypes
IL10.R and IL10.G allele frequencies for the 458 individuals studied are 
shown in figures 3.3.3 and 3.3.4. The individual allele frequencies were 
similar to those previously reported, although IL10.R2 occurred more 
frequently (63%) and IL10.G9 less frequently (37%) than in some other 
studies. The existence of 12 alleles for IL10.G ranging from 14 CA repeats to 
29 CA repeats was confirmed. However no IL10.G allele with a length of 15, 
16, 17 or 18 CA repeats was found (fig 3.3.4 and table 3.3.1). This 
accounted for the apparent shortfall from the theoretical number of 16 alleles. 
If the missing alleles exist their frequency in Caucasians is less than 0.001.
Association testing for IL10.R and IL10.G as individual markers was possible 
in 157 families (IL10.G) and 162 families (IL10.R). TDT analysis using the 
software program TRANSMIT (section 1.2.10.3) identified an association for 
IL10.R (global x2, (3 degrees of freedom (df) = 8.7; p < 0.05). IL10.R1 alleles 
were transmitted more frequently than expected (x2 = 4.3(1 df); p < 0.025) and 
IL10.R3 alleles less frequently than expected (x2 = 4.1 (1df); p < 0.025) (table 
3.3.2). IL10.G was not found to be associated with RA (global %2 = 9.6(11df), 
NS).
The frequencies of IL10.R/IL10.G haplotypes are shown in figure 3.3.5. The 
commonest haplotype was IL10.R3/IL10.G9 at a frequency of 18.7%. TDT 
haplotypic analysis using TRANSMIT revealed a strong association with the 
haplotype IL10.R3/IL10.G10 (x2=8.835 (1df), p<0.005) and a slightly weaker 
association with IL10.R1/IL10.G12 (x2= 5.1 (1 df), p<0.025) (table 3.3.3). The 
haplotypic association for IL10.R3 / IL10.G10 was stronger than when any of 
the IL10.R alleles were analysed individually (table 3.3.2).
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Differing PCR product sizes depending upon the 
amplifying primers
IL10.G1 14 124 142
IL10.G2 15 126 144
IL10.G3 16 128 146
IL10.G4 17 130 148
IL10.G5 18 132 150
IL10.G6 19 134 152
IL10.G7 20 136 154
IL10.G8 21 138 156
IL10.G9 22 140 158
IL10.G10 23 142 160
IL10.G11 24 144 162
IL10.G12 25 146 164
IL10.G13 26 148 166
IL10.G14 27 150 168
IL10.G15 28 152 170
IL10.G16 29 154 172
Fig 3.3.1 lists two differing sets of IL10.G PCR product size. The size of the 
products depended upon which set of primers were used to amplify the IL10.G 
microsatellite. The Initial primers used to amplify IL10.G were those published 
by Eskdale et al [Eskdale, 1997 #532] but the primers were re-designed 
because of frequent primer failure. The re-designed primers amplified a larger 












Allele Frequency Allele Frequency
IL10.G1 0.002 IL10.G9 0.366
IL10.G2 0 IL10.G10 0.095
IL10.G3 0 IL10.G11 0.108
IL10.G4 0 IL10.G12 0.108
IL10.G5 0 IL10.G13 0.169
IL10.G6 0.001 IL10.G14 0.058
IL10.G7 0.022 IL10.G15 0.005
IL10.G8 0.063 IL10.G16 0.005
Fig 3.3.4 illustrates the frequency of IL10.G alleles in this Caucasian 
population. The most frequent allele was IL10.G9 with a frequency of 
0.366. The second most frequent allele was IL10.G13 at 0.169. The 
table lists the frequency of all the IL10.G alleles in this population.
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3.3.5 Discussion
IL10.R was found to be associated with RA whereas IL10.G was not. This is 
in keeping with the results of the case control study reported by Eskdale and 
colleagues (Eskdale et a/., 1998b) but it is in contrast to the results of the two 
case control studies discussed above. The IL10.R3 allele was under­
represented in this rheumatoid population and excess transmission of the 
less common IL10.R1 allele was identified. The under-representation of 
IL10.R3 corresponds to a previous study (Eskdale et al., 1998b) but the over­
representation of IL10.R1 has not been reported previously. Finally, the over­
representation of IL10.R2 that was noted in a previous study was not 
confirmed (Eskdale et al., 1998b). Haplotype analysis revealed a stronger 
negative association with the haplotype IL10.R3 / IL10.G10. This suggests 
that the locus IL10.R is not the primary association but that another 
polymorphism on the IL10.R3 / IL10.G10 haplotype may be involved.
The results of IL10 microsatellite association studies may vary because of 
differences in disease severity between the patient cohorts. A number of 
groups have reported associations between IL10 and disease severity rather 
than susceptibility [Mok, 1998 #327; Huizinga, 2000 #634]. In addition to any 
anti-inflammatory properties, IL10 plays an important role in B cell 
proliferation and differentiation (Rousset et al., 1992). High levels of IL10 
have been found in rheumatoid arthritis and may actively contribute to 
disease progression by elevating autoimmune activity (Perez et al., 1981). 
IL10.R3 alleles have been associated with lower levels of IL10 secretion in 
vitro (Eskdale et al., 1998a) and it may be of importance that IL10.R3 alleles 
have been found to be under-represented in this family association study and 
an earlier case-control study (Eskdale et al., 1998b). Although, the cohort in 
this study was not specifically chosen for disease severity, the individuals 
developed RA at a relatively young age and many of them had a family 
history of RA. Both early age of onset and family history are risk factors for
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TDT analysis of IL10.R alleles
R1 28 22 4.3 <0.025
R2 222 217 0.6 NS
R3 86 98 4.1 <0.025
R4 6 5 0.6 NS
1 df = 1 degree of freedom
Table 3.3.2 summarises the results of transmission disequilibrium testing 
(TDT) of IL10.R alleles. It can be seen that the IL10.R1 allele has a low 
population frequency but was inherited more frequently than expected. 
The IL10.R3 allele (second most frequent allele) was inherited less 
frequently than expected. The IL10.R1 results need to be treated with 
caution because the allele is rare and therefore the difference in allele 
frequency between ‘observed’ and ‘expected’ is small and may be prone 
to bias.
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more severe disease (Deighton et al., 1994; Grennan and Sanders, 1988; 
Lynn e ta i, 1995).
An alternative explanation for these differing results could be the high IL10.R2 
allele frequency in the general population as this may make the detection of a 
weak genetic effect unreliable. Small differences in the control IL10.R2 allele 
frequency could therefore alter results. Table 3.2.4 lists the IL10.R2 allele 
frequencies of the patient and control groups from the various IL10 
microsatellite studies. The IL10.R2 allele frequencies of the Caucasian 
control populations do vary but the only statistically significant difference is 
between the controls used in the case-control study described above and 
those used by Eskdale and colleagues (0.65 versus 0.59, p=0.03) (Eskdale et 
al., 1998b). The ‘control’ IL10.R2 allele frequencies in the TDT study do not 
differ statistically from those in either of the two case-control studies.
Although IL10.R has now been associated with RA in two independent 
studies, different IL10.R alleles have been identified as being associated with 
the disease in each report. Unidentified population stratification in a case 
control study could lead to a type 1 or type 2 error and it is possible that the 
reported association with the IL10.R2 allele is spurious. A family based 
association study avoids population stratification by using the un-transmitted 
parental allele as the ‘control’ hence avoiding one potential source of error. 
As both studies identified an under-representation of the IL10.R3 allele, on 
present evidence this seems to be the most likely true association.
The use of IL10 promoter polymorphisms to investigate the relationship of the 
IL10 gene with RA is based upon two assumptions. Firstly, that these 
polymorphisms are associated with differences in IL10 production. Secondly, 
that differences in IL10 secretion are associated with RA susceptibility or 
severity. However the relevant stimulus for the production of IL10 is unknown 
and the polymorphisms studied may be in linkage disequilibrium with other
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IL10.G8/R1 0.016 IL10.G12/R2 0.066
IL10.G10/R1 0.002 IL10.G13/R2 0.166
IL10.G11/R1 0.009 IL10.G14/R2 0.057
IL10.G12/R1 0.032 IL10.G15/R2 0.003
IL10.G13/R1 0.012 IL10.G16/R2 0.003
IL10.G5/R2 0.002 IL10.G8/R3 0.009
IL10.G6/R2 0.002 IL10.G9/R3 0.187
IL10.G7/R2 0.023 IL10.G10/R3 0.053
IL10.G8/R2 0.041 IL10.G11/R3 0.022
IL10.G9/R2 0.157 IL10.G12/R3 0.010
IL10.G10/R2 0.039 IL10.G9/R4 0.010
IL10.G11/R2 0.074 IL10.G10/R4 0.002
Fig 3.3.5 illustrates the frequency of the commonest IL10.G and R 
haplotypes in this Caucasian population. The most frequent 
haplotype was IL10.G9/R3 with a frequency of 0.187. The table lists 
the frequency of all the IL10.G and R haplotypes within this 
population.
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relevant mutations within the gene. Hence, the polymorphisms studied to 
date may not be truly associated with RA and defining a common DNA 
sequence transmitted en-block that is inherited by those with the disease 
would improve the chances of identifying a true disease associated 
polymorphism. Extended haplotyping in a family based association study can 
narrow down the DNA sequence of interest by identifying strong associations 
between specific haplotypes and RA. Therefore, the stronger negative 
association with the haplotype IL10.R3 / IL10.G10 suggests that the locus 
IL10.R is not the primary association and that another polymorphism on the 
IL10.R3 / IL10.G10 haplotype may be involved.
In conclusion, IL10 haplotypes are associated with RA. The IL10.R3 allele is 
under-represented and the IL10.R1 allele over-represented in individuals with 
RA. The haplotype IL10.R3 / IL10.G10 is more strongly associated 
suggesting that a polymorphism on this particular haplotype may be primarily 
involved with disease. Extended haplotyping, using both microsatellites and 
SNPs in a further independent family dataset, would be the next step to 
confirm the association and narrow down the DNA sequence of interest.
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TDT analysis of IL10 G and R haplotypes
IL10.G12/R1 14 10 5.7 <0.025
IL10.G8/R2 13 13 0 NS
IL10.G9/R2 52 52 0 NS
IL10.G10/R2 15 12 1.4 NS
IL10.G11/R2 29 24 2.6 NS
IL10.G12/R2 21 22 0 NS
IL10.G13/R2 52 55 0.5 NS
IL10.G14/R2 20 19 0 NS
IL10.G9/R3 61 61 0 NS
IL10.G10/R3 9 17 8.8 <0.005
1 df = 1 degree of freedom
Only haplotypes with a frequency above 0.03 are shown
Table 3.3.3 illustrates the results of transmission disequilibrium testing (TDT) 
of the IL10 G and R haplotypes. The haplotype IL10.G12/R1 is shows a 
positive association with RA because the observed inheritance is greater than 
expected. This is in keeping with the TDT analysis of the IL10.R alleles. 
However, the result must be treated with caution because it is an uncommon 
haplotype and the numbers involved in the analysis are small.
Of greater importance, the haplotype IL10.G10/R3 shows a significant 
negative association with RA (p < 0.005) because it is inherited less 
frequently than expected. This negative association is in keeping with the 
results of the IL10.R TDT analysis but is stronger than that identified with 
IL10.R3 alone. This may indicate that the haplotype rather than the IL10.R3 
allele is associated with RA. Although this haplotype is also uncommon the 
results can be viewed with a greater degree of confidence because the x2 




Conclusions and future work
Rheumatoid arthritis (RA) is a chronic inflammatory disease predominantly 
involving synovial joints. It is common, affecting up to 1% of the population 
and is costly with a two-fold increased mortality, significant morbidity and high 
financial costs. Evidence from twin (Aho etal., 1986; Silman etal., 1993) and 
family (Deighton and Walker, 1991) studies suggest that both genetic and 
environmental factors contribute to susceptibility and disease heritability has 
been estimated to be approximately 60% (MacGregor et al., 2000). The 
major histocompatibilty complex (MHC) on chromosome 6 has been 
consistently linked to and associated with RA susceptibility (Oilier and 
Thomson, 1992). However, family studies suggest that this accounts for only 
one-third of the genetic susceptibility (Deighton et al., 1989; Wordsworth, 
1991). It is likely that a number of other susceptibility loci exist, each 
contributing less than the MHC to the total genetic component.
Systematic linkage screening of the entire genome has the potential to detect 
all disease susceptibility loci if appropriately powered. However, it is 
necessary to study very large numbers of affected sibling pair (ASP) families 
if adequate power to detect linkage to non-MHC genes is to be generated 
(Brown and Wordsworth, 1998). Recruitment is difficult in a late onset 
disease such as RA and may require international collaboration. Undertaking 
whole genome analysis on such large numbers of individuals is both 
expensive and time consuming. Therefore the strategy has been to perform 
genome-wide screens on manageable numbers of families aiming to study 
any overlapping regions of nominal linkage (p<0.05) reported in two or more 
independent data sets in greater detail with larger numbers of independent 
ASPs (Holmans and Craddock, 1997).
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Results from three whole genome scans (WGS) in Japanese (Shiozawa et 
al., 1998), European (Cornelis et al., 1998) and North American (Jawaheer et 
al., 2001) RA families have already been reported and linkage to the MHC 
was confirmed (p<2.5x10'5) in the European and North American studies. A 
number of non-MHC regions with evidence of nominal linkage (p<0.05) were 
also identified. A number of these apparent linkages will be false positives 
and it is therefore important that all findings are independently confirmed in 
further data sets. Of the three reported WGS, nominal linkage to overlapping 
regions has been reported in two or more data sets for eight regions on 
chromosomes 3q, 8p, 12q, 14q, 16p, 16q, 18q and Xp (8, 9, 10) (Tables
2.2.1). These are therefore important candidate regions for containing true 
RA susceptibility loci, but, since the individual RA WGS have relatively low 
power to identify linkage to genes of small effect, some regions of true linkage 
are likely to have been missed.
Although linkage analysis is an integral part of the search for susceptibility 
genes it is both expensive and time consuming. The search for candidate 
genes, undertaken in parallel, can be a useful method of investigating 
biologically plausible candidate genes at considerably less cost in time and 
resources. Genes that control cytokine parameters are among the most 
obvious candidates to study in a chronic inflammatory disease such as 
rheumatoid arthritis.
Association studies are generally used to study candidate genes. The 
simplest form of association study is the case control study. This has the 
advantage of relatively easy collection of ‘cases’ as other family members are 
not required. However, non-random mating in a population leading to 
population stratification or assortative mating can produce spurious results. 
Family based association studies where the non-transmitted parental allele is 
used as the ‘control’ can overcome this problem. Most polymorphisms
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studied are unlikely to be the real cause of disease susceptibility unless there 
is convincing evidence that the polymorphism is directly involved in 
influencing the production of a protein such as producing a stop codon and 
therefore a truncated protein. It is more likely that the polymorphism is a 
marker for other relevant mutations within the gene. Therefore, haplotyping, 
using a family based association study, is often undertaken to narrow down 
the region of interest.
This thesis presents results from both linkage and candidate gene studies 
designed to identify novel susceptibility loci, confirm linkage to previously 
identified regions and confirm or refute the involvement of IL10 as a gene 
involved in the susceptibility or severity of RA. This is a common and costly 
disease and learning more about factors predisposing to disease 
susceptibility and severity is without doubt of great importance.
SUMMARY OF LINKAGE STUDY RESULTS
Replication study
This study was designed to test for linkage to candidate susceptibility loci 
identified in the ECRAF study (Cornelis et al., 1998), which was the first 
systematic linkage screen of the whole genome in RA. An independent 
cohort of 368 UK ASPs, fulfilling 1987 ACR criteria for RA (Arnett et al., 
1988), were used. Eighteen regions with nominal evidence of linkage 
(p<0.05) identified by single or multi-point analysis were studied using 59 
suitable and informative microsatellites based within the regions of interest. 
Nominal evidence for linkage was identified for three markers by single point 
analysis: D12S95 (p<0.05), CYP19 (p<0.05) and D21S1252 (p<0.02). Multi­
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point analysis, using MAPMAKER/SIBS, did not provide further evidence for 
linkage.
It was not surprising that only three of the 14 regions identified by the 
European genome screen were reproduced in the UK replication study. 
Linkage analyses undertaken in other complex diseases reveal the same lack 
of consistent results when studying independent family collections. Examples 
include studies of insulin dependent diabetes mellitus (IDDM) (Concannon et 
al., 1998; Davies etal., 1994; Luo et al., 1996) and multiple sclerosis (Ebers 
et al., 1996; Haines et al., 1996). This inconsistency has been attributed to a 
number of factors including clinical and genetic heterogeneity, the use of 
different markers and analytical methods and poorly powered study designs 
unable to detect weak genetic effects. It is also accepted that a large 
proportion of apparent linkages identified by genome-wide linkage analysis 
will be false positives requiring confirmation of results in independent data 
sets (Lander and Kruglyak, 1995).
Two other regions identified by the European WGS, 18q22-23 and 3q13 
contain the IDDM6 and IDDM9 loci and were studied in a further 194 
European ASPs from 164 families (Cornelis et al., 1998). The region 18q22- 
23 did not reach significance in the larger cohort. Suggestive linkage to the 
chromosome 3 region was found in the combined data set but was only 
evident in HLA concordant RA pairs (p=0.001). Linkage was not significant in 
the remaining RA pairs (p=0.08). Candidate genes within the 3q13 region 
include genes coding for CD80 and CD86 which interact with T cell molecules 
CTLA4 and CD28 in the co-stimulatory pathway (Cornelis et al., 1998). No 
evidence for linkage in either region was identified by the UK replication study 
although the region on chromosome 3 at 3q13 may warrant further 
investigation as this area has been identified in two independent datasets 
(Cornelis etal., 1998).
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Whole genome linkage analysis
The UK genome-wide linkage analysis was initiated prior to the publication of 
the NARAC study and the aim was to generate additional regions where 
linkage may be found and to replicate any evidence of linkage at specific loci 
already identified. Once the North American WGS was reported nominal 
linkage to eight overlapping regions reported in two or more data sets 
(Cornelis et al., 1998; Jawaheer et al., 2001; Shiozawa et al., 1998) was 
identified (table 2.2.1). These were important candidate regions for including 
true RA susceptibility loci. However, some regions of true linkage are likely to 
have been missed because most whole genome screens have relatively low 
power to identify linkage to genes of small effect (Brown and Wordsworth,
1998).
The UK WGS performed on a large well-characterised cohort of 182 UK 
Caucasian RA families and included 252 ASPs. The whole genome was 
spanned with a mean marker distance of ~ 10-cM using 368 highly 
informative microsatellites. Linkage to the HLA region on chromosome 6 was 
confirmed by multipoint analysis (max LOD = 4.7 at marker D6S276, 
p=0.000003, 1cM from HLA-DRB1). Suggestive evidence of linkage by 
multipoint analysis was identified on chromosome 6q nominal evidence of 
linkage by multipoint analysis was found for 3 additional linkage intervals; 1q, 
and two areas on 14q. Single point analysis also identified suggestive 
linkage for one marker on chromosome 6q and nominal linkage (p<0.05) was 
identified for 10 additional linkage intervals on chromosomes 3p, 4q, 7p, two 
sites on both 10q and 14q, 16p, 21q and Xq (table 2.3.6). Six of these non- 
HLA regions were also reported by the ECRAF (Cornelis et al., 1998) and/or 
NARAC (Jawaheer et al., 2001) studies (chromosomes 3q, 6q, 10q, 14p, 14q 
and 16p) and a number overlapped with regions linked to other autoimmune 
diseases (Tables 2.3.7 and 2.3.8). No supporting evidence was found for the 
IDDM 6 locus on chromosomes 18 or the IDDM 9 locus on chromosme 3,
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sites which had shown evidence for linkage in the ECRAF study (Cornelis et 
al., 1998).
A number of other studies have been undertaken using UK ASP families that 
overlap with those used in the UK WGS. John et al reported linkage to a 
single marker mapping to an intron within the Estrogen Synthase gene (CYP- 
19) (John et al., 1999). Fife et al investigated Corticotrophin Releasing 
Hormone (CRH) as a candidate RA susceptibility locus and have reported 
both linkage and association at this site (Fife et al., 2002; Fife et al., 2000). 
The replication study discussed above identified three sites of nominal 
linkage by single point analysis: D12S95 (p<0.05), CYP19 (p<0.05) and 
D21S1252 (p<0.02). However, none of these regions were identified by the 
UK genome-wide linkage analysis. With the marker density used in this study 
(as with all WGS to date) linkage to these (and other postulated disease) loci 
could have been missed. Therefore, these regions cannot be excluded as 
potential disease genes.
Power calculations suggested that the WGS should have 80% power to 
detect loci contributing X = 1.6 using the threshold for detection as a LOD >
1.0. This may have been an overestimate because power calculations 
assume that all families are fully informative. Parental DNA was available in 
just over one third of the families but DNA from unaffected siblings was 
available in 94% of the remaining families. This was used to infer parental 
haplotypes when these were not directly obtainable and is one of the 
strengths of the study. However, HLA-DRB1 is thought to have a X = 1.6 and 
the WGS (despite the fairly large numbers of ASPs studied) was calculated to 
have 80% power to detect loci contributing X = 1.6 i.e. the equivalent to HLA. 
Non-HLA loci are thought to contribute to smaller X values than HLA hence 
the power to detect such loci will be less. This may be an additional reason 
why a number of suspected regions were not identified.
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In order to make best use of the information arising from this and other similar 
sized WGS, a number of strategies have been suggested. One proposal is to 
perform the initial screen in a relatively small data-set and then to test those 
loci demonstrating nominal evidence of linkage (p<0.05) in a larger data-set 
(Holmans and Craddock, 1997). Hence, the UK WGS could be seen as a 
replication data set in which to test positive linkages detected in the US and 
European whole genome studies. A complementary but alternative approach 
would be to undertake a meta-analysis analysis of the genotype data already 
obtained by published whole genome screens. By combining this data it 
should be possible to make more robust interpretations of the evidence so 
focusing the efforts of the replication studies.
SUMMARY OF CANDIDATE GENE STUDY RESULTS 
IL10 case con tro l studies
IL10 may be involved in susceptibility and/or severity to RA for a number of 
reasons. It is a cytokine with anti-inflammatory capabilities (Cassatella et al., 
1993; de Waal Malefyt et al., 1991; Fiorentino et al., 1989; Fiorentino et al., 
1991a; Katsikis et al., 1994) but is a potent up-regulator of B cell production 
and differentiation (Rousset et al., 1992). Transgenic mice with inactivated 
IL10 show normal development of lymphocytes and antibody responses but 
most animals are growth retarded, anaemic and suffer from chronic 
enterocolitis. Repeated administration of IL10 into these mutants can 
transiently cure their disease (Kuhn et al., 1993). Variation in IL10 secretion 
is largely genetically determined (Westendorp et al., 1997) and differences in 
secretion have been associated with various chronic inflammatory and 
infectious diseases (Derkx etal., 1995; Kurtzhals etal., 1998; Lehmann etal., 
1995; Westendorp et al., 1997). The IL10 gene maps to the junction of 1q31- 
q32 (Eskdale et al., 1997a). IL10 secretion has been associated with 
particular haplotypes defined by the microsatellite polymorphisms, IL10.G and
210
IL10.R (Eskdale and Gallagher, 1995; Eskdale et al., 1996). Various 
genotypes of IL10.R, IL10.G and SNPs have been reported to show 
association with a variety of chronic inflammatory diseases (Crawley et al., 
1999; Mok et al., 1998). The IL10.G microsatellite has been associated with 
SLE (Eskdale et al., 1997b) and the IL10.R2 allele was over-represented and 
the IL10.R3 allele under-represented in rheumatoid arthritis (Eskdale et al., 
1998b).
The simplest form of association study is the case control study. It has the 
advantage of relatively easy collection of ‘cases’ as other family members are 
not required. In genetic studies, where only DNA is needed from the control 
population, normal blood donors can be used providing they are of the same 
ethnic background and sex match as the cases. To investigate whether an 
association could be identified between RA susceptibility and IL10.R 
microsatellite alleles two case control studies were undertaken; one in a 
Caucasian population consisting of individuals with severe RA and the other 
in a Black South African population not specifically selected for disease 
severity. No differences were observed in IL10.R allele frequencies between 
patients and controls in either racial group (table 3.2.2). The frequency of 
IL10.R2 was significantly higher (p=1x10-6) in the South African population 
overall (0.78) compared to the UK Caucasians (0.66) while the frequency of 
IL10.R3 was correspondingly reduced (0.16 versus 0.30, p=1x10"8). 
Subgroup analysis of the UK Caucasian RA cohort did not identify any 
association with IL10.R alleles.
These results were in contrast to previous reports of an increase in IL10.R2 
and a reduction in IL10.R3 alleles (Eskdale et al., 1998b). There are several 
possible explanations for this. Firstly, the previously reported association with 
the IL10.R2 allele may have been spurious. Secondly, it may have been 
relevant that the IL10.R2 allele frequency in UK Caucasian controls in the 
Oxford study were significantly higher (0.65 versus 0.59, p=0.03) than that
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reported by Eskdale et al and the IL10.R3 frequency significantly lower (0.31 
versus 0.38, p=0.02). This may suggest that IL10 contributes a weak genetic 
effect but the relatively high frequency of IL10.R2 in the general population 
made the effect more difficult to detect reliably. Since the frequency of 
IL10.R2 was even higher in South African Sotho and Zulu populations, the 
power to detect association with RA would be further reduced. Thirdly, 
genetic heterogeneity may be operating. The UK patients in this study were 
specifically selected for having more severe forms of RA and were only 
included if they had undergone an early large joint replacement or fulfilled the 
criteria for rheumatoid vasculitis or Felty’s Syndrome. This was in contrast to 
the previous report where the main recruitment criteria was RA fulfilling the 
1987 ACR criteria (Eskdale et al., 1998b). It is therefore likely that the 
disease severity of the Caucasian patients included in the two studies was 
different and it is conceivable that the IL10.R2 allele is not as strongly 
associated with severe forms of RA as it is with milder variants.
IL10 family based association study
Non-random mating in a population leading to population stratification or 
assortative mating can produce spurious results in a case control study. 
Also, most polymorphisms studied are unlikely to be the real cause of disease 
susceptibility unless there is convincing evidence that the polymorphism is 
directly involved in influencing the production of a protein such as producing a 
stop codon and therefore a truncated protein. It is more likely that the 
polymorphism is a marker for other relevant mutations within the gene. 
Therefore, haplotyping is often undertaken to narrow down the region of 
interest (section 1.2.10.5) but this can only be performed using family based 
association methods e.g. TDT analysis.
A third study using TDT analysis was undertaken so that haplotyping of the 
IL10.R and IL10.G microsatellite markers in a cohort of UK Caucasians with
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RA could be performed to determine whether specific haplotypes were 
associated with RA susceptibility. Families included 163 simplex Caucasian 
RA families recruited from UK; 55 from the Oxfordshire area and the 
remaining 108 from the ARC-UK National Repository of RA families.
TDT analysis using TRANSMIT (section 1.2.10.3) identified an association for 
IL10.R (p<0.05) but not for IL10.G. This was in keeping with the results of a 
previous case control study (Eskdale et al., 1998b) but was in contrast to the 
results of the two case control studies discussed above. The IL10.R3 allele 
was under-represented in this rheumatoid population and excess 
transmission of the less common IL10.R1 allele was identified. The under­
representation of IL10.R3 corresponded to an earlier study (Eskdale et al., 
1998b) but the over-representation of IL10.R1 had not been reported 
previously. Haplotype analysis revealed a stronger negative association with 
the haplotype IL10.R3/IL10.G10. This suggested that the locus IL10.R was 
not the primary association but that another polymorphism on the IL10.R3 / 
IL10.G10 haplotype may be involved.
The results of IL10 microsatellite association studies may vary because of 
differences in disease severity between the patient cohorts. A number of 
groups have reported associations between IL10 and disease severity rather 
than susceptibility (Mok et al, 1998; Huizinga et al, 2000). Although, the 
cohort in the study was not specifically chosen for disease severity, the 
individuals developed RA at a relatively young age and many of them had a 
family history of RA. Both early age of onset and family history are risk 
factors for more severe disease (Deighton et al., 1994). Secondly, the high 
IL10.R2 allele frequency in the general population may make the detection of 
a weak genetic effect unreliable. The reported association with the IL10.R2 
allele could be spurious and may be the effect of unidentified population 
stratification in one of the case control studies. A family based association 
study would have avoided this problem. Extended haplotyping in a family
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based association study can narrow down the DNA sequence of interest by 
identifying strong associations between specific haplotypes and RA. 
Therefore, the stronger negative association with the haplotype 
IL10.R3/IL10.G10 suggests that the locus IL10.R is not the primary 
association and that another polymorphism on the IL10.R3/IL10.G10 
haplotype may be involved. Extended haplotyping, using both microsatellites 
and SNPs in a further independent family dataset, would be the next step to 
confirm the association and narrow down the DNA sequence of interest.
IDENTIFYING THE PREDISPOSITION TO AND SEVERITY OF A DISEASE 
BY GENETIC STUDIES: THE PROBLEMS AND POSSIBILITIES FOR THE 
FUTURE
Genetic studies have the potential to help identify the causes of many difficult 
and complex diseases. The technology is in place and is advancing at great 
speed. However, the studies are hampered by a number of factors. The very 
nature of the work is complex and open to a considerable level of human 
error. This will continue to be problematic until further ‘error proof and 
affordable automated systems can be developed.
A number of statistical packages are being developed which attempt to 
extract the maximum power from a data set. However, these will not be used 
to the full until the diseases under study are more accurately defined (Roses, 
2002b). Many of the complex diseases under investigation have no single 
specific test that can identify an individual sufferer. Most diagnoses rely on a 
series of clinical diagnostic criteria and therefore individuals included within 
the same study may have very different symptoms and signs. The long-term 
disease severity may also be very different. For instance, some individuals 
may not have RA if reviewed some years after the initial diagnosis as the 
original joint symptoms may have been due to a reactive arthritis which has
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subsequently settled. Major advances in defining and understanding 
inherited and non-inherited factors contributing to RA may lead to the 
abandonment of the concept of RA as a single entity the acceptance of a 
heterogeneous model of the disease. Identifying distinct RA subsets and 
stratifying patients into categories that differ with respect to aetiology, disease 
course, clinical pattern and treatment response (Weyand and Goronzy, 1995) 
should improve the ability to identify the genes involved with disease 
predisposition. As understanding of the disease pathogenesis of RA 
improves new biological markers associated with RA may become apparent. 
For example recent research suggests that anti-cirtrulline antibodies could be 
used in conjunction with rheumatoid factor leading to a specificity for RA of 
99.6% (Bizzaro et al., 2001). Studies are ongoing to determine whether anti- 
cirtrulline antibodies could be used as a prognostic marker in conjunction with 
other factors.
Statistical programs assume 100% accuracy and availability of information. 
They do not account for unavailable parents leading to an inability to define 
identity by descent, PCR failures leading to a less than ideal success rate for 
a marker or series of markers. All these factors lead to a reduced level of 
power to identify the gene or region linked or associated to the disease. The 
non-paternity rate often quoted by genetic studies is in the region of 10 -  
20%. Some of this must be in part due to a series of simple but common 
errors such as mislabelling a sample, placing DNA into the wrong row in a 
Costar plate, pipette contamination and other simple, well recognised 
laboratory errors.
Problems with ascertainment, diagnositic criteria, aetiological heterogeneity 
and failure to correct for the testing of multiple genetic models have all been 
blamed for the failure to replicate linkages in other family data sets (Risch, 
1990a; Suarez and Hampe, 1994). To achieve replication in a complex trait 
caused by 6 loci with equal effects computer simulation has shown that
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approximately five times the number of families needed for the first detection 
would be required (i.e. n-1, where n is the number of loci) (Davies et al., 
1994; Suarez etal., 1994).
The human genome is vast and the information currently available is 
enormous and expanding. Microsatellite markers placed approximately 10- 
cM apart mean that some markers are within 10 million base pairs of each 
other but others may be nearer to 20 million base pairs away. Given these 
figures, it is not surprising that regions of possible linkage may be missed. 
Stringent correction for multiple testing is required when undertaking a WGS 
but because of this sites of potential linkage could be missed.
Technological advances will enable whole genome linkage studies using 
saturated bi-allelic markers to be undertaken. Already The SNP Consortium 
(TSC), a collaboration between ten pharmaceutical companies and the 
Wellcome Trust, have identified approximately 200,000 SNPs and placed 
them in the public domain (Group, 2001). The SNP assays have been tested 
and validated and can be used as the basis of a polymorphism map which 
could become a pharmaceutical industry standard (Roses, 2002b). An 
example of this approach is the mapping of APOE4 using a high density SNP 
map (Kruglyak, 1999; Martin etal., 2000; Roses, 2000). APOE4 is the variant 
in the APOE gene associated with Alzheimer disease whereas APOE2 is 
protective (Roses, 2002a). Another example is in psoriasis with the 
construction of a SNP map over a 1.2 million base-pair (bp) linkage region. A 
small 80-100,00 bp region containing specific SNPs associated with psoriasis 
was localised (Hewett et al., 2002). However, with hundreds of thousands of 
markers used the size of the correction will need to be very large.
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Despite technological advances to generate adequate power to detect linkage 
to non-MHC genes it will be necessary to study very large numbers of 
affected sibling pair (ASP) families (Brown and Wordsworth, 1998). 
Alternative ways of genotyping these markers will be identified. DNA 
microarray technology is already being used as are robotics in some centres. 
Mixing of the DNA of 100 individuals into one tube will cut costs and speed 
results (Roses, 2002b). Although cost per SNP genotype in fully automated 
laboratories has fallen from $1.00 to $0.10 with the ultimate aim of reducing 
this cost to $0.01 per SNP genotype (Roses, 2002a). A genome-wide SNP 
screen will involve approximately 200,000 genotypes and cost reductions 
brought about by multiplexing and mixing techniques can reduce the cost per 
individual from $200,000 to $20,000 or possibly $2,000 per individual (Roses, 
2002a). But even at $2,000 per person, with the large numbers of individuals 
to be studied this will be expensive and time consuming.
Recruitment remains difficult in a late onset disease such as RA and may 
require international collaboration. Time must be spent on careful study 
design and stringent diagnostic criteria for recruitment. One way forward 
would be to undertake case control studies using very large numbers of 
carefully identified individuals with very similar patterns of disease and 
genetic backgrounds. If extended haplotyping using SNPs had already been 
undertaken using family based methods, the haplotypes could be studied in 
the cases and control populations. This would have the advantage of 
avoiding problems of extensive multiple testing and the quantity of genotyping 
in relation to the number to affected individuals would be halved. However, 
these studies would only be able to investigate candidate genes and would 
not be able to generate additional regions where linkage may be found (i.e. 
unable to generate ‘hypotheses’). Up to 80% of human genes remain 
unknown hence concentrating solely on candidate genes would reduce the 
possibilities for non-MHC detection. Even amongst identified genes,
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candidates may not be considered until a linkage study identifies the region of 
the genome they reside in.
Candidate regions and genes can be inferred from investigations into other 
autoimmune diseases such as ankylosing spondylitis, insulin-dependent 
diabetes mellitis, inflammatory bowel disease and lupus erythematosus. This 
approach has been used for some time and studies have investigated the 
possibility of a set of ‘autoimmune genes’ common to al! the autoimmune 
diseases such as cytokine genes (Myerscough et al., 2000). Another area 
under study is that of animal models where synteny with animal 
chromosomes is investigated (Jacob et al., 1992; Risch et al., 1993). For 
instance candidate gene studies and genome-wide linkage studies have been 
undertaken in various forms of murine induced arthritis (Bergsteinsdottir et al., 
2000; Kawahito et al., 1998; Otto et al., 1999). As discussed in section 2.3.5 
a WGS conducted using mice with proteoglygan induced arthritis identified a 
linkage interval (named pgia-3) homologous to a region identified by the UK 
genome-wide linkage study in RA and both the American and European 
genome screens (Cornelis et al., 1998; Jawaheer et al., 2001; Otto et al.,
1999). An area homologous to the TNF 2 receptor (TNFR II) on chromosome 
17 was identified in mice and this has since been studied in RA families with 
interesting results (Barton etal., 2001).
Another approach is to tackle the problem of disease heterogeneity by 
studying founder populations. Here the genetic background will be more 
homogeneous than for many data sets and the range of genes involved in a 
disease may be similar for all individuals. However, the results may not be 
fully representative of the general population. An example of this approach is 
in SLE where a region 2q37on chromosome 2 was identified within the 
Icelandic population (Lindqvist etal., 2000).
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Overall, as technology advances genetic studies will be undertaken with ever 
increasing complexity and greater numbers of genetic markers and DNA 
samples. Automation should reduce the chance of human error inherent in 
current studies so improving power. However, until it is easier to classify 
diseases, group individuals into selected cohorts based upon disease severity 
and identify their genetic backgrounds with greater care it will remain difficult 
to pick out the combinations of genes underlying the various complex 
diseases under study.
ADVANCES IN THERAPEUTICS AND POSSIBILITIES FOR THE FUTURE
Understanding the natural history of a disease at the molecular level, 
particularly in relation to the susceptibility to and severity of the disease, is 
important but unlikely to alter the incidence and prevalence of most 
multifactorial diseases for the foreseeable future. However, the advances in 
therapeutics forwarded by molecular biological techniques should (and 
already have) improve our ability to treat and control certain diseases. An 
example in RA is the recent introduction of biological therapies such as anti- 
TNF treatments which very successfully help to control disease activity in 
people with severe RA. These new therapies depend upon both the 
technological advances in molecular biology and a much broader 
understanding of the disease pathogenesis. Therapeutic avenues include 
recombinant DNA (rDNA) derived drugs, monoclonal antibodies (for diagnosis 
and treatment), vaccines, gene therapy including methods of gene delivery, 
modulating expression of genes, gene marking and the introduction of new 
genes.
Recombinant DNA technology has lead to the production of recombinant 
DNA (rDNA) derived drugs such as factors 8 and 9, erythropoietin, growth 
hormone and haematopoietic growth factors such as GM-CSF (granulocyte
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Other individuals are sensitive to certain drugs as a result of differences in 
absorption, distribution, metabolism and elimination.
Pharmacogenetic differences between individuals can have profound effects 
on a drug’s metabolism and efficacy. A genetic profile is difficult to change 
but if these differences were readily determined the drug dosage could be 
altered. An example of this approach in RA would be the measurement of the 
thiopurine methyltransferase (TMPT) enzyme prior to starting treatment with 
azathioprine (Corominas et al., 2003; Marra et al., 2002). Cytochrome P-450 
enzymes form a family of ~30 liver-specific proteins involved in oxidative 
metabolism of a range of drugs and chemicals. The gene coding CYP2D6 is 
on chromosome 22 and is the best understood of the P-450 cytochrome 
enzymes. It is involved in the biotransformation of a wide range of drugs 
including anti-depressants, anti-arrythmics and proton pump inhibitors. Some 
individuals are slow and others fast metabolisers. Point mutations and 
deletions have been identified (slow metaboliser) and in a few individuals 
multiple copies of the gene have been present (fast metaboliser). Molecular 
analysis could, in the future, lead to drug metabolism status being assessed 
prior to starting any form of treatment thus avoiding toxic side effects. A 
example in the musculoskeletal clinic could be the individual taking warfarin 
whom is started on a proton pump inhibitor (e.g. omeprazole) to treat peptic 
ulceration (possibly as a result of other drug treatment). Omeprazole can 
induce the cytochrome P-450 system interfering with the action of warfarin.
An immediate impact of molecular biological techniques such as SNP 
technology will be in the area of pharmacogenetics. This is a discipline 
aiming to characterise a person with respect to disease susceptibility, severe 
adverse events (SAE) associated with taking a medicine or whether the 
medicine is effective for treatment or prevention of disease (Roses, 2002a). 
The generation of genetically associated targets for drug discovery in humans 
remains a goal but realistically even under the best circumstances of finding a
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and macrophage colony stimulating factor). Previously individuals were 
treated with factors and hormones derived from pooled plasma, blood or 
pituitary extract obtained from cadavers. This lead to a number of 
iatrogenically acquired life threatening illnesses such as HIV infection, 
hepatitis C infection and Creutzfeldt-Jakob disease. rDNA derived drugs 
have meant that those newly diagnosed with conditions such as haemophilia 
are no longer at risk of developing another disease as a result of the 
treatment given to them for their primary condition. Other widely used rDNA 
derived drugs include human insulin and the recombinant hepatitis B virus 
vaccine. Work is underway to produce a recombinant HIV vaccine. In the 
future it may be possible to produce recombinant anti-inflammatory cytokines 
to treat RA. If a single infective cause is ever found to be the trigger for 
disease onset in a genetically susceptible individual a recombinant vaccine 
against that infective cause could be produced.
Antibodies are proteins made as a defence against foreign cells and 
organisms. Antibodies comprise two heavy and two light chains and the part 
that binds to the recognition sequence on the target (or antigen) is called the 
Fab portion. The remainder is called the Fc segment and defines the 
antibody’s properties. Each antibody can recognise a single unique antigen 
and this ability is utilised in many diagnostic strategies. Antibodies are 
conventionally produced by immunising an animal (e.g. a rabbit) with an 
antigen but the antiserum produced contains a mixture of antibodies. This 
heterogeneity was overcome with the development of monoclonal antibodies. 
Monoclonal antibodies are used diagnostically in radioimmunoassays (RIAs), 
enzyme immunosorbent assays (ElAs), flow cytometry and in situ 
hybridisation for histological immunotyping of tissue sections. Monoclonal 
antibodies to tumour specific antigens can be linked to effector molecules 
such as drugs, radionucleotides or toxins thereby targeting treatment and 
minimising treatment side effects. IT is possible that such a method could be 
used in the future to target localised therapies to sites of chronic inflammation
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such as an inflammed joint. Currently in RA and other inflammatory 
conditions (e.g. Crohns disease) recent advances have lead to the very 
successful use of anti-TNF treatments (e.g. infliximab (Maini et al., 1999)) to 
control disease activity. These are mouse-derived monoclonal antibodies 
which have been ‘humanised’ as the treatments need to be given repetitively 
and a mouse-derived monoclonal antibody will have a short survival time in a 
human because it is foreign and will induce an immunological response 
against it’s Fab and Fc segments. To humanise the antibody portions of the 
heavy and light chains are replaced with gene segments that are human in 
origin. The antigen recognition portion remains murine but the remainder 
including the Fc component is human. Some antigenicity is still directed at 
the Fab component hence these drugs are often used in conjunction with 
other immunosuppressents (e.g. infliximab and methotrexate are used 
together to treat RA).
Drug resistance remains a common problem in the treatments for cancer, 
infection but can also be a problem when treating inflammatory conditions 
such as RA where a small proportion of individuals initially respond to 
DMARDs but quickly become unresponsive to their effects. There are many 
ways that drug resistance can be influenced and include the route of 
administration, the concentration attained at the target site. Changes at the 
molecular level could include mutations that alter protein-binding affinity, 
increased gene expression via amplification or enhanced transcription and 
decreased uptake of the drug. One example of drug resistance in cancer is 
resistance to methotrexate where dihydrofolate reductase (DHFR) enzyme 
activity is increased as a result of gene amplification within the tumour cells. 
As the antimetabolite effect of methotrexate occurs through the inhibition of 
DHFR an increase of tumour cell DHFR expression negates this. A small 
proportion of patients with RA are also resistant to methotrexate even when 
the route of administration is changed from oral to subcutaneous therapy.
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disease-specific gene target quickly, the drug development will take between 
7 - 1 2  years hence (Roses, 2002b). Adverse event pharmacogenetics and 
efficacy pharmacogenetics however should produce results in the short to 
medium term. SNP profiles of individuals who develop side effects to drugs 
could be compared with those who are side effect free and a similar system 
could be applied to those who do not respond to a drug therapy. Ultimately a 
series of SNPs could be developed for each new drug to test a patient prior to 
starting treatment for both SAE and efficacy. The abbreviated informative 
SNP panels are called a Medicine Response Test or SNP Print™. These 
tests could be performed with current technologies, such as microarrays at 
reasonable cost (Roses, 2002a). This would have both safety and cost 
benefits by avoiding treatment of those individuals at risk of an adverse drug 
event or those for whom the medicine is ineffective. Approximately 30 -  40 
per cent of patients with RA are unresponsive to anti-TNF therapies (Maini et 
al., 1999; Weinblatt et al., 2003; Weinblatt et al., 1999). These are expensive 
treatments costing on average £10,000 per patient per year. Currently trial 
and error for a minimum of a three month period is the only way to determine 
efficacy. At approximately £1000 per person, costs mount for the 30 percent 
who fail treatment. Many other DMARDs used to treatment RA, although 
relatively inexpensive, are costly in terms of drug side effects (section 1.1.10). 
Any method of predicting these in individual patients prior to treatment would 
be of great benefit.
Gene therapy can be defined as the transfer of genetic material (DNA or 
RNA) into the cells of an organism. In humans it has involved somatic cell 
transfer, in animals it could also mean germline gene therapy. It can be used 
to alter the natural immunity of cells, to kill or interfere with the growth of cells, 
suppress oncogenes, insert genes and includes anti-sense technology. This 
therapy has the potential to treat genetic diseases such as 
immunodeficiencies (e.g. adenosine deaminase deficiency), cystic fibrosis or 
haemophilia and acquired disease such as cancer or AIDS. It also has the
223
potential to treat some multifactorial diseases such as those where 
inflammation is prominent. For example, a study in a SCID mouse transfer 
model has shown that colitis can be prevented by IL-10 transduced T 
lymphocytes (van Montfrans et al., 2002). IL-10 plays a key role in
maintaining the immune balance in the intestinal mucosa (in a similar manner 
to the anti-inflammatory role it plays in the joint). Primary CD4+ cells were 
engineered to express 11-10 and this expression protected against 
experimental colitis. It is possible a similar approach could be used in 
inflammatory arthritis. The IL-10 produced would counter-balance the high 
levels of pro-inflammatory cytokines and limit their production by leucocytes. 
Molecular biological techniques will continue to play a major role in many 
areas of medical research and this potential will increase with each new 
advance. From the point of view of more common multi-factorial diseases 
affecting large numbers of individuals knowledge of disease pathogenesis is 
paramount if progress is to continue and the molecular techniques are to be 
used to their full advantage. In RA improved diagnostic criteria are required 
to determine exactly which patients are included in the different disease sets 
to be studied. If a wide range of patients with differing clinical signs are 
included in the same data-set it is possible that different diseases at a 
molecular level are being studied. This would reduce the power of any study 
to identify disease associations and ultimately reduce the likelihood of 
identifying successful drug therapies. Molecular biological techniques may 
lead to a diagnostic test for RA so patients could be categorised reliably (as in 
insulin-dependent diabetes mellitus). This should improve the outcome of 
both immunopathogenic and therapeutic studies. Until this is possible the 
way forward is to further define disease using clinical criteria and to take great 
care in the recruitment for such studies. Pharmacogenetics with the aim of 
avoiding adverse drug events and identifying those individuals who should 
respond to a drug therapy is likely to be another area of progress. This would 
be particularly valuable in chronic condition such as RA where many 
individuals either develop side effects or to do not respond drug treatments.
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The advantages of avoiding adverse drug events are obvious as are the 
financial incentives, what is less obvious but of equal benefit in a progressive 
disease is identifying the ‘correct’ drug first time and so avoid the ‘cost’ of joint 
destruction that will continue until the disease is controlled. The BMJ in 
February 2002 may not have thought that RA was a genetic disease but 
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Appendices
5.1.1 Core set of variables to assess
disease activity in rheumatoid arthritis
The table below lists a set of core variables designed to assess disease 
activity in RA. There are a number of instruments designed to measure this 
and most use the same core variables. The three most commonly used 
measures are listed beiow.
A C R 5 EULAR * OMERACT *
Tender joint count V (68) § V (28)§ ?
Swollen joint 
count
V (6 8 )§ V (28) § ?
















Adapted from van Reil PLCM, van de Putte LBA |[van Reil, 1994 #1219]
VAS = visual analogue scale
§ numbers in brackets indicate the number of joints assessed 
* EULAR = European League against Rheumatism 
$ ACR = American College of Rheumatology 
A OMERACT = Outcome Measures in RA Clinical Trials
2 51
5 . 1 . 2 EULAR response definition
Unlike the Paulus [Paulus, 1990 #1095] and ACR [Felson, 1995; Felson, 
1993] response criteria (appendix 5.1.4) the EULAR response criteria [van 
Gestel, 1996] are based on a combination of current disease activity and 
change in disease activity.
> 1.2 > 0.6 and <1.2 <0.6
<2.4 GOOD MODERATE NONE
> 2.4 and < 3.7 MODERATE MODERATE NONE
>3.7 MODERATE NONE NONE
EULAR = European League against Rheumatism 
§ DAS = disease activity score
2  b  3
ACR criteria for the clinical remission of Rheumatoid 
Arthritis
Table 5.1.3a
1 Early morning stiffness not exceeding 15 
minutes
2 No fatigue
3 No joint pain
4 No joint tenderness or pain on motion
5 No soft tissue swelling in joints or tendon 
sheaths
6 ESR < 30mm/h in females or < 20mm/h in 
males
Table 5.1.3b




5 +/or unexplained weight loss or fever secondary to 
rheumatoid arthritis
Tables 5.1.3a and b have been adapted from Gordon [Gordon, 1998 #704], 
Table 5.1.3a lists the criteria used to determine clinical remission of RA. A 
minimum of five out of the six criteria listed in the table need to be fulfilled for a 
minimum of two months before remission can be diagnosed. However there are 
some exclusions and these are listed in table 5.1.3b. Hence an individual 
cannot be described as being in remission if they fulfil the criteria listed in table
1.1.4a but have the clinical manifestations of active vasculitis or a pericarditis.
The American College of Rheumatology criteria for 
classification of global functional status in 
rheumatoid arthritis
Class I
Completely able to perform usual activities of daily living (self-care, 
vocational and avocational)
Class II
Able to perform usual self-care and vocational activities, but limited 
in avocational activities
Class III
Able to perform usual self-care activities but limited in vocational 
and avocational activities
Class IV
Limited in ability to perform usual self-care, vocational and 
avocational activities
Table 5.1.5 summarises the American College of Rheumatology criteria for 
the classification of global functional status in rheumatoid arthritis [Hochberg, 
1992]. The criteria relate to an individual’s ability to self-care, work and 
undertake any activities or hobbies they may wish to. The higher the class, 
the poorer the function and the more severe the disease. One of the aims of 
treatment is to maintain an individual in the lowest class possible.
Date:
d d m m
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Global VAS: Overall well-beinq: Please indicate on the scale below
0 100
|------------------------------------------- -----------------------------------------1
Best Imaginable Worst Imaginable
Health State Health State
E S R
C R P
You do not need to return  this sheet: it is to help you complete the questionnaire
HEALTH ASSESSMENT QUESTIONNAIRE (HAQ)
Date: Patient Name:
Please tick the one response which best describes your usual abilities over the past week
Without ANY With SOME With M UCH UNABLE 
difficulty difficulty difficulty to do
1. DRESSING and G R O O M IN G
Are you able to:
a. Dress yourself, including tying 
shoelaces and doing buttons? U u □
b. Shampoo your hair? □ □ □ n
2. R IS IN G
Are you able to:
a. Stand up from an armless 
straight chaif?
♦
b. Get in  and out o f bed?
3. E A T IN G
□ □ □ □□ □ □ □
Are you able to:
a. Cut your meat?
b. L if t  a fu ll cup or glass to your mouth?
c. Open a new carton o f  m ilk  
(or soap powder)? <
4. W A L K IN G
□ □ □□ □ i i □□ n i i □
Are you able to:
a. Walk outdoors on fla t ground?
b. C lim b up five steps?
PLEASE T IC K  ANY A ID S  OR DEVIC ES T H A T  YOU U S U A LLY  USE FO R  A N Y  OF THESE 
A C T IV IT IE S :
□ □ □ □□ □ □ □
Cane (W ) 
Crutches (W )
□□ Built-up or special utensils (E) Special or built-up chair (A )W alking frame(W) | |Wheelchair (W ) Q
Devices used for dressing (button hooks, zipper pull, shoe horn) □
Other (specify)..................................................................................................................
PLEASE T IC K  ANY C ATEG O R IES FOR W H IC H  YOU U S U A LLY  NEED H E LP  FR O M  A N O TH ER  
PERSON:
Dressing and Grooming □ Eating □
Rising □ W alking □
Page 1
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Please tick the one response which best describes yourusual abilities over the past week
Without ANY With SOME With M UCH UNABLE 
difficulty difficulty difficulty to do
5. H Y G IE N E
Are you able to:
a. Wash and dry your entire body?
b. Take a bath?
c. Get on and o f f  the toilet?
6. R E A C H
□ □ □ □□ □ □ □□ □ □ □
Are you able to:
a. Reach and get down a 5 lb object 
(e.g. a bag o f  potatoes) from  just 
above your head?
b. Bend down to pick up clothing 
o ff  the floor?
♦
7. G R IP
□ □ □ □
□ □ □ □
Are you able to:
a. Open car doors?
b. Open jars which have been 
previously opened?
c. Turn taps on and off?
8. A C T IV IT IE S
□ □ □ □□ □ □ □□ □ □ □
Are you able to:
a. Run errands and shop?
b. Get in and out o f a car?
c. Do chores such as vacuuming, 
housework or light gardening?
1 1 □ i i nn □ i i □n □ i i □
PLEASE T IC K  A N Y  A ID S  OR DEVICES T H A T  Y O U  U S U A LLY  USE FO R  A N Y  OF THESE 
A C T IV IT IE S : □Raised toilet seat (H ) |____ | Bath seat (H)
Long handled appliances fo r reach (R) □
Jar opener (for jars previously opened) (G)
Other (specify)
□ Bath ra il (H) □
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Patient Name:
Today's Date 
c c m m y y y y
SF-36 v2
Patient ID
1co r o ffic e  use
The following questions ask fo r  your views about your health, how you fee  I and how well you 
are able to do your usual activities. I f  you are unsure about how to answer any questions 
please give the best answer you can. Do not spend too much tim e in answering, as your 
immediate answer is likely to be the  most accurate.
1. In  general, would you say your health is: (Please tick one)
PoorExcellent Very Good Good Fair
o o o o o
2. Compared to one year ago, how would you rate  your health in general now? (Please tick one)
Much better now 
than one year ago
Somewhat better now 
than one year ago
o o
About the same 
as one year ago
o
Somewhat worse now 
than one year ago
o
Much worse now 
than one year ago
o
3. The following questions are about activities you might do during a typical day 
Does your health now limit you in your activities? I f  so, how much?
a) Vigorous activities, such as running, lifting  heavy 
objects, participating in strenuous sports?
b) Moderate activities, such as moving a table, pushing 
a vacuum cleaner, bowling or playing golf?
c) Lifting or carrying groceries?
d) Climbing several flights of stairs?
e) Climbing one fligh t o f stairs?
f)  Bending, kneeling or stooping?
g) Walking more than one mile?
h) Walking several hundred yards?
i) Walking 100 yards?







o oo oo oo oo oo oo oo o






4. During the past fo u r weeks, how much o f the  tim e have you had any o f the  following problems with 
your work or other regular daily activities as a resu lt o f your physical health?
a)Cut down on the amount o f  tim e you spent 
on work or other activities?
b) Accomplished less than you would like?
c) Were limited in the kind of work or other 
activities?
d) Had d i f f  icu lty  perf orming the work or 
other activities, i.e. i t  took extra  e ffo rt?










o o o o oo o o o oo o o o o
o o o o o
5. During the past fou r  weeks, how much o f the  tim e have you had any o f the  following problems with 
your work or other regular daily activities as a result o f any emotional problems (such as feeling 
depressed or anxious)? Please tick one
All of
the time
Most o f Some of 
the time the time




a) Cut down on the amount of tim e you spent 
on work or o ther activities?
b) Accomplished less than you would like to?







6. During the  past four weeks, to  what extent has your physical health or emotional problems 
in te rfe red  with your normal social activities with family, friends, neighbours o r groups? Please tick one
Not at all Slighty Moderately Quite a bit Extremely
o o o o o
7. How much bodily pain have you had during the past four weeks? Please tick one
None Very mild Mild Moderate Severe Very severe
O O 0 o o o
8 . During the past four weeks, how much did pain in te rfe re  with your normal work? Please tick one 
(including work both outside the home and housework)
Not at A little  Moderately Quite a Extremely
all b it bit
O 0 - 0  o o
Patient ID
9. The following questions are about how you feel and how things have been w ith you during the past 4 weeks, 
( fo r each question, please indicate the one answer tha t comes closest to  the  way you have been feeling)
How much time during the past 4 weeks:
a) Did you feel fu ll o f life?
b) Have you been very nervous?
c) Have you fe lt so down in the dumps that nothing 
could cheer you ud?
*
d) Have you fe lt  calm and peaceful?
e) Did you have a lot o f enerqy?
f)  Have you fe lt  downhearted and depressed? 
q) Did you feel worn out?
h) Have you been happy?
i) Did you feel tired?
All of 
the time








o o o o oo o o o o
o o o o oo o o o oo o o o 0o o o o oo o o o oo o o o oo o o o o
10. During the  past fou r weeks, how much o f the time has your physical health or emotional problems
in te rfe red  w ith your social activ ities? (like visiting friends,  relatives, etc...) Please tick one
All of the time Most of Some of A little  o f None of
the time the time the time the time
o o o o o
11. How TRUE or FALSE are each o f the following statements? Please tick one
Definitely Mostly Don't Mostly Definitely
true true know false false
a) I  seem to get ill more easily than other people o o o o o
b) I  am as healthy as anybody I  know o o o o o
c) I  expect my health to get worse o o o o o
d) My health is excellent 0 o o o o
THANK YOU FOR TA K IN G  THE T IM E  TO  COMPLETE T H IS  Q U E S T IO N N A IR E .
5.2 Definitions
Analysis -  Parametric linkage analysis
Linkage analysis requiring a model for the segregation of the trait and marker 
data in multigenerational pedigrees. This analysis is quite sensitive to model 
mis-specifi cation.
Analysis -  Non-parametric linkage analysis
Used for complex traits where the a priori model of trait segregation is 
unknown. This form of analysis only requires the marker and trait data but no 
model for segregation.
Association
A population association between two traits exists if the population frequency 
of persons with both traits is not equal to the product of the population 
frequency of persons with each individual trait, e.g. blood group and disease. 
Association of a marker locus with a disease locus is a population-based 
phenomenon.
Allelic association
Allelic association refers to a significantly increased or decreased frequency 
of occurrence of a marker allele in combination with a disease trait. It can be 
explained either by biological interaction of the marker allele with the disease- 
trait gene or by linkage disequilibrium.
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Bonferroni correction
It is inherent in the definition of p-value and significance levels that some 
false positive results will be generated. The Bonferroni correction assumes 
that the tests that have been applied to a data set are mutually independent 
and sets the threshold of significance at p=0.05/n, where n is the number of 
independent potential associations checked. If n loci with m alleles each are 
tested the rigorous correction factor would be n(m-1).
Causality
Any association identified could be due to direct causation, chance, bias, or 
confounding factors. Causality is more likely if the exposure precedes 
outcome and the association is biologically plausible, strong, consistent 
between studies or supported by good evidence.
Classification criteria
The standards of classification criteria include validity or the accurate 
definition of disease and an appropriate selection of cases and controls. The 
potential criteria selected should be comprehensive and there should be 
absence of circular reasoning (i.e. avoiding the identification of criteria 
identical to those used to select cases). The criteria need to be validated 
independently and any statistical techniques need to be appropriately applied.
Epidemiology -  analytical
Analytical epidemiology tests hypotheses of causation and involves a 
comparison group e.g. a prospective or retrospective case-control or cohort 
study.
Epidemiology -  descriptive
Descriptive epidemiology investigates the distribution of disease in relation to 
person, place and time.
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Epistasis
Two or more loci show epistasis if they interact i.e. if the alleles at each locus 
influence the phenotype produced by the other locus.
Errors
A type I error (a) is a false positive and the null hypothesis is rejected when it 
is true. The correct decision is 1-a.
A type II error (p) is a false negative and the null hypothesis is not rejected 
when it is false. The correct decision is 1-p.
Genotype
The frequency of each genotype in a population is a function of the 
frequencies of the alleles in that population. For a gene with n alleles there 
are n(n+1)/2 possible genotypes.
Heterogeneity - allelic or intragenic
This occurs when many different mutations within a given gene product 
produce the disease in different families e.g. cystic fibrosis, thalassemia or X 
linked hypophosphataemic rickets. Allelic heterogeneity cannot be detected 
by linkage analysis because all mutations occur within the same locus. 
However, different mutations within the same gene also can cause different 
diseases e.g. different mutations of type 1 collegen can cause different types 
of osteogenesis imperfecta or Ehlers Danlos syndrome.
Heterogeneity - genetic
Different mutations of a genotype cause similar phenotypes.
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Heterogeneity - locus
Locus heterogeneity is expected in conditions where a general pathway has 
failed e.g. blindness, mental retardation or deafness. It covers the situation 
where defects in different genes produce the same clinical abnormality. For 
instance profound hearing loss can occur as a result of defects in number of 
different genes and is an example of complementation. This can often be 
detected by linkage analysis as the defects are at different loci.
Heterozygosity
Heterozygosity is a measure of the informativeness of a marker locus. It 
represents the extent of genetic variation of a marker locus within a given 
population i.e. the frequency of heterozygote individuals.
Incidence
The number of individuals within a defined population who first develop the 
disorder over a given time period e.g. one year.
Likelihood
A likelihood (L) is the numerical estimate of the fit of the pedigree data to a 
particular genetic transmission model.
Linkage analysis
The primary goal is to determine whether two or more genetic traits (the 
marker locus (or multiple marker loci) and the disease trait) are co- 
segregating within a pedigree.
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Linkage disequilibrium
Linkage disequilibrium occurs when a particular marker allele is associated 
with the disease-trait locus at a greater than expected frequency across 
multiple families.
LOD score
The LOD score was defined by Morton in 1955 and represents log-io of the 
odds for linkage. LOD is a contraction of ‘logarithm of the odds ratio’. The 
two hypotheses being compared in linkage analysis are whether the trait is 
linked or unlinked to the marker (i.e. the recombination fraction between the 
trait and the marker is 0 < 0.5 (linkage) or 0 = 0.5 (no linkage). 
Conventionally a LOD score of 3.0 is regarded as the minimum criteria for 
claiming linkage and this corresponds to odds of 1000 to 1 in favour of 
linkage. A LOD score of -2.0 is the conventional threshold for excluding a 
site from linkage.
Maximum likelihood method
This was described by Morton in 1959. This technique permits joint 
consideration of several parameters of the genetic model including: degree of 
dominance, penetrance, gene frequency, ascertainment probability and 
measures of Mendelian transmission of the disease allele. To find the most 
likely hypothesis, parameter values are set to maximise the likelihood of the 
observed data. The parameter values are called the maximum likelihood 
estimates. This method can be used to establish whether or not the disease 
has a major genetic component.
Models for genetic interaction
A multifactorial disease will generally involve two or more genetic loci that 
may interact in several ways (epistasis). In an additive model the penetrance
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of a disease is represented by the sum of the separate terms contributed by 
two or more loci. In a multiplicative model, the penetrance of a disease is 
represented by the product of separate terms (or penetrance factors) 
contributed by two or more loci. The heterogeneity model assumes that 
genetic loci act independently (i.e. not epistatically) so that an individual can 
become affected through possessing a particular genotype at a locus 
regardless of the alleles at the other loci.
Mortality number of deaths in population studied
total population
Mortality (Case-fatality) number of deaths
number of cases
Multi-factorial inheritance
Multi-factorial inheritance is an extension of polygenic inheritance where 
additional nongenetic factors may also be involved.
Mutation
This is a change in DNA sequence, usually conferring a deleterious effect.
Odds ratio and Relative risk
Disease (+) Disease (-)
Exposure (+) a b a+b
Exposure (-) c d c+d
a+c b+d
Odds ratio (OR) = odds of disease in exposed cohort = ad
Odds of disease in unexposed cohort cb
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Relative risk (RR) = risk (incidence) of disease in exposed cohort = a(c+d)
risk in unexposed cohort c(a+b)
Oligenic inheritance
A trait is oligogenic if a few genetic loci acting together cause the trait or 
disease.
Penetrance
The penetrance of a particular genotype at a disease locus is the probability 
that individuals possessing that genotype will develop that disease. The 
penetrance of a disease is complete if all individuals with the high-risk 
genotype will eventually develop the disorder (if they live for long enough). 
The penetrance of a disease is incomplete, reduced or partial if not all 
individuals possessing the disease genotype develop the trait. Incomplete 
pentrances may be a function of many variables including age of onset, sex, 
environment and the presence of certain alleles at other genetic loci. If the 
mutant gene is expressed subclinically the disease may appear non­
penetrant upon clinical examination e.g. Wilson disease.
Phenotype
A phenotype is an observable biochemical, cellular or clinical characteristic 
that is associated with the expression of a gene.
Pleiotropy
This is where the risk association can be attributed to a specific allele. This is 




In mathematical terms, a polygenic trait is one in which there are an infinite 
number of genes each exerting a tiny and equal influence on the trait value. 
However, the term generally implies that the disease is the result of the 
additive effects of many of different genes, each of which, acting alone, would 
be insufficient to cause the disease. Each of the contributory genes may not 
have equal weight; some may have major effects in conferring risk for the 
disease, whereas others might provide a relatively minor contribution.
Polymorphism
DNA sequence difference, usually of no pathologic significance. For a locus 
to be polymorphic there must be identifiable alternative forms (alleles) at that 
locus. A locus is generally considered to be polymorphic if it has at least two 
alleles each with a population frequency > 0.01. Any allele with a frequency >
0.01 is termed a variant
Population attributable risk fraction
This is the proportion of the disease in the population attributable to the risk 
factor e.g. not all Gl bleeds can be attributed to NSAIDs
Power
The power of a test is the probability of rejecting the null hypothesis given an 
alternative hypothesis is true. It is defined in the context of specific 
circumstances.
Prevalence - point prevalence
The proportion of the population with the disorder at a particular time
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Prevalence - period prevalence
The proportion of the population with the disorder at some stage during a 
given time period e.g. one year
Prevalence - cumulative prevalence
The proportion of the population who have had the disorder by a specified 
time point e.g. age 60 years
Probability
Events are independent if knowledge of any subset of them does not allow 
any inferences to be made about the remainder. However, the disease 
prevalence for a sibling of an affected individual is a conditional probability i.e. 
it depends upon the sibling recurrence risk Xs. The prior probability of some 
event is the probability assigned to that event before any new tests have 
been carried out. The posterior probability is the probability calculated using 
the prior probability and any new information gathered.
Qualitative trait
An example of a qualitative trait is one where the individual either has the trait 
or does not e.g. eye colour.
Quantitative trait
Quantitative traits are phenotypes that can fall anywhere along a continuous 
distribution of measurements e.g. height
Segregation analysis
The primary goal is to determine the most likely genetic model for an 
observed trait -  i.e. to delineate whether the trait is autosomal dominant, 
autosomal recessive, X-linked or polygenic. To investigate mode of
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inheritance by segregation analysis accurate phenotype and genealogical 
data on a set of families must be obtained. The means by which families are 
ascertained must be uniform to avoid bias and incidence of the disease in the 
general population as well as sex and age dependencies must be 
incorporated in the analysis. Common diseases or those associated with 
reduced penetrance will necessitate a larger sampling of families.
Single-gene inheritance
Any trait caused by a single gene mutation is said to be Mendelian or to have 
single gene inheritance e.g. Huntington disease or cystic fibrosis.
Variable expressivity




ISOLATION OF DNA FROM BLOOD USING GUANIDINE HYDROCHLORIDE
• The following protocol works best on whole blood which has been frozen at - 
20C for at least 24.hrs, although it does work for fresh blood.
• Digestion of WBC pellet in step 6 can be done at 60C for 2hrs or at 37C 
overnight.
• Set water-bath at chosen temp, before starting procedure, so ready when 
needed.
STAGE 1: RBC LYSIS
1. Defrost blood thoroughly at room temp (2-3hrs). The centrifuge capacity is 
frequently 16 tubes, hence this is the recommended number of DNA 
extractions per run.
2. In fume hood, pour 10-20ml of blood into 50ml Falcon tube and make up to 
40ml with cold lysis buffer and vortex.
3. Centrifuge at 2,500rpm for 15 minutes then gently tip off the supernatant into 
waste pot being careful not to disturb the pellet
4. Add 20ml of cold lysis buffer to pellet and vortex until the pellet is completely 
dispersed. Note:- this step is very important! Ensure that the pellet is fully 
dispersed.
5. Centrifuge at 2,500rpm for 15 minutes then gently tip off the supernatant into 
waste pot to leave clean WBC pellet.
6. If the blood is old and/or clotted, it may be necessary to redo the washing 
steps (steps 4-5 above) again until a pinkish-white pellet is obtained.
STAGE 2: GUANIDINE-HCL DNA EXTRACTION
1. Add 3.5 mis of 6M guanidine hydrochloride (GuHCI) and vortex to re-suspend 
pellet.
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2. Add 250mls of 7.5M ammonium acetate (NH4Ac) and mix by inversion.
3. Add 50(al of Proteinase K at 10mg/ml then add 250ul of 10% sodium dodecyl 
sulphate (SDS) and shake. (Note the SDS tends to precipitate out as lumps.)
4. Incubate at 37°C overnight or at 60°C for 1 hour.
5. Cool tube to room temperature and add 2ml COLD Chloroform (CHCI3) - 
vortex well.
6. Centrifuge at 3000 rpm for 5 minutes.
7. Use disposable plastic pipette to collect the upper layer into a clean 50ml 
Falcon tube and add 10mls of 100% cold ethanol. Mix thoroughly by 
inversion.
8. Centrifuge briefly at 3000 rpm, drain supernatant and add 10ml 80% ethanol 
(use 80% Ethanol only, othenA/ise DNA begins to re-suspend), gently swirl to 
dislodge pellet.
9. Repeat steps 7 and 8.
10. Drain the ethanol off and re-spin to collect the last drops of ethanol at the 
bottom of the tube. Remove the last traces of ethanol with a yellow tip.
11. Leave the Falcon tube open for 15-20 minutes or until the DNA pellet is 
visibly dry.
12.Add 1ml of 1xTE (pH 8.0), replace the lid and leave overnight at room 
temperature to re-suspend.
13. Transfer to eppendorf tubes, ensuring that the DNA is fully re-suspended 
(clean DNA which has not been over-dried will go into solution very easily). If 
it does not re-suspend easily warm to 37°C for 1-2 hours.
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RE-EXTRACTION OF SAMPLES
1. Split the samples into eppendorf tubes (up to 500pl of DNA per tube).
2. Add 500pl of a 1:1 mixture of phenol and Chloroform (CHCb).
3. Vigorously mix by inversion until an emulsion is formed.
4. Centrifuge at top speed in the microfuge for 5 minutes.
5. Using a blue tip carefully transfer the top layer into a clean eppendorf (do not 
transfer the interphase - this contains the contaminating protein).
6. Add 1ml of 100% Ethanol and mix by inversion.
7. Pellet the DNA by briefly spinning in the microfuge at top speed.
8. Remove all of the Ethanol.
9. Add 800pl of 80% Ethanol, ensuring the pellet is dislodged. If the pellet sticks 
then flick the tube until it is washed in the Ethanol.
10. Centrifuge briefly to collect the DNA in the bottom.
11. Remove all of the 80% Ethanol. Re-centrifuge and remove the last traces of 
80% Ethanol with a yellow tip.
12. Leave the samples to stand open for 10-15 minutes or until visibly dry.
13. Add 400jnl of 1xTE (pH 8.0) and allow to re-dissolve.
14. Re-analyse by spectrophotometry as above.
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TO MAKE LYSIS BUFFER
1. Place 109.4g of Sucrose in a 1L Schott bottle.
2. Add ~500 mis of distilled water, 1 ml of 1M (molar) Tris-HCI* (pH 7.8), 1.2 mis 
4.9M MgCb§ and 10 mis of Triton x -100.
3. Mix by swirling until the sucrose has more or less dissolved.
4. Make up to 1 L with Milli-Q water. The sucrose should dissolve after a while - 
store at 4°C.
* Tris = hydroxy-methyl-amino-methane 
§ MgCb = magnesium chloride
TO MAKE 6M GUANIDINIUM HYDROCHLORIDE (GuHCI)
To make up 500 mis:
1. Dissolve 286.59g of solid guanidine hydrochloride in ~300 mis of distilled 
(Milli-Q) water.
2. Make up to 500 mis with Milli-Q water.
3. Sterilize by autoclaving.
TO MAKE 7.5M AMMONIUM ACETATE (NhLAc)
To make up 100 mis:
1. Dissolve 57.81 g of solid NH4 Ac. in ~75 mis of Milli-Q water.
2. Make up to 100 mis with Milli-Q water.
3. Sterilize by autoclaving.
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TO MAKE 10% SDS (SODIUM DODECYL SULPHATE)
To make up 100 mis:
1. Dissolve 10g SDS powder in -75 mis Milli-Q water.
2. Make up to 100 mis with Milli-Q water.
Tris-EDTA BUFFER (TE8)
1. take 1ml of Tris-EDTA buffer (1M Tris 100* concentrate)
2. dilute in 99ml distilled water
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SPECTROPHOTOMETRIC ASSESSMENT
1. Take 2 jliI of the extracted DNA sample and add to 98jnl of sterile de-ionised 
water (SDW), vortex.
2. Switch on the UV lamp on the spectrophotometer (leave to warm up).
3. Quit any windows currently open on the spectrophotometer, then open ‘DNA 
analysis’.
4. Put 1 OOjllI of SDW into a cuvette and place in the spectrophotometer.
5. Press ‘Read Blank’.
6. Wash out the cuvette and replace with the sample.
7. Press ‘Read Samples’.
8. Record the O D 26o and the ratio of O D 26o/OD28o. If the ratio is 1.8 - 2.0 then the 
D NA is very clean but if the ratio is less than 1.5, then the sample is heavily 
contaminated with protein and needs to be re-extracted.
9. Repeat steps 6-8, but redo the blank for every 8th sample.
DNA is often diluted to 10ng/pl (in 500pl water) therefore to work out quantity of 
DNA stock required:
10 x 500 / concentration of DNA = pi DNA needed 
(hence water needed = 500pl - pi DNA needed)
i.e. for any concentration of DNA in any volume = 
ng needed x volume needed / concentration of DNA [ng/pl]
EQUATION:
• 1 optical density @ 260nm
• concentration of DNA [ng/pl]
• concentration of DNA [ng/pl]
= 50ng/pl dsDNA
= optical density x 50 x dilution factor 
= optical density x 50 x 50 (i.e. 2500)
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“HYDRA ” GUIDELINES
• MAIN SWITCH is at the back of the HYDRA, at the power connection point.
• SET/RESET button takes you through the different files and through the 
steps of each file.
• Buttons FILL, EMPTY and WASH only function at the end of each file, when 
the display is showing ‘A’ (for aspirate) or ‘D’ (for dispense):
FILL - fills the syringes up to the maximum (290pl)
EMPTY - empties the syringes
WASH - starts the wash cycle (max. fill and empty, 3 times)
Files 1-6 have been programmed as follows:
FILE 1 Aspirating from clear boxes
FILE 2 Dispensing into clear boxes (to get rid of bubbles)
FILE 3 Dispensing into U-bottom plates
FILE 4 Dispensing into V-bottom plates
FILE 5 Aspirating from V-bottom plates
FILE 6 Aspirating from ‘Beckman’ boxes
These files alter the height of the platform only while aspirating/dispensing liquid. 
The volume to be aspirated/dispensed can be varied and can be set by pressing 
the UP or DOWN buttons when the display is showing AV (aspiration volume) or 
DV (dispensing volume).
The heights of the platform are set up by pressing the UP button, with the 
chosen box/plate in place, while watching closely until the needles are about 
3mm from the bottom of the tubes/wells.
OPERATING THE HYDRA
• Place the box/plate (containing the liquid to be transferred) onto the platform.
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• Press SET/RESET button until the display shows ‘File’. Pressing UP button 
will change the file number.
• Once in the correct file, press SET/RESET button until the display shows AV 
or DV. This also indicates whether the set function is aspiration or dispensing 
(pressing the UP button will change between the two modes).
• Adjust the desired volume to be aspirated or dispensed.
• Keep pressing the SET/RESET button to go through all the steps of the file.
• When the display shows A or D, press the ASPIRATE/DISPENSE button 
which will perform the set operation.
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Whole-Genome Linkage Analysis of Rheumatoid Arthritis 
Susceptibility Loci in 252 Affected Sibling Pairs in 
the United Kingdom
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Objective. To undertake a systematic whole- 
genome sqreen to identify regions exhibiting genetic 
t linkage to rheumatoid arthritis (RA).
Methods. Two hundred fifty-two RA-affected sib­
ling pairs from 182 UK families were genotyped using 
365 highly informative microsatellite markers. Micro­
satellite genotyping was performed using fluorescent 
polymerase chain reaction primers and semiautomated 
DNA sequencing technology. Linkage analysis was un­
dertaken using MAPMAKER/SIBS for single-point and 
multipoint analysis.
Results. Significant linkage (maximum logarithm 
of odds score 4.7 [P = 0.000003] at marker D6S276, 1 
cM from HLA-DRB1) was identified around the major 
histocompatibility complex (MHC) region on chromo­
some 6. Suggestive linkage (P <  7.4 x 10~4) was 
identified on chromosome 6q by single- and multipoint 
analysis. Ten other sites of nominal linkage (P <  0.05) 
were identified on chromosomes 3p, 4q, 7p, 2 regions of 
lOq, 2 regions of 14q, 16p, 21q, and Xq by single-point 
analysis and on 3 sites (lq, 14q, and 14q) by multipoint 
analysis.
Conclusion. Linkage to the MHC region was
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confirmed. Eleven non-HLA regions demonstrated evi­
dence of suggestive or nominal linkage, but none 
reached the genome-wide threshold for significant link­
age (P =  2.2 x 10-s). Results of previous genome 
screens have suggested that 6 of these regions may be 
involved in RA susceptibility.
Rheumatoid arthritis (RA) is a chronic, systemic, 
inflammatory condition predominantly involving syno­
vial joints and affecting up to 1% of the population. 
Evidence from twin (1,2) and family (3) studies suggests 
that both genetic and environmental factors contribute 
to susceptibility to RA, and disease heritability has been 
estimated to be —60% (4). To date, only the major 
histocompatibility complex (MHC) on chromosome 6 
has been consistently linked to and associated with RA 
susceptibility (5). However, results of family studies 
suggest that this association accounts for only one-third 
of the genetic susceptibility (6,7). It is likely that a 
number of other susceptibility loci exist, each of which 
contributes less than the MHC to the total genetic 
component.
If appropriately powered, systematic linkage 
screening of the entire genome has the potential to 
detect all disease susceptibility loci. Results from 3 
previous whole-genome scans in Japanese (8), European 
(European Consortium on Rheumatoid Arthritis Fami­
lies [ECRAF]) (9), and North American (North Amer­
ican Rheumatoid Arthritis Consortium [NARAC]) (10) 
RA families have been reported, and linkage to the 
MHC (P <  2.5 X 10 5) was confirmed in the European 
and North American studies. In all 3 studies, a number 
of non-MHC regions with evidence of nominal linkage 
(P <  0.05) were also identified. It is inevitable that many 
suspected linkages will not be confirmed; therefore, it is
632
WHOLE-GENOME SCAN OF RA SUSCEPTIBILITY LOCI





iq D1S238 (203 cM) D1S238 (203 cM )t D1S235 (259 cM)
(P =  0.05) (P = 0.022) (P =  0.005)
3q D3S1267 (139 cM )t D3S4523 (138 cM )f(P =  0.039) (P =  0.029)
6q D6S434 (109 cM) D6S1021 (112.2 cM)
(P =  0.0007) (P =  0.008)
8p D8S1825 (15.4 cM )f D8S277 (8.3 cM)
(P =  0.040) (P -  0.009)
12q D12S95 (96.1 cM) D12S1052 (83.2 cM)
(P = 0.043) (P =  0.023)
14q D14S275 (28 cM) D14S1280 (25.9 cM)
(P =  0.03) (P =  0.017)
14q D14S276 (56.4 cM) D14S285 (59.4 cM )t D14S578 (55.8 cM)
(P=0.05) {P =  0.049) (P =  0.037)
16p D16S420 (44.5 cM) D16S403 (43.9 cM)
(P =  0.039) (P =  0.004)
18q D18S474 (71.3 cM) D18S858 (80.4 cM)
(P =  0.012) (P =  0.043)
* Ail results were obtained by multipoint linkage analysis unless indicated otherwise. Distance from 
HLA-DRB1 is shown in parentheses. Marker positions obtained from Marshfield map (sex-averaged 
positions) (www.marshfieldclinic.org/research/genetics). ECRAF = European Consortium on Rheuma­
toid Arthritis Families; NARAC = North American Rheumatoid Arthritis Consortium, 
t  By single-point analysis. 
t  Insulin-dependent diabetes mellitus 9 locus.
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important to independently validate all findings in fur­
ther data sets. To date, at least 2 studies have demon­
strated nominal linkage to overlapping regions on chro­
mosomes 3q, 8p, 12q, 14q, 16p, 16q, 18q, and Xp (8-10) 
(Tables 1 and 2). These regions are important candi­
dates for containing true RA susceptibility loci, but 
because the individual RA whole-genome scans under­
taken to date had relatively low power to identify linkage 
to genes of small effect, some regions of true linkage are 
likely to have been missed.
We now describe a systematic whole-genome 
scan and affected-sibling pair linkage analysis, which 
was performed on a large, well-characterized cohort of 
RA families in the UK in order to identify novel 
susceptibility loci and confirm linkage to previously 
identified regions.
PATIENTS AND METHODS
RA-affected sibling pairs. The study group comprised 
252 Caucasian sibling pairs affected by RA. The affected 
sibling pairs, from 182 families, were identified from The 
Arthritis and Rheumatism Council’s U K  National Repository 
of family material (http://www.arc.man.ac.uk) (11). A ll family 
members were examined according to a standard protocol and 
given a detailed, structured interview regarding jo int symp­
toms. A  trained metrologist performed a jo int examination to
detect any swelling, tenderness, or deformity. Hand radio­
graphs were reviewed, and rheumatoid factor (RF) status was 
ascertained using a particle agglutination test. Subjects were 
classified as having RA i f  they satisfied the 1987 American 
College of Rheumatology (formerly, the American Rheuma­
tism Association) criteria (12) modified for genetic studies 
(13).
DNA from the affected individuals and their first- 
degree relatives was prepared from peripheral blood. Parental 
DNA was available in 37% o f the families. In 94% o f the 
remaining families, D NA from unaffected siblings was avail­
able, facilitating the assignment o f parental genotypes. In 26 
families, 3 or more siblings were affected by disease. O f the 650 
individuals included in the study, 403 had R A  (393 siblings, 10 
mothers, and 3 fathers; 3 of the affected parents were also 
members o f an affected sibling pair). Seventy-six percent of 
affected individuals were female, 85% were seropositive for 
RF, and 80% had radiographically apparent hand erosions. 
The mean (±SD) age at disease onset was 39.4 ±  13.2 years, 
and the mean disease duration at recruitment was 15.3 ±11.3 
years. In 60% of cases, both affected siblings were female, both 
were male in 7%, and the other cases comprised mixed-sex 
pairs.
HLA-DR status. H LA-DRB1 genotypes were deter­
mined using a commercially available semiautomated polymer­
ase chain reaction (PCR)-sequence-specific oligonucleotide 
probe typing technique (INNO-LiPA; Abbott Laboratories, 
Maidenhead, UK).
Microsatellite markers. Three hundred sixty-five 
highly informative microsatellites from the A B I PRISM Link­
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Table 2. Loci detected by single-point linkage analysis in 252 affected sibling pair families with 
rheumatoid arthritis in the UK*
Data set, marker (position)
Chromosome





















16 D16S3103 D16S420 D16S403 Pgia3t/








* Results are from whole-genome scans. Marker positions were obtained from Marshfield map (sex- 
averaged positions) at www.marshfieldclinic.org/research/genetics. MS =  multiple sclerosis; CD/UC = 
Crohn’s disease/ulcerative colitis; IBD = inflammatory bowel disease (see Table 1 for other definitions), 
t  Studies of related autoimmune diseases with linkage to the region. Linkage results are summarized in 
ref. 29.
t  Refs. 20 and 21.
§ Ref. 22.
age Mapping Set version 2 marker set (Applied Biosystems, 
Warrington, U K ) were genotyped. The microsatellites 
spanned the whole genome, with a mean distance between 
markers o f —10 cM and mean heterozygosity o f 0.78.
Microsatellite genotyping. A  semiautomated analysis 
of microsatellite genotypes was carried out in 2 centers; 
chromosomes 1-7, 16, 21, and 22 were typed at the Wellcome 
Trust Centre for Human Genetics (WTCHG), and chromo­
somes 8-15,17-20, and X  were typed at the Arthritis Research 
Campaign Epidemiology U nit (ARC-EU). The microsatellites 
were amplified by PCR using fluorescently labeled primers, 
and reactions were performed in 10-p l volumes (each contain­
ing 50 ng of DNA, 5 pmoles o f each PCR primer, 4 nmoles of 
each o f the 4 deoxynucleotide triphosphates, and 0.2 units of 
Taq polymerase [Bioline, London, UK] in 1-3 mM  MgCl2 
buffer, overlaid with liquid paraffin). The reactions were 
performed in 96-well microtiter plates with 30-35 cycles of 
denaturation (1 minute at 95°C), primer annealing (30 seconds 
at 55-60°C), and extension (30 seconds at 72°C). Annealing 
temperatures and MgCl2 buffer concentration were optimized 
for each primer.
Amplification o f each microsatellite was performed 
separately, and the PCR products were then combined into 
pools of 10-20 markers before loading. Products were sepa­
rated by electrophoresis on either 6%  polyacrylamide gels 
using ABI 373 semiautomated D NA sequencers (Applied 
Biosystems) over 3 hours (WTCHG) or 4% polyacrylamide 
gels using A B I 377 D N A  sequencers over 2 hours (ARC-EU).
Products were sized using the program GeneScan 672, version 
2.1 (Applied Biosystems), and genotypes were semiautomati- 
cally assigned using the program Genotyper, version 1.1.1 
(Applied Biosystems). A  PCR product from a DNA reference 
sample (Centre d’Etudes du Polymorphisme Humain [CEPH] 
1347-02) was included on every gel to monitor possible gel-to- 
gel variation.
Statistical analysis. Error checking. To minimize data 
errors, extensive error-checking procedures were used. Allele 
assignment by Genotyper was checked manually for all geno­
types, and the CEPH control sample was used to ensure the 
consistency o f allele assignment. Size data were converted into 
discrete allele numbers, and samples not following Mendelian 
patterns of inheritance were identified in PedCheck (14) and 
removed from the data set. The family data were then assessed 
using R ELATIVE software (15). R ELA TIV E  identifies prob­
able monozygotic twins, half-siblings, or unrelated individuals 
by testing whether the proportion o f alleles sharing identity by 
descent at unlinked loci (on the basis of ^50 markers) is 
consistent with the expected proportion for each relative pair.
Inter- and intraobserver variation. To assess interob­
server variation, at both centers a panel of samples was 
genotyped for 6 microsatellites on chromosome 7. An addi­
tional 10 markers were regenotyped in a blinded manner by 
those researchers undertaking the genotype analysis. Intraob­
server variation was then determined.
Nonparametric analysis. A llele frequencies were calcu­
lated from all o f the scored genotypes using the software
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package D O W N FR E Q  (T e rw illige r J: unpublished) 
(WTCHG) or SPLINK, version 1.05 (David Clayton, MRC 
Biostatistics Unit, Cambridge, U K) (ARC-EU). Sibling pair 
analysis methods were then used to test for excess allele 
sharing between affected siblings. Nonparametric single-point 
and multipoint analysis was implemented in M APM AKER / 
SIBS, version 2 (16). Multiple sibships were given a conserva­
tive weighting o f 2/n to account for their lack o f independence 
(17). Analysis o f markers on the X  chromosome was carried 
out using MAPMAKER/SIBS modified for X-iinked loci (18). 
The program calculates sharing between affected sister-sister, 
brother-brother, and sister-brother sib pairs.
Both multipoint and single-point analyses are pre­
sented. We used the suggested thresholds of logarithm o f odds 
(LOD) scores >3.6 ( P < 2 x  10-5) for significant linkage and 
>2.2 (P ^  7.4 X 1CT4) for suggestive linkage (18). Nominal 
evidence of linkage was based on an LO D score 2:0.8 (P <
0.05) by either multipoint or single-point analysis.
RESULTS•' #
Linkage analysis. The results of the nonpara­
metric single-point and multipoint analyses imple­
mented in MAPMAKER/SIBS are shown in Figure 1. 
Linkage to the HLA region on chromosome 6 was 
confirmed by multipoint analysis (maximum LOD score 
4.7 at marker D6S276, P =  0.000003; 1 cM from 
HLA-DRB1). The allele-sharing ratio for DRB1 was 
16:49:35 for 0-, 1-, and 2-allele sharers. This significant 
increase in the inheritance of 2 alleles identical by 
descent provides evidence for linkage to DRB1 (single­
point LOD score 1.9). Suggestive evidence of linkage by 
multipoint analysis was identified on chromosome 6q 
(D6S434, P  = 0.0007) at 109 cM, and nominal evidence 
of linkage by multipoint analysis was found for 3 addi­
tional linkage intervals: lq  (D1S2842 and D1S2836, P — 
0.05) at 277-290 cM, 14q (.D14S283, P  = 0.05, and 
D14S275, P  =  0.03) at 28 cM, and 14q {D14S276, P  =  
0.03) at 56.4 cM. Single-point analysis also identified 
suggestive linkage for 1 marker on chromosome 6q 
(D6S434, P  =  0.0006) at 109 cM, and nominal linkage 
(P < 0.05) was identified for 10 additional linkage 
intervals on chromosomes 3p (D3S2338 at 42 cM), 4q 
(.D4S1592 at 69.5 cM), 7p (D7S484 at 53.5 cM), lOq 
(D10S192 at 124 cM), lOq (.D10S217 at 158 cM), 14q 
ID14S275 at 28 cM), 14q (D14S276 at 56.4 cM), 16p 
(D16S3103 at 32 cM), 21q (D21S1256 at 9.7 cM) and Xq 
(DXS1106 at 66.6 cM).
Comparisons with data from the European and 
North American whole-genome screens are shown in 
Tables 1 and 2.
Microsatellite markers. The microsatellite mark­
ers spanned the genome, with a mean distance between 
markers of 10 cM and a median distance of 9.3 cM.
Eighty-eight percent of markers were within 14 cM of 
each other. Only 11 markers had a gap of >20 cM, using 
the Marshfield map, as a result of marker failure. The 
mean (±SD ) heterozygosity was 0.78 ± 0.07, and the 
mean polymorphism information content was 0.75 ±
0.08.
Error checking. Fifteen individuals whose DNA 
samples did not follow Mendelian inheritance patterns 
were identified by PedCheck (14) and removed from the 
analysis. Three previously unrecognized half-siblings 
and 2 other individuals (whose samples did not fit 
Mendelian inheritance patterns) were identified by 
RELATIVE (15) and were also removed from the 
analysis.
Inter- and intraobserver variation. For the 6
microsatellite markers on chromosome 7 that were 
genotyped at both centers, concordance was 98.9%. 
Intraobserver variation, measured by regenotyping 10 
markers in a blinded manner, ranged from 0% to 3%.
DISCUSSION
Consistent with the results of 2 previously re­
ported RA whole-genome screens (9,10), this study has 
confirmed genetic linkage to the HLA region on chro­
mosome 6. In addition, suggestive evidence of linkage 
(P <  7.4 X 10-4) to a non-HLA region on 6q was 
identified by both single- and multipoint analyses. Nom­
inal evidence of linkage (P  <  0.05) to 10 other regions 
(chromosomes 3p, 4q, 7p, 2 regions on lOq, 2 regions on 
14q, 16p, 21q, and Xq) was detected by single-point 
analysis, and to 3 linkage intervals (chromosomes lq, 
and 2 regions on 14q) by multipoint analysis.
Regions identified as nominal-linkage intervals 
by 2 or more whole-genome scans are of greater interest 
than are sites identified by only 1 study, especially when 
corroborative evidence from other autoimmune diseases 
or animal studies is available. Six of the non-HLA 
regions identified in this study were also reported by the 
ECRAF (9) and/or NARAC (10) studies (chromosomes 
3q, 6q, lOq, 14p, 14q, and 16p), and several of them 
overlap with regions linked to other autoimmune dis­
eases (Tables 1 and 2). The non-HLA region on 6q with 
suggestive evidence of linkage was also identified in the 
NARAC study (10). On chromosome 10, the linkage 
interval including D10S185 (116 cM) and D10S192 (124 
cM) was identified in the NARAC study (10) and has 
also been identified in an ankylosing spondylitis whole- 
genome scan (20,21). In addition, the interval around 
D10S217 (167 cM) has been identified in a recent 
second-generation whole-genome scan in insulin- 
dependent diabetes mellitus (IDDM) (22). The region
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Figure 1. Results of single- and multipoint linkage analysis 
for all chromosomes, obtained using MAPMAKER/SIBS. 
Bars represent the results of single-point linkage analysis. 
The continuous lines represent the results of the multipoint 
linkage analysis. The logarithm of odds (LOD) score is on 
the y axis, and for all graphs except that for chromosome 6, 
the scale is the same (maximum LOD score 2). Marker 
names are on the x axis.
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on 14q including D14S276 (56 cM) was identified by 
both the ECRAF (9) and NARAC (10) studies, as was 
the interval on 16p (D16S3103). Recently, a whole- 
genome scan conducted using mice with proteoglycan- 
indifced arthritis (23) also identified a linkage interval 
(named Pgia3) homologous to this same region on 16p.
In accordance with findings in the NARAC study 
(10), we are unable to provide supporting evidence for 
the ID D M  6 locus on chromosomel8, a site that showed 
evidence for linkage in the ECRAF study (9). Previous 
investigations using some of the same RA affected 
sibling pair families as in this study reported linkage to 3 
candidate genes and are described below. The current 
study did not attempt to replicate these findings.
Using a number of single-nucleotide polymor­
phisms apd microsatellite markers spanning the 
, interleukin-1 gene cluster, Cox et al detected some 
evidence of linkage using the combined transmission 
disequilibrium test (TDT) and sib-TDT in a subset of 
families sharing only 1 or 0 DRB1 alleles identical by 
descent. However, they found no evidence of linkage 
using nonparametric allele-sharing methods (24). John 
et al reported linkage to a single marker mapping to an 
intron within the estrogen synthase gene (CYP19) (25). 
In the current study, the closest marker mapped 5 cM 
from CYP19, which may explain the failure to replicate 
the previous finding.
Fife et al investigated corticotropin-releasing 
hormone (CRH) as a candidate RA susceptibility locus
(26). Linkage to a 10 cM region adjacent to CRH was 
reported. No statistically significant evidence of linkage 
was detected in the current study, although there was 
some overlap of the families used in the 2 investigations. 
It is interesting to note, however, that there is an 
apparent small peak on multipoint linkage analysis to 
the same region in the current study (Figure 1). With the 
marker density used in this study, linkage to these (and 
other postulated disease) loci could have been missed 
and cannot, therefore, be excluded as potential disease 
genes.
Power calculations suggest that the current study 
should have 80% power to detect loci contributing A =  
1.6, using the threshold for detection as a LOD ^1.0
(27). This, in fact, may be an overestimate, because 
power calculations typically assume that all families are 
fully informative (i.e., DNA is available from all parents, 
and marker heterozygosity is 100%), and that all af­
fected sibling pairs are independent (which is not the 
case in families with >2 affected siblings). Recruitment 
of complete affected sibling pair families in a late-onset 
disease such as RA is difficult. Thus, parental DNA was
available in just over one-third of our families. However, 
one of the strengths of this study is that DNA from 
unaffected siblings was available in 94% of the remain­
ing families, and this was used to infer parental haplo- 
types in families in which they were not directly avail­
able.
Because of the high chance of false-positive 
results in a genome-wide linkage study, we applied the 
stringent thresholds for significance (P <  2.2 X 10-5) 
recommended by Lander and Kruglyak (18). However, if 
stringent thresholds for significance are interpreted too 
strictly in a disease such as RA, with a relatively low As, 
it would be easy to overlook potentially relevant evi­
dence emerging from whole-genome scans.
In order to make best use of the information 
arising from this and similar-sized whole-genome scans, 
a number of strategies are available. One proposal is to 
perform the initial screen in a relatively small data set 
and then to test those loci demonstrating^ nominal 
evidence of linkage .(.P <  0.05) in a larger data set (28). 
In this respect, our study can be seen as a replication 
data set in which to test positive linkages detected in the 
US and European whole-genome scans. As outlined 
above, a number of positive linkages from the NARAC 
and ECRAF studies have also shown evidence of linkage 
in our data set, suggesting that true RA susceptibility 
genes may map to these regions. A  complementary but 
alternative approach would be to undertake a meta-ana­
lysis of the genotype data in previously published whole- 
genome screens. By combining these data, it should be 
possible to make more robust interpretations of the 
evidence, thereby focusing the efforts of the replication 
studies.
In conclusion, our results of the UK whole- 
genome linkage analysis of RA susceptibility loci con­
firm significant evidence of linkage in the HLA region by 
single-point and multipoint analysis. Suggestive linkage 
was identified by single- and multipoint analysis at a 
non-HLA region on 6q. Nominal evidence of linkage 
(P <  0.05) was found by single-point analysis for 10 
other regions on chromosomes 3p, 4p, 7p, 2 regions of 
lOq, 2 regions of 14q, 16p, 21p, and Xq, and by multi­
point analysis for 3 non-MHC regions on chromosomes 
lq  and 2 regions on 14q.
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Rheumatoid arthritis susceptibility and 
interleukin 10: a study of two ethnically 
.diverse populations
K. MacKay, A. Milicic, D. Lee, M. Tikly1, S. Laval, J. Shatford 
and P. Wordsworth
Introduction. IL-10 is an immunoregulatory cytokine which may modulate disease 
expression in rheumatoid arthritis (RA). The IL-10 gene is highly polymorphic 
with a number of single nucleotide polymorphisms in the promoter region and two 
microsatellite loci, EL10.R and IL10.G, 4 kb and 1.1 kb 5' of the transcription 
initiation site. It has been reported that allele 2 of the IL10.R microsatellite 
(IL10.R2) is associated with increased IL-10 secretion and IL10.R3 with reduced 
secretion. Subsequently, over-representation of IL10.R2 and under-representation 
of IL10.R3 in three independent RA groups has been reported. The aim of the 
current study is to determine whether there is an association between the IL10.R2 
allele and RA in two ethnically distinct populations.
Methods. IL10.R genotypes were determined by semi-automated DNA sequencing 
technology in 186 UK Caucasians and 138 South Africans of Zulu or Sotho origin, 
fulfilling the 1987 American College of Rheumatology (ACR) criteria for RA. 
The Caucasian patients had relatively severe disease and comprised 75 patients 
with RA vasculitis, 22 with Felty’s syndrome and 89 who had undergone a joint 
replacement (hip or knee) within 15 years of the onset of disease. Allele frequencies 
were compared with 296 Caucasians and/or 73 South Africans.
Results. The frequency of the IL10.R2 allele was significantly greater in the South 
Africans (RA and controls) than in the Caucasians (0.78 vs 0.66, P = 1  xlO-6), 
while the frequency of IL10.R3 was less common (0.16 vs 0.3, P = l x l 0 ~ 8). 
No differences were observed in either IL10.R2 or IL10.R3 frequencies between 
patients and controls in either population.
Conclusions. We were unable to confirm any association between IL10.R alleles 
and RA in this study. However, significant differences were demonstrated in the 
frequency of IL10.R2 and IL10.R3 between the two ethnic groups. The relatively 
high frequency of IL10.R2 in the South African population (0.78) would have 
reduced the power to detect an association with RA.
K e y w o rd s :  Rheumatoid arthritis, Interleukin 10, Disease susceptibility, Ethnic diversity.
Rheumatoid arthritis (RA) is a common systemic inflam­
matory arthropathy characterized by chronic synovitis 
and progressive joint destruction. Pro-inflammatory 
cytokines, such as tumour necrosis factor (TNF) and 
interleukin 1 (IL-1), play a significant pathogenic role
and the disease can be ameliorated by treatments speci­
fically targeting TNF [1] or IL-1 [2]. Anti-inflammatory 
cytokines can also be found in the affected joints and 
it has been postulated that chronic synovitis may reflect 
an imbalance in pro- and anti-inflammatory cytokine
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production in RA [3], Consequently, the potential 
beneficial effects of anti-inflammatory cytokines such 
as interleukin 10 (IL-10) [4] and interleukin 4 (IL-4) [5] in 
RA are of great interest.
The immunomodulatory cytokine IL-10 is produced 
"by a variety of cell types, including monocytes [6] 
and B lymphocytes [7]. It is a potent up-regulator of 
B-cell production and differentiation [8], but has anti­
inflammatory capabilities that can directly down-regulate 
TNFa, IL-1, IL-8 and interfeton-y production - [6, 9]. 
Variation in IL-10 secretion is largely genetically 
determined [10] and differences in secretion have been 
associated with various chronic inflammatory and infec­
tious diseases. High levels of secretion are associated 
with a poor or fatal outcome in meningitis [10] and low 
levels are associated with susceptibility to severe malarial 
anaemia [11].
The IL-10 j*ene maps to the junction of lq31—q32 [12] 
and exhibits substantial polymorphism in the promoter 
region which appears to correlate with variation in trans­
cription [13, 14], Two microsatellite polymorphisms, 
IL10.G and IL10.R, situated 1.1 and 4 kb 5' of the 
transcription initiation site, respectively, are of particular 
interest [15, 16] since variation in IL-10 secretion has 
been associated with particular haplotypes defined by 
these microsatellite markers. Haplotypes containing 
the IL10.R2 allele are associated with higher levels of 
secretion than those including IL10.R3 [17]. Eight single 
nucleotide polymorphisms (SNPs) have also been iden­
tified in the promoter region of this gene [18-20], three of 
which have been studied in some detail: -1082 (G to A), 
-819  (C to T) and -5 9 2  (C to A) [13, 18, 20]. Increased 
IL-10 secretion has been described with the common 
GCC haplotype and reduced IL-10 secretion with the 
least common ATA haplotype, but direct comparisons 
between these studies are difficult as they have employed 
different experimental protocols [13, 20].
Various IL10.R, IL10.G and SNP genotypes have 
been reported to show association with a variety of chro­
nic inflammatory diseases, including the ATA haplotype 
with extended oligo-articular juvenile idiopathic arthritis 
[13], IL10.G with systemic lupus erythematosus [21] and 
recently the IL10.R2 allele with RA [22].
This study was undertaken to investigate further the 
association of IL10.R2 with RA in UK Caucasians and 




Two groups o f racially distinct patients w ith RA and ethnically 
matched controls were recruited from the United Kingdom and 
South Africa. The patients consisted o f 186 Caucasian and 
138 South African (SA) patients o f Sotho or Zulu ethnicity, 
fulfilling the American College o f Rheumatology (ACR) 1987 
criteria fo r RA. The Sotho and Zulu groups have a similar 
genetic background [23]. A ll the U K  Caucasian patients had 
relatively severe disease and comprised 75 patients with RA 
vasculitis, 22 with Felty’s syndrome and 89 who had undergone
a large jo in t replacement (hip or knee) within 15 years o f the 
onset o f disease. The mean age ( ±  s .d .)  o f the Caucasian RA 
patients was 64 ( ±  11.6) yr and 70 per cent were female. Mean 
disease duration was 18.7 (±10.5) yr and mean age o f disease 
onset was 44.9 (±14.5) yr. The SA patients were not chosen 
specifically fo r disease severity but were all recruited from a 
tertiary hospital out-patient clinic and required disease- 
modifying therapy. The mean age ( ± s .d .) o f the SA patients 
was 49.5 (±10.9) yr, average disease duration was 7.6 (±7 .3 ) 
yr and 76 per cent were female. The U K  Caucasian control 
group consisted o f 210 healthy blood donors and 86 unaffected 
spouses o f patients attending a skeletal dysplasia clinic. The 
South African controls included 73 healthy, ethnically matched 
hospital workers or hospital out-patients attending with minor 
trauma.
IL 1 0 .R  genotyping
Genomic D N A  was extracted from peripheral venous blood 
samples using standard techniques. The IL10.R microsatellite 
was amplified by polymerase chain reaction (PCR) [primers 
were 5' CCC TCC A A A  A TC  T A T  TTG C AT A  (upstream) 
and 5' CTC CGC CCA G TA  A G T TTC ATC (downstream), 
the latter being tagged w ith a fluorescent dye (HEX)]. Reac­
tions were performed in 96-well plates (Costar) in 10 ml 
reactions consisting o f 50 ng D N A , 400 nM each primer, 50 mM 
each dNTP, 2.0 mM M gCl2 and 0.2 units D N A  polymerase 
(Bioline, U K ) in the manufacturer’s N H 4 buffer. The cycling 
conditions were 94°C fo r 1 min, annealing 60°C fo r 1 min, 
extension 72°C for 1 min, fo r 32 cycles. PCR products were 
diluted with water and separated by electrophoresis using 
an A B I 373 semi-automated sequencer (Applied Biosystems, 
Warrington, U K ) and 6% denaturing polyacrylamide gels over 
3 h. Products were sized using the program G ENESCAN™  
Version 2.1 (Applied Biosystems, Warrington, U K ) and genotypes 
semi-automatically assigned using the program GENOTYPER™  
Version 1.1 (Applied Biosystems, Warrington, UK). A ll genotypes 
were then verified manually. The program GAS (Version 2) 
(A. Young, unpublished) was used to convert the size data into 
discrete allele numbers.
H L A -D R  typing
Sequence-specific PCR, using 35 primers, was used to differ­
entiate between the different H LA-D R  alleles and undertake 
DR4 and DR1 subtyping [24].
Statistical analysis
Allele and genotype frequencies were calculated by direct 
counting. Since a common source o f error in genotype assign­
ment is the over-calling o f homozygotes, Hardy-Weinberg 
equilibrium was used to predict the likely frequencies o f 
IL10.R2 and IL10.R3 homozygotes and these figures were 
compared w ith the observed frequencies. IL10.R allele fre­
quency distribution was compared between the Caucasians 
and South Africans and then between patients and controls. 
Subgroup analysis included disease severity (RA vasculitis, 
Felty’s syndrome or an early large jo in t replacement), sex, and 
shared epitope status (homozygosity or heterozygosity). The 
significance o f differences between groups was calculated from 
contingency tables by x2 analysis. Odds ratios with confidence 
intervals were calculated.
Results
The frequency of the IL10.R2 allele was significantly 
higher ( P = l x l 0 -6) in the South African population
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overall (0.78) than the UK Caucasians (0.66), while 
the frequency of IL10.R3 was correspondingly reduced 
(0.16 vs 0.30, P =  1 x 10-8). However, no differences were 
observed in IL10.R allele frequencies between patients 
and controls in either racial group (Table 1). Eighty-four 
' per cent of the UK Caucasian patients and 58 per cent of 
the SA patients were positive for the shared epitope.
A variety of subgroups were defined from the UK 
Caucasian RA cohort to analyse any possible associations
with IL10.R alleles. All allele frequencies were very 
similar whether the groups were divided by sex, age of 
onset, shared epitope status, extra-articular disease (RA 
vasculitis and Felty’s syndrome) or early large joint 
replacement. The observed frequencies of IL10.R2 and 
IL10.R3 homozygous genotypes compared well with 
the predicted frequency of homozygotes by Hardy- 
Weinberg equilibrium suggesting alleles were being 
appropriately assigned.
T able  1. Frequencies of IL10.R alleles in the South African and Caucasian populations studied*
Comparison groups IL10.R alleles Alleles Alleles P Odds ratio (C.I. 95%)
Caucasian South African
No. % No. %
Caucasians vj IL10.R1 4 0.4 11 2.5 ND
South Africans IL10.R2 640 66 350 79 1 x 10-6
IL10.R3 287 30 69 16 1.4x 10-8
IL10.R4 32 3.3 11 2.6 0.4
IL10.R5 1 0.1 1 0.3 0.6
Patients Controls
No. % No. %
Caucasian patients IL10.R1 3 0.8 1 0.2
vj controls IL10.R2 253 68 387 65 0.4 1.3 (0.8-1.5)
IL10.R3 103 28 184 31 0.2 0.85 (0.6-1.4)
IL10.R4 13 2.7 19 3.2 0.8
IL10.R5 0 0 1 0.2 ND
South African IL10.R1 9 3.2 2 1.4 ND
patients vs controls IL10.R2 223 78 127 77 0.4 0.8 (0.5-1.4)
IL10.R3 47 17 22 15 0.5 1.25 (0.7-2.2)
IL10.R4 7 2.5 4 2.7 ND
IL10.R5 0 0 1 0.7 ND
“Allele frequencies were compared using x2 analysis.
ND, not done because numbers were too small for reliability.
T able 2. IL10.R2 and IL10.R3 allele frequencies in RA patients (from different ethnic backgrounds) vs controls using data from this study and the 










This study Caucasians with severe RA 
RA (n =  186)
Control (n =  296) 68 65 28 31
This study Black South Africans (DSND) 
RA (n =  138)
Control (n =  73) 78 77 17 15
Lancet 1998 
(Eskdale et al.)
Oxford Caucasians (DSND) 
RA (n=  148)
Control (n =  87) 70 61 25 36
Lancet 1998 
(Eskdale et al.)
Glasgow Caucasians (DSND) 
RA («=  103)
Control (n =  94) 69 56 29 40
Lancet 1998 
(Eskdale et al.)
African Americans (DSND) 
RA (n=61)
Control (n =  38) 87 72 11 24
DSND, disease severity not documented.
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Discussion
No association between IL-10 alleles and RA was 
apparent in the current study, in contrast to previous 
reports o f an increase in IL10.R2 and a reduction in 
„ IL10.R3 alleles [22]. There are several possible explana­
tions for this. First, the previous reported association 
with the IL10.R2 allele may be spurious. Second, it may 
be relevant that the IL10.R2 allele frequency in UK  
Caucasian controls in our study is significantly-higher 
(0.65 vs 0.59, P=0.03) than that reported by Eskdale 
et a l  and the IL10.R3 frequency significantly lower (0.31 
vs 0.38, J°=0.02). No differences in allele frequencies 
of IL10.R2 or IL10.R3 were apparent when the UK  
Caucasian patient groups from the two studies were 
compared (Table 2). This may suggest that IL-10 con­
tributes a weak genetic effect but the relatively high 
frequency of IL10.R2 in the general population makes 
the effect-mbre difficult to detect reliably. Since the 
•' frequency of IL10.R2 is even higher in South African 
Sotho and Zulu populations, the power to detect 
association with RA would be further reduced. Pre­
viously reported estimates of relative risk for IL10.R 
in RA range between 1.5 and 2.5 [22]. We estimate 
that our study in UK Caucasians had 80 per cent 
power to exclude an association between IL-10 and RA 
with an odds ratio of >1.8. However, in the South 
African study the higher frequency of the IL10.R2 allele 
(SA control frequency 77 vs 65% in Caucasians) means 
that the power to detect an effect with an odds ratio of 
> 1.8 was only 36 per cent. In contrast the study had 
80 per cent power to exclude a putative genetic effect 
with an odds ratio of >3 . Third, genetic heterogeneity 
may be operating. The UK patients in this study were 
specifically selected for having more severe forms of 
RA and were only included if they had undergone an 
early large joint replacement or fulfilled the criteria for 
rheumatoid vasculitis or Felty’s syndrome. This is in 
contrast to the previous report where the main recruit­
ment criteria was RA fulfilling the 1987 ACR criteria 
[22], It is therefore likely that the disease severity of the 
Caucasian patients included in the two studies was 
different and it is conceivable that the IL10.R2 allele is 
not as strongly associated with severe forms of RA as it 
is with milder variants.
Inter-ethnic differences in IL-10 allele frequencies 
were not unexpected as similar differences have been 
described previously for the TNF locus [25-27] although 
in the case of TNF, linkage disequilibrium within the 
MHC may contribute to this variation [25].
A number of studies in normal individuals have 
demonstrated associations between IL-10 secretion and 
microsatellite or SNP polymorphisms characterizing 
distinct IL-10 haplotypes [17, 20]. Other studies have 
suggested that some of these haplotypes are associated 
with inflammatory diseases [13, 21, 28], although there is 
no really convincing evidence that these polymorphisms 
are directly involved in influencing IL-10 production or 
disease susceptibility. However, they may be markers 
for other relevant mutations within the gene and it is
conceivable that only certain IL10.R2 haplotypes include 
specific SNPs associated with increased IL-10 secretion. 
Equally, only certain IL10.R3 haplotypes may truly be 
under-represented and associated with reduced IL-10 
secretion. Discrimination between the various IL10.R2 
or IL10.R3 extended haplotypes is not possible in a case- 
control study. As current evidence regarding a pos­
sible association of IL-10. with RA is inconclusive it would 
be appropriate to conduct a within-family association 
study to define the effects of specific haplotypes.
In conclusion, this study did not confirm an associa­
tion between ILI0.R2 and RA. However, as the data are 
inconclusive, further large studies investigating IL-10 
as a candidate gene are justified but will require large 
numbers to achieve adequate statistical power. Extended 
haplotyping of the IL-10 promoter region should help to 
define any disease-causing haplotypes and so improve 
the chances of identifying an association.
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